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Atypical antipsychotics are commonly prescribed for the treatment of psychiatric 
disorders such as schizophrenia. However, long term use of atypical antipsychotics 
lead to metabolic adverse effects such as weight gain, insulin resistance, and 
dyslipidemia, all of which are independent risk factors for cardiometabolic disease. 
Adipose tissue plays an important role in glucose and lipid homeostasis and has been 
linked to atypical antipsychotic-induced metabolic toxicity. The main aim of this 
thesis was to characterise the effect of atypical antipsychotics in vitro using murine 
3T3-F442A preadipocyte cell lines and primary human adipocytes. Cells were 
incubated with clozapine (1-20μM), olanzapine (0.2-20μM) and aripiprazole (0.2-
20μM) every 48 hours for 10 (3T3-F442A) or 13 (primary human adipocytes) days. 
Lipid accumulation was measured by Oil Red O assay. Protein and gene expression 
of peroxisome proliferator-activated receptor gamma and lipin 1 were measured by 
Western Blot and RT-PCR respectively. Adipokine secretion was measured by 
ELISA. Global lipidomic profiling of drug-treated adipocytes was undertaken using 
LC-MS and selected lipid species were validated by RT-PCR of enzymes that mediate 
the ceramide metabolism pathway. In differentiating 3T3-F442A cells clozapine 
(20µM:1.56 absorbance units±0.097; p=0.001) and olanzapine (20µM:1.57±0.14; 
p=0.07) but not aripiprazole showed an increase in lipid accumulation as compared to 
the vehicle. Clozapine but not olanzapine or aripiprazole upregulated the protein 
expression of peroxisome proliferator-activated receptor gamma (Mean fold 
change±SD; 307.34±26.30; p=0.0001) and lipin1 (213.46±26.43; p=0.02), and 
increased the secretion of adiponectin (736.77ng/ml±66.06; p=0.001; Vehicle: 323.26 
ng/ml±53.07) and tumour necrosis factor alpha (45.24pg/ml±0.16; p=0.0001; Vehicle: 
32.89pg/ml±0.34). In primary human adipocytes clozapine significantly increased 
lipid accumulation (1µM: 1.10±0.08; p=0.04) and leptin secretion (1µM: 1.06±0.10; 
p=0.04) but both clozapine and olanzapine led to a reduction in adiponectin secretion 
(Clozapine: 0.31±0.18; p=0.03, olanzapine: 0.39±0.21; p=0.01). Aripiprazole showed 
opposite effects to that of clozapine and olanzapine on lipid accumulation, gene 
expression and adipokine release. Drug uptake experiments showed that there was a 
20-fold increase in clozapine uptake by differentiating primary human adipocytes 
(1293.4 pmol/million cells±170.56; p=0.006) in comparison to the murine adipocytes 
(64.25pmol/million cells±26.96). Co-incubation of clozapine with aripiprazole 
showed that aripiprazole significantly reversed clozapine-mediated reduction in 
secretion of adiponectin (1.23±0.09; p=0.04). Higher doses of both clozapine and 
olanzapine but not aripiprazole resulted in significant changes in the global lipidome 
profile of primary human adipocytes. Clozapine and olanzapine but not aripiprazole 
significantly decreased the ceramide 18 species and resulted in significant 
downregulation in the gene expression of ceramide biosynthesis enzymes, serine 
palmitoyltransferase long chain base subunit 2 (Clozapine: 0.60±0.13; p=0.003; 
Olanzapine: 0.62±0.16; p=0.007) and Delta-4-Desaturase Sphingolipid 1 (Clozapine: 
0.67±0.18; p=0.01; Olanzapine: 0.83±0.11; p=0.02).  
In conclusion, we have shown that atypical antipsychotics may cause metabolic 
toxicity by directly affecting adipocyte function and metabolism; however, this could 
be potentially reversed in vitro by various therapeutic strategies. Atypical 
antipsychotics also significantly alter the adipocyte lipidome which may contribute to 
metabolic adverse effects in schizophrenia patients. The mechanisms and pathways 
identified in this study now need to be validated in in vivo and clinical models which 
will aid the identification of toxicity biomarkers in atypical antipsychotic-treated 























Schizophrenia is a chronic, debilitating psychiatric disorder. It is estimated that 
approximately 0.5-1% of the world population is suffering from schizophrenia 
(Moustafa et al., 2016b). There is no specific age for schizophrenia to occur however 
the peak incidence of schizophrenia for men is between 10 and 25 years and 25 and 
35 years for women (Rajji et al., 2009). Schizophrenia can occur at very late age, after 
60 years, called as very-late-onset schizophrenia-like psychosis or in childhood after 
the age of 5 (Howard et al., 2000). The prevalence of schizophrenia is about 1 per 
10,000 in children and 1-2 per 1000 in adolescents. Also in early adolescent, higher 
rates has been reported in young males compared to young females (Rajji et al., 2009). 
1.2 Symptoms 
Schizophrenia is characterised by (Weickert et al., 2000, Moustafa et al., 2016a); 
Positive symptoms which include, 
 hallucinations and  
 delusions 
Negative symptoms which include, 
 lack of motivation, 
 social withdrawal,  
 disorganized speech and  
 behaviour  
Cognitive symptoms which includes impairment in,  
 attention, memory and learning  
According to Diagnostic and Statistical manual of Mental disorder (DSM-V) of the 
American Psychiatry Society and International Classification of Diseases (ICD-11) of 
the World Health Organization (WHO), the schizophrenia diagnostic criteria includes 
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two or more of the positive or negative symptoms for a significant portion of time 
during a one month period (Biedermann and Fleischhacker, 2016, Gaebel et al., 2013). 
1.3 Risk Factors 
Several risk factors have been identified which may lead to schizophrenia. Birth 
season is one of the factors identified with studies showing that schizophrenia may 
develop in individuals born in winter as compared to other seasons. This might be 
attributable to the infection which is more prevalent in winter especially in northern 
hemisphere (Messias et al., 2007). It was also found that individuals with antibodies 
to Toxoplasmosis Gondi have a higher prevalence to develop schizophrenia. 
Schizophrenia is also linked to herpes simplex virus or meningitis infections 
(Elsheikha and Zhu, 2016, Buka et al., 2008). Several studies and meta-analysis 
showed that the onset of schizophrenia is linked to prenatal and birth complications 
which includes prenatal exposure to infections, pregnancy complications, abnormal 
foetal growth and development or delivery complications (Cannon et al., 2002, 
Verdoux et al., 1997). Head injury has also been considered as a possible risk factor. 
Severe head injury has been associated with schizophrenia like symptoms (Dean and 
Murray, 2005). Drug abuse is also considered as possible risk factor for schizophrenia. 
Study conducted in Taiwan showed that large amount of methamphetamine use was 
associated with increased risk of schizophrenia (Chen et al., 2003).Cannabis use has 
also been found to increase the risk of schizophrenia (Messias et al., 2007).However 
there are studies which argued that cannabis does not linked to schizophrenia. More 
research is required to see cannabis association with schizophrenia (Sami and 
Bhattacharyya, 2018). Some studies also mentioned risk of schizophrenia with 
unemployment, low education, low socioeconomic status or being living alone. 
However more research is required to explore minority status association with 
schizophrenia (Dean and Murray, 2005). Numerous studies also mentioned that 
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individuals born in an urban environment develop schizophrenia much more than to 
those born in a remote area (Hosak and Hosakova, 2015, van Os et al., 2005, Torrey 
and Yolken, 1998). 
1.3.1 Genetics 
 
Family, twin and adoption studies have demonstrated that the susceptibility to 
schizophrenia is associated with genetics. Studies by Cardno and Lewis showed that 
the incidence rate for third degree relatives to be schizophrenic is approximately 2%. 
This incidence rate rose to 6% in second degree relatives and up to 17% in first degree 
relatives while the rate is 27% if both parents are affected (Cardno and Gottesman, 
2000, Lewis and Lieberman, 2000). Also the incidence of schizophrenia is 17% in 
dizygotic twins and 50% in monozygotic twin. It has also been reported that there is 
6-10 times more risk to develop schizophrenia in offspring in biological parents who 
already have schizophrenic disorder compared to adopted parents without disorder 
(Lewis and Lieberman, 2000). Linkage studies showed allele on chromosome 5 
(5q11.2 to 5q13.3) might have linked to schizophrenia but it couldn’t be replicated by 
others (Giegling et al., 2017). However, meta-analysis of genome-wide linkage studies 
of schizophrenia by Ng and colleagues suggested the evidence of linkage observed on 
chromosome 5q (142-168Mb) as well as 2q (103-134Mb). They also proposed that 
chromosomes regions 1, 2q, 3q, 4q, 5q, 8p and 10q might link to schizophrenia (Ng et 
al., 2009). Another meta-analysis, by Gatt and colleagues incorporating 97 
schizophrenic variants separated the possible candidate genes linked with 
schizophrenia; these  include; Catechol-O-methyltransferase (COMT), Dopamine 
receptor(DR) 2,3,4, D-Amino Acid Oxidase (DAOA), Gamma-aminobutyric acid type 
A receptor beta 2 (GABRB2), Methylenetetrahydrofolate reductase (MTHFR), 5-




Apart from isolated environment and genetic risk factors, studies are now focussing 
on gene-environment interactions. Evidence showed that concordance rate for illicit 
drug use was 22.3% for monozygotic twins and 14.5% for dizygotic twins (Oh and 
Petronis, 2008). This showed that individual who has an inherited risk for 
schizophrenia may have potential to use illicit drugs. Studies showed that 
polymorphism in catechol-O-methyltransferase gene modulated the influence of 
adolescent illicit drug use on developing schizophrenia (Caspi et al., 2005). Another 
study showed gene-environment interaction between pregnancy complications and 
polymorphism in genes, regulated by hypoxia, for increased risk for schizophrenia 
(Nicodemus et al., 2008). A combined genome-wide association study (GWAS) data 
extracted from International Schizophrenia Consortium (ISC) and European-
American portion of the Molecular Genetics of Schizophrenia Consortium (MGSC) 
indicated a large number of genes which are associated with schizophrenia in 
interaction with environment. GWAS study found three novel candidate schizophrenia 
loci; NRGRN (neurogranin), TCF4 (transcription factor 4) and MHC (major 
histocompatibility  complex) however, most of the schizophrenic GWAS showed 
association with MHC (International Schizophrenia et al., 2009, Stefansson et al., 
2008, Giegling et al., 2017).However more research is required to explain the 
association between environmental risk factors and genes for schizophrenia. 
1.4 Mortality 
Schizophrenia, if not treated properly, can lead to adverse outcome which ultimately 
reduce the life span. Meta-analysis from 25 countries showed 2.5 times higher risk of 
death than the general population (Azad et al., 2016). A study by Laursen et al showed 
that overall mortality increase 2-3 times in schizophrenic patients compared to the 
general population (Laursen et al., 2013). There are both natural and unnatural causes 
of death in schizophrenic patients. Natural death arises as a result of cardiovascular 
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problems, respiratory diseases, poor compliance, cancer, unhealthy life style and 
antipsychotic effects. Unnatural death include suicide and accident which account for 
40% of all death in schizophrenia (Ringen et al., 2014). Among the disease-related 
deaths, cardiovascular disease (CVD) is the leading cause of mortality. Several studies 
have shown that there are 90% higher deaths in schizophrenic patients compared to 
general population due to CVD (Harris and Barraclough, 1998, Ringen et al., 2014, 
Healy et al., 2012). 
1.5 Risk factors of CVD in schizophrenic patients 
Meta-analysis by Vancampfort and colleagues showed several risk factors may lead 
to CVD in schizophrenic patients. These include:- smoking, unhealthy eating pattern, 
sedentary behaviour, side effects of antipsychotics and low socio-economic status. 
According to National Cholesterol Education Program (NCEP), metabolic syndrome 
is one of the main risk factor for CVD (National Cholesterol Education Program 
Expert Panel on Detection and Treatment of High Blood Cholesterol in, 2002). Stress 
involved in schizophrenia itself might  lead to metabolic syndrome due to over activity 
of sympathetic nervous system (Scigliano and Ronchetti, 2013).Various studies have 
mentioned that metabolic syndrome is more prevalent among schizophrenic patients 
compared to general population (McEvoy et al., 2005, Weeke et al., 2014). 
1.6 Pathophysiology 
Interrupted connections in various brain regions including midbrain, nucleus 
accumbens, thalamus and prefrontal cortices might involve in pathophysiology of 
schizophrenia. Risk factors might have an effect on these neural circuits which 
ultimately lead to schizophrenia. Important neurotransmitters involved are dopamine, 
glutamate, serotonin and acetylcholine but dopamine and glutamate has been studied 
more (Lewis and Lieberman, 2000). 
1.6.1 Dopamine hypothesis 
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Dopamine is produced in substantia nigra and ventral tegmental regions. It has 
connections to nigrostriatal, mesolimbic and mesocortical system and any 
disturbances in these connections cause abnormality in individual. Dopamine theory 
was suggested by Carlsson and Lindqvist, proposing that increased activity of 
dopamine transmission in brain leads to schizophrenic symptoms (Carlsson and 
Lindqvist, 1963). This theory was supported by other studies showing that dopamine 
releasing drug, for example amphetamine, as well as dopamine D2 receptor agonist, 
may increase the schizophrenia-like symptoms (Angrist et al., 1974, Creese et al., 
1996, Seeman and Lee, 1975). Later it was found that drugs, for example 
chlorpromazine and haloperidol which block D2 receptor, improved the schizophrenic 
symptoms in patients of schizophrenia (Carpenter, 1996). However this theory was 
modified later proposing that hyper- and hypodopaminergic condition might occur in 
schizophrenic patients in different regions of the brain. It was further proposed that 
hyperactive dopamine transmission in subcortical areas trigger positive symptoms 
whereas negative symptoms and cognitive impairment may occur due to hypoactive 
dopamine transmission in cortical regions (da Silva Alves et al., 2008, Brisch et al., 
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1.6.2 Glutamate Hypothesis 
A study in healthy volunteers showed that glutamatergic N-methyl D aspartate 
(NMDA) receptor antagonist such as phencyclidine (PCP) or ketamine produced 
psychotic symptoms similar to what is seen in schizophrenia (Krystal et al., 1994). 
This was also confirmed in an experiment on mice which showed schizophrenia like 
symptoms on blockade of NMDA receptors (Mohn et al., 1999). This gave an idea 
that schizophrenic symptoms might involve dysregulation of NMDA receptor-
mediated neurotransmission. This model is now currently used for aetiology and  new 
treatment development of schizophrenia (Javitt, 2010). 
1.6.3 GABA hypothesis 
It was hypothesised that reduced gamma aminobutyric acid (GABA) neurons function 
could lead to psychotic symptoms (Roberts, 1972); however the result was 
inconsistent in other study (Deakin and Simpson, 1997). Recently Chang and 
colleagues suggested Akt1 deficiency have effect on GABAergic interneurons and 
GABAAR expression, which can lead to cognitive functional impairment. This can 
lead the research towards development of GABA agonist in treatment of schizophrenia 
(Chang et al., 2016). 
1.6.4 Serotonin Hypothesis 
Serotonin or 5-hydroxytryptamine (5HT) has been proposed to have an effect in 
pathophysiology of neuropsychiatric disorders (Chang et al., 2016). However, results 
obtained from initial studies were disappointing although later studies identified the 
role of various 5HT receptors subtypes and their effect on other neurotransmitters on 
behaviour (Javitt, 2010). It was suggested that atypical antipsychotics improved 





1.6.5 Cytokine Hypothesis 
The cytokine hypothesis or model grabbed the attention of researchers for explaining 
the pathophysiology of schizophrenia. Several studies on adult rodents showed 
interactions between cytokines and dopaminergic signalling. Studies showed that 
giving repeated interleukin-6 (IL-6) along with amphetamine, produces symptoms 
similar to schizophrenia suggesting a role for cytokines in the pathophysiology of 
schizophrenia (Zalcman et al., 1998, Zalcman et al., 1999). The cytokine model is also 
in support of glutamate hypothesis which suggested that phencyclidine and ketamine 
induced schizophrenic symptoms. Connection between IL-6 and ketamine suggested 
that IL-6 could be mediator of ketamine which ultimately have devastating effect on 
paralbumain-positive (PV+) interneurons. These interneurons play role in cognition, 
disturbing them would lead to cognitive impairment (Kantrowitz and Javitt, 2010, 
Girgis et al., 2014, Lewis et al., 2005). Clinically various cytokines had been reported 
to be increased in schizophrenic patients which includes interleukins1, 2, 8, 6 and 
tumour necrosis factor-alpha (TNF-α) (Miljevic et al., 2013). It has also been reported 
that IL-6 levels increased in schizophrenic patients which then reduced significantly 
after treatment (Miller et al., 2011) but the data is not consistent as another study 
reported no effect of antipsychotics on plasma IL-6 levels. This inconsistent result 
suggest that effect on IL-6 may be due to illness itself instead of drug treatment 




1.7.1 Non Pharmacological treatment 
Various studies reported that psychosocial treatment is as important as 
pharmacological and patient can escape from the illness by using various ways 
(Rummel-Kluge and Kissling, 2008, Pharoah et al., 2010, Larsen et al., 2001). 
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Psychosocial intervention is suggested to be effective not only in improving patient’s 
symptoms but also providing cost-effectiveness  compared to standard treatment 
(Chien et al., 2013). There are 5 types of interventions which help the patients in their 
recovery. These include cognitive behavioural therapy (CBT) and cognitive 
remediation therapy (CRT), psychoeducation program, family intervention, social 
skills and Assertive community treatment (ACT) (Patterson et al., 2005, Chien et al., 
2013). Among all 5 types, CBT and CRT are considered the most important in which 
the therapist usually evaluate and examine the thoughts and perceptions of the 
patients’ symptoms and give a guided line to solve psychotic problems. It was 
suggested that CBT have a role in relieving positive symptoms but not negative 
symptoms (Pilling et al., 2002, Rathod and Turkington, 2005). However in terms of 
relapse there is difference in result. Gumley et al reported the significant effect of CBT 
(Gumley et al., 2003) while Durham et al showed a modest result in relapsing 
schizophrenic symptoms (Durham et al., 2003). Despite the differences in relapse, 
CBT still could be used as an adjunct to other psychosocial interventions. Cognition 
Remediation therapy is another intervention which include improved methodology 
related to neurocognition and social cognition, in order to improve the working 
memory, attention and psychomotor functions. McGurk and colleagues reported 
improvement in schizophrenic symptoms, memory and cognition abilities by using 
remediation technique during 1 year of follow up (McGurk et al., 2007). Several 
studies showed improvement in symptoms by going through psychoeducation 
programs, family-focussed intervention and social skills training (Pekkala and 
Merinder, 2002, Zapata Ospina et al., 2015, Weisman et al., 2005, Magliano et al., 
2003). Another important non pharmacological intervention is ACT which is basically 
for refractory schizophrenia. This encompasses people who need immediate support, 
noncompliance with treatment and social breakdown. Clarke et al reported 
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improvement in symptoms and better life in patient used ACT technique (Clarke et 
al., 2000). 
1.7.2 Pharmacological treatment 
Antipsychotic drugs form the mainstay of treatment in schizophrenia patients. 
However due to neurological side effects of first generation antipsychotics, focus is 
now more on second generation or atypical antipsychotics (AAPs). Current guidelines 
recommended continuous therapy for one year after first psychotic episode and for 5 
years or more in case of multiple episodes (Stip and Tourjman, 2010). Previously focus 
of pharmacotherapy was on synaptic modulation of dopamine system by acting on 
dopamine D2 receptors but studies on AAPs showed the role of other 
neurotransmitters like serotonin, norepinephrine, acetylcholine, histamine and 
glutamate (Lewis and Lieberman, 2000). These drugs have either low affinity for D2 
and 5-HT2 receptors or might have effect through other dopamine receptors such as D 
1, 2, 3, 4 or 5-HT1A, B, 2A, C, 3, 6, 7 . However AAPs also cause certain important 
side effects such as the metabolic adverse effects. To reduce these adverse effects, 
adjunctive drugs such as metformin, aripiprazole, topiramate and sibutramine are 
given along with AAPs. The details will be discussed in thesis chapter 4. 
Others adjunctive drugs prescribed include benzodiazepines to control agitation;  
mood stabilisers to control mood;  antidepressants to control depression;  and, anti-
cholinergics to reduce extrapyramidal symptoms (Lewis and Lieberman, 2000). 
 
1.8 Antipsychotics under development or in clinical trials 
1.8.1 N-methyl-D-aspartate receptor agonists  
It was proposed that hypofunctioning of N-methyl-D-aspartate (NMDA) receptor-
mediated neurotransmission may produce schizophrenic symptoms. Whereas 
increased NMDA receptor activity will lead to have increased effect on glutamatergic 
circuit which ultimately improve the dopamine neurocircuit pathway resulted in 
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improvement in schizophrenic symptoms. Glycine and D-cycloserine are the most 
studied agents in relation to their effect on NMDA receptor. The cognitive and 
negative symptoms in schizophrenia trial (CONSIST) showed no improvement in 
schizophrenic symptoms by glycine and D-cycloserine (Buchanan et al., 2007). 
However the meta-analysis by Tsai et al showed improvements in schizophrenic 
symptoms by using glycine, D-serine and sarcosine in schizophrenic patients. Large-
term clinical trials are required to determine their in-depth functional role in 
improvement of schizophrenic symptoms (Tsai and Lin, 2010). 
1.8.2 Glycine Transporter 1 inhibitors 
It was proposed that synaptic glycine levels were increased on blocking glycine 
transporter 1 which blocks glycine reuptake, and in turn improved NMDA 
neurotransmission. Sarcosine works by this mechanism. NMDA neurotransmission is 
useful for regulation of memory and cognition. A clinical trial of sarcosine showed 
improvement in schizophrenic symptoms however further studies are required to 
understand detailed mechanisms involved (Lane et al., 2010). 
 
1.8.3 Kynurenic acid blocking agents 
In brain, kynurenine pathways work by degradation of tryptophan and generate 
kynurenic acid (KYNA) metabolite which blocks glutamate and nicotine receptors. 
KYNA acts as an antagonist at the glycine site of NMDA receptor. KYNA levels were 
found to be increased in post-mortem brain of schizophrenic patients suggested 
KYNA involvement in psychotic symptoms. A Study on mice reported  that targeted 
deletion of kynurenine aminotransferase II (enzyme that block the degradation of 
tryptophan) leads to low levels of KYNA  and increased cognitive functions (Erhardt 
et al., 2009, Schwartz et al., 2012). Long-term clinical trials are required to get detailed 
role of KYNA blocking agents in treatment of schizophrenia. 
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1.8.4 Anti-inflammatory Agents  
Anti-inflammatory agents can be helpful in improving symptoms of schizophrenia. It 
was reported in randomised clinical trials (RCT) that anti-inflammatory drug 
(celecoxib, a cyclooxygenase-2 inhibitor), which was used as an adjunctive drug in 
schizophrenic patients) showed partial improvement in positive and negative 
symptoms of schizophrenia (Muller et al., 2002, Muller et al., 2010, Akhondzadeh et 
al., 2007, Rapaport et al., 2005) while another trial which used aspirin, showed  no 
improvement in symptoms (Laan et al., 2010). Various studies also reported 
improvement in schizophrenic symptoms by using drugs having anti-inflammatory 
effect such as minocycline, N-acetylcysteine, oestrogen, davunetide and 
corticosteroids along with antipsychotic drugs (Nitta et al., 2013, Sommer et al., 2014, 
Chaudhry et al., 2012). These studies broaden the way of developing new therapies 
targeting neuroimmune system. 
 
1.9 Antipsychotic Drugs 
Antipsychotic drugs are one of the most widely prescribed medications and mainly 
used for treatment of psychotic conditions like schizophrenia, mania and bipolar 
disorder (Newcomer, 2005).These drugs act by blocking D2 receptor in the central 
nervous system but they also affect other receptors such as D1, D4, 5HT, α-adrenergic, 
histaminic (H) receptors and muscarinic (M)  receptors. Antipsychotics have been 
divided into two classes: the first generation antipsychotics are known as neuroleptic 
or typical antipsychotics and are potent dopaminergic D2 antagonists with 
extrapyramidal side effects; the second generation antipsychotics, also known as 
atypical antipsychotics (AAPs), show much less extrapyramidal side effects 
(Newcomer, 2007) .  
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1.9.1 History  
The antipsychotic agents were originated from phenothiazine compounds which were 
initially used as antiseptics, anthelminthic and anti-malarials. In 1930, one of 
phenothiazine derivative, promethazine, was suggested to have antihistaminic and 
sedative properties. This was used by the anaesthetists during surgery to prolong and 
stabilise anaesthesia. Later on, another phenothiazine derivative, chlorpromazine, was 
synthesised by the French Pharmaceutical Company and it was found to reduce 
anxiety and induce mild sedation without causing loss of consciousness. In the early 
50’s, chlorpromazine was also found to be effective in improving symptoms in 
psychotic patients which led to its licensing in the USA in 1955 (Ban, 2007). In 1958,  
another antipsychotic, haloperidol (HALO) was synthesised and  found to have 
neuroleptic activity (Ramachandraiah et al., 2009). In 1958, Carlsson and colleagues 
found that dopamine worked as an independent neurotransmitter in the brain. After 
few years, they suggested that both chlorpromazine and haloperidol increase the 
metabolism of noradrenaline and dopamine which provide the idea of involvement of 
dopamine in schizophrenic pathophysiology (Yeragani et al., 2010).  
 
1.9.2 First generation (Typical) antipsychotics 
The classification, chemical structure and receptor affinities of typical antipsychotics 













            Table 1.1 Classification of first generation (Typical) antipsychotics   
                          (Modified from Katzung and Trevor, 2015) 





























Dihydroindolones   Low/Medium Molindone 
Dibenzepines   Low/Medium Clotiapine 





1.9.2.1 Mechanism of action 
The first generation antipsychotics act by blocking D2 receptors in the CNS. They also 
act on 5HT2, H1, adrenergic and cholinergic receptors but D2 is the main receptor on 
which these drugs act. D2 receptors which are located in limbic and striatal areas of 
CNS are mostly responsible for antipsychotic efficacy and extrapyramidal side effects. 
Typical antipsychotics are found to be effective in first-episode schizophrenia. They 
also have improved effect on the positive symptoms but less effect on the negative 
symptoms as compared to AAPs. Typical antipsychotics also reduce the occurrence 
of relapse but do not provide much help in refractory schizophrenia as compared to 
AAPs (Joy et al., 2006, Lieberman et al., 2003b, Lieberman et al., 2003a, Thornley et 
al., 2003). 
 
1.9.2.2 Adverse effects  
 
1.9.2.2.1 Neurological 
D2 receptors are important in locomotor functions especially through extrapyramidal 
motor system. Other functions related to D2 include learning, rewards, attention, 
memory, sleep and regulation of food intake. D2 receptor also control prolactin and 
aldosterone secretion and have role in vasodilation and gastrointestinal motility 
(Beaulieu and Gainetdinov, 2011). Due to the blockade of D2 receptor, it causes 
various neurological side effects; these include Parkinson’s like symptoms such as 
bradykinesia, rigidity, tremor and appearance of mask-like face. Other effects include 
akathisia, where the patient become restless, agitated and distressed and show dystonic 
movement with muscular spasms limited to face, neck and back leading to abnormal 
posture (van Harten et al., 1999). After long-term treatment with typical 
antipsychotics, patients develop disfiguring and disabling effects involving 
irreversible involuntary movements, called as tardive dyskinesia. The symptoms 
comprise of continuous movement of tongue in and out of the mouth, movement of 
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fingers without any purpose and choreathetoid  movement of entire limbs (Moore and 
Furberg, 2017). It is observed in about 3% of the patients who have used 
antipsychotics for long period of time. If not treated, it may lead to permanent 
disability (Chandra et al., 2017). 
1.9.2.2.2 Endocrine effects 
 
It has been recognised that typical antipsychotics increase the levels of prolactin. 
Infact, D2 receptor activation regulates the release of prolactin. On D2 antagonism, 
there is increased release of prolactin which causes hyperprolactinemia leading to 
gynaecomastia, galactorrhoea and erectile dysfunction (Haddad and Wieck, 2004). 
Several studies also showed that typical antipsychotics result in loss of bone mineral 
density (Liu-Seifert et al., 2004, Meaney et al., 2004, Meaney and O'Keane, 2007) and 
breast cancer (Harvey et al., 2008). No doubt, positive symptoms have been reduced 
in many patients with typical antipsychotics but these drugs have less effect on 
negative symptoms. It should also be noted that the D2 receptor occupancy by typical 
antipsychotics is more than 80% and that mediates these neurological adverse effects 
(Moore and Furberg, 2017). 
 




Clozapine (CLO) use started in 1960 and initially it was meant to be used as an 
antidepressant because of its chemical structure. However it was found later that it had 
neuroleptic properties as well (Hippius, 1989). It was reported that CLO was useful in 
the treatment of psychosis without causing extrapyramidal side effects and that 
attracted many researchers to do more research on this drug (Hippius, 1989). A later 
study, carried out in Finland, reported agranulocytosis as a severe adverse effect of 
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CLO (Crilly, 2007, Idanpaan-Heikkila et al., 1975); this resulted in the withdrawal of 
CLO from the market. However, CLO was studied extensively in the following years 
which resulted in the discovery of its effectiveness in resistant-schizophrenia and led 
to the re-entry of CLO back to the market in 1990 (Crilly, 2007). AAPs have been 
found to be cause less extrapyramidal side effects in comparison to typical 
antipsychotics. Extensive research on AAPs resulted in development of newer drugs 
with less adverse effects than typical antipsychotics and is discussed below. 
 
1.9.3.2 Atypical antipsychotics drugs  
 
The AAP drugs and their approval by the US Food and Drug Administration (FDA) 










































Clozapine CLO Clozaril 1990 Novartis 
 




Risperidone RISP Risperdal 1993 Janssen  
 
Olanzapine OLA Zyprexa 1996 Eli Lilly 
 
Quetiapine QTP Seroquel  1997 AstraZeneca 
 
Ziprasidone ZIP Geodon 2001 Pfizer 
 
Aripiprazole ARI Abilify 2002 Otsuka 
 
Paliperidone PLP Travicta 2006 Janssen 
 
Asenapine  ASP Sycrest 2009 Lundbeck 
 
Iloperidone ILO Fanaptum  2009 Vanda 
 
Lurasidone LSD Latuda 2010 Sunovion 
 
Brexipiprazole BXP Rexulti 2015 Lundbeck 
 






    Figure 1.2 Chemical structures of Second Generation (Atypical)   





1.9.3.2.1 Clozapine  
 
CLO is preferred over the first generation antipsychotics in the treatment of 
schizophrenia because of its better efficacy on treatment-refractory schizophrenia, 
reduced induction of extrapyramidal side effects, restoration of prolactin levels to its 
normal state and improvement in positive as well as negative schizophrenic symptoms 
(Mauri et al., 2014). In a study conducted by Lieberman et al (Lieberman et al., 2003a), 
better efficacy of CLO over chlorpromazine was found over a period of 52 weeks in a 
first episode schizophrenic patients. CLO has also been shown to be more effective 
for treatment-resistant schizophrenia than other AAPs in a meta-analysis carried out 
by Chakoe and colleagues (Chakos et al., 2001). CLO is better than HALO and RISP 
in reducing positive symptoms (Azorin et al., 2001, Volavka et al., 2002); it is more 
effective than switching to other AAPs  (McEvoy et al., 2006) and significantly more 
effective than RISP, OLA, QUET and AMI in improving positive and negative 
symptoms (Lewis et al., 2006). Effectiveness of CLO was also shown in two of the 
largest randomized controlled clinical trials. In CUtLASS (Cost Utility of the Latest 
Antipsychotic drugs in Schizophrenia Study), a phase 2  clinical trial  CLO was found 
significantly better than other AAPs in terms of efficacy and symptoms; it  also 
improved the quality of life of schizophrenic patients. A second phase 2 trial, Clinical 
Antipsychotic Trials of Intervention Effectiveness (CATIE) also reported CLO to be 
better than other AAPs in the treatment of poorly responsive schizophrenia. However 
CLO did not show any evidence of its efficacy in first episode schizophrenia although 
it showed excellent effect in treatment-resistant schizophrenia (Naber and Lambert, 
2009, Tandon et al., 2008). Studies also showed effectiveness of CLO in controlling 
aggressive behaviour in adults as well as in children having schizophrenia (Sarkar and 
Grover, 2013, Krakowski et al., 2006). Various studies have also shown the 
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effectiveness of CLO in bipolar disorder, mania (Arafat et al., 2016), reducing 
substance abuse and decreasing suicidal risks in schizophrenic patients (Iqbal et al., 
2003). 
1.9.3.2.1.1 Mechanism of action 
 
Compared to other AAPs, CLO was found to have a greater effect in improving 
negative symptoms and cognitive deficits (Meltzer and McGurk, 1999). CLO has 
broader spectrum of receptor affinities; it not only act as an antagonist at several 
dopamine receptors (D2, D3, D4), but also on others receptors like serotonin 5HT2C, 
5HT2A, adrenergic alpha (α) receptors, muscarinic (M) and histaminergic (H) 
receptors. CLO also act as a partial agonist at D1 and 5HT1A receptor which might 
play a role in its atypicality (Mauri et al., 2014). Through Positron emission 
tomography studies in schizophrenia, it was found that CLO showed 45-50% D2 
receptor occupancy as compared to typical antipsychotics which occupied more than 
80% .This might explain the atypicality and production of less extrapyramidal side 
effects by CLO compared to typical antipsychotics (Mauri et al., 2014, Wiesel et al., 
1990). A study by Meltz and colleagues also suggested that CLO has greater D4 
receptor occupancy than D2 and this might have some effect in its atypicality (Meltzer 
and Gudelsky, 1992). Serotonin receptor also plays an important role in the 
mechanism of action of CLO. It acts on 5-HT1A, 2A, 2C, 5-HT6, and 5-HT7 
receptors. 5HT1A agonism and 5HT2A and 2C antagonism produce antipsychotic and 
improved cognitive effect. It has also been shown that increased dopamine release by 
CLO in rat prefrontal cortex might be due to 5HT1A receptor agonism (Meltzer and 








OLA is one of the common AAPs prescribed for schizophrenia. OLA, structurally and 
pharmacologically similar to CLO, is effective in treating schizophrenia, bipolar 
disorder as well as mania (Duggan et al., 2003). Compared to typical antipsychotics, 
OLA has proven to be a safer drug in terms of improvement in psychotic symptoms 
and adverse effects. It shows significantly reduced extrapyramidal symptoms along 
with decrease in prolactin levels. Chen et al reported improvement in positive 
symptoms of schizophrenic patients and decrease in prolactin levels when treated with 
OLA (Chen et al., 2009). Another study by Hartling and colleagues showed 
improvement in both positive and negative symptoms by OLA when compared with 
typical  antipsychotics (Hartling et al., 2012). Johnsen and colleagues reported that 
OLA showed better treatment adherence and longer time to discontinuation compared 
to other AAPs showing advantage of OLA over other drugs. However it caused more 
metabolic adverse effects than other AAPs (Johnsen and Jorgensen, 2008). Komossa 
and colleagues gathered data regarding comparison of OLA with other AAPs; they 
reported both CLO and OLA as efficacious in improving symptoms. These contradict 
with CATIE and CUtLASS trials which showed superiority of CLO over other AAPs 
including OLA in terms of efficacy. However Komossa and colleagues argued that the 
dose might play role in the study; CATIE and CUtLASS used a dose between 500-
600mg/day, whereas the maximum dose utilised in Komossa et al study was 
400mg/day (Komossa et al., 2010a). The efficacy of OLA over QTP, RISP and ZIP in 
terms of mental state and symptoms has been reported; however there was limited data 
showing comparison of OLA with ARI (Komossa et al., 2010a). 
 




OLA showed higher affinity to serotonergic receptors and binds to 5HT2A, 2C, 5HT3 
and 5HT6. It also binds to D2, D1, M1, H1 and  α1 and α2 receptors (Mauri et al., 
2014). Another study conducted in rats reported the role of brain derived neurotrophic 
factor (BDNF) and tyrosine kinase receptors in schizophrenia. They showed the 
restoration of BDNF and tyrosine kinase receptors by OLA. However more research 




ARI works by acting on D2, D3 and 5HT1A, 2A and 2B receptors. The unique point 
is that ARI act as a partial agonist at dopamine D2, D3 and serotonin 5HT1A receptors 
and possesses antagonistic activity at 5HT2A receptors. A study by Yokoi and 
colleagues observed no extrapyramidal side effects after giving maximum (30mg/day) 
dose of ARI in normal individuals (Yokoi et al., 2002). The exact mechanism of action 
is not known but it was suggested that ARI improves positive and negative symptoms 
of schizophrenia and has less tendency to cause extrapyramidal symptoms due to its 
partial agonist activity at D2 receptors. Because of its partial agonist activity at D2 and 
5HT1A and antagonist activity at 5HT2A receptors, it has been called a dopamine-
serotonin stabilizer (Mauri et al., 2014). In various clinical trials, ARI was compared 
with CLO, OLA, QTP, RISP and ZIP. It was reported that ARI showed similar 
efficacy but less adverse effects compared to other AAPs (Khanna et al., 2014). 
Various studies showed a range of ARI doses used, ranging from 10-20mg/day and it 
was found that doses 10-20mg/day showed greater improvement in positive and 
negative symptoms compared to placebo. This observation was further supported by 
other clinical trials such as Broad Effectiveness Trial with Aripiprazole (BETA) 
(Tandon et al., 2006) and the schizophrenia Trial of Aripiprazole (STAR). STAR was 
a 26 week randomized, multicentre trial that compared ARI with OLA, QTP and RISP 
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in terms of efficacy for the patients requiring antipsychotic medication switch;  
patients symptoms were found to improve after switching to ARI (Kerwin et al., 2007). 
ARI cause less adverse effect compared to other AAPs. In various trials ARI was 
administered in doses from 2 to 30mg/day for 6 weeks and akathisia was the only 
adverse effect observed (Stip and Tourjman, 2010). Less weight gain has also been 
reported with ARI by other studies (Stip and Tourjman, 2010, Newcomer, 2007, Kane 
et al., 2009). Because of it propensity to cause less adverse effects, ARI has become a 
more favourable drug to use as an adjunct or on its own. 
1.9.3.2.4 Risperidone 
 
RISP binds to serotonin 5HT2A, 7 and dopamine D2 receptors. It affinity to D3 and 
D4 is less than D2. It also binds to α1 and α2 adrenergic and H1 histaminergic 
receptors (Leysen et al., 1988). RISP is useful in schizophrenia and bipolar disorder 
and is effective both for positive and negative symptoms of schizophrenia (Rabinowitz 
and Davidson, 2001). According to Cochrane library database, RISP is not as effective 
as OLA but it is more effective than QTP and ZIP. RISP produced more 
extrapyramidal side effects and more prolactin when compared with CLO, OLA and 
ZIP and was also associated with more weight gain than AMI, ARI and ZIP but less 




QTP binds to serotonin 5HT2 and dopamine D2 receptors; however it has low affinity 
for D1 receptors. QTP has higher affinity to 5HT2 as compared to D2; this makes it 
more favourable to use in schizophrenia. It also bind to H1 and adrenergic α1 receptors 
and with lesser effect to  α2, serotonin 5HT1A, 2A and 2C and muscarinic receptors 
(Mauri et al., 2014). Various studies have showed less efficacy of QTP compared to 
ARI (Citrome, 2012, Shoja Shafti and Kaviani, 2015). QTP produced less 
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extrapyramidal side effects than PLP, ZIP, ARI and OLA, but produced similar levels 




AMI is dopamine D2 and D3 receptor antagonist but it shows no affinity at D1, D4 
and D5. It also has less affinity for adrenergic, serotonergic and histaminergic 
receptors. AMI also produce less extrapyramidal side effects and it was suggested that 
it bind to D2 receptors for a short time and then dissociate quickly allowing dopamine 
transmission to  follow its normal route (Seeman, 2002). On comparison with other 
AAPs, it was reported that AMI had the same efficacy as OLA and RIS but better 
efficacy than ZIP. AMI also induced less weight gain than RISP and OLA (Komossa 
et al., 2010b). 
1.9.3.2.7 Ziprasidone 
 
ZIP acts as a D2, 5HT2A, 2C and 1D receptor antagonist with greater affinity for the 
5HT2A receptor (Schmidt et al., 2001). It also acts as a partial agonist at 5HT1A 
receptor. It does not block α1 adrenergic, M1 and H1 receptors (Mattei et al., 2011). 
Various clinical trials have reported that ZIP was less effective than AMI, OLA and 
RISP however it caused less weight gain than OLA, QTP and RISP. It also cause less 
cholesterol increase compared to OLA, QTP and RISP. However ZIP caused slightly 
more extrapyramidal side effects than OLA and resulted in more prolactin release than 
QTP (Komossa et al., 2009). No doubt ZIP show slightly increased extrapyramidal 
symptoms; however this is offset by the reduced impact of ZIP on body weight and 
effect on cholinergic, muscarinic and histaminergic receptors.  Hence, this drug could 
be considered as metabolically friendly drug (Mattei et al., 2011). Another interesting 
point related to ZIP is its effectiveness in treatment-resistant schizophrenia is 
comparable to CLO. Kuwilsky et al reported that when CLO was combined with ZIP 
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or RISP, it resulted not only in the improvement in efficacy for long term but also 
improvement in CLO-associated adverse effects (Kuwilsky et al., 2010). Another trial, 
Monitoring Oral Ziprasidone as Rescue Therapy (MOZART), monitoring ZIP as an 
alternative to CLO in treatment-refractory schizophrenia reported that both CLO and 
ZIP have same efficacy. The authors suggested that ZIP was considered to be better 
compared to CLO as it caused less weight gain and less effect on cholesterol levels 
(Sacchetti et al., 2009). 
 
Newer Atypical antipsychotics  
Several newer antipsychotic drugs were approved by the US Food and Drug 
Administration (FDA) in recent times and the section below will discuss these agents 
in detail. In addition, clinical trials of various newly developed antipsychotic agents 
such as pomaglumetad methionil and bitopertin had been recently completed 




PLP is basically an active metabolite of RISP. It acts as an antagonist at D2 with 
predominant effect on serotonin 5HT2A receptors. It also has antagonistic effect on 
α1, α2 and H1 histaminergic receptors however it does not bind to muscarinic or β1 
and β2-adrenergic receptors. Various studies have reported the effectiveness of PLP 
in improving schizophrenic symptoms (Fu et al., 2014, Zhang et al., 2015). It was also 
reported to cause moderate weight gain at therapeutic dose however at higher doses it 
caused extrapyramidal side effects (Bossie et al., 2017, Dlugosz and Nasrallah, 2007).  
1.9.3.2.9 Asenapine 
 
 ASP has high affinity for serotonin receptors (5HT1A, 1B, 2A, 2B, 2C, 5HT5, 6, and 
7), α adrenergic receptors, dopamine D1-D4 receptors and histaminergic receptors but 
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show less affinity for muscarinic receptors (Bobo, 2013, Peeters et al., 2011). A 
systematic review of ASP reported its effectiveness in controlling negative symptoms 
of schizophrenia and observed that ASP cause minimal adverse effects. However this 
review did not report any extrapyramidal side effects (Hay et al., 2015). 
1.9.3.2.10 Iloperidone 
 
ILP act as an antagonist on serotonin 5HT2A, dopamine D2, D3 and adrenergic α1 
and α2 receptors. However it showed medium to low affinity for D3, 5HT1A, 2C, 
5HT6, and histaminergic H1 receptors (Mauri et al., 2014). Various clinical trials have 
reported ILP to reduce positive and negative symptoms of schizophrenia and result in 
reduced weight gain and lesser extrapyramidal side effects (Scarff and Casey, 2011, 
Potkin et al., 2008, Cutler et al., 2008). It was also reported that ILP is as efficacious 
as HALO, RISP and ZIP in reducing schizophrenic symptoms and cause less adverse 
effects, favouring its use as first-line therapy (Tonin et al., 2016). A recent trial, 
RElapse PRevention Iloperidone EVidence Evaluation (REPRIEVE),  conducted to 
evaluate the effectiveness of ILP for prevention of schizophrenic relapse reported that 
ILP was more effective than placebo in preventing relapse events in schizophrenic 
patients (Weiden et al., 2016). 
 
1.9.3.2.11 Lurasidone  
 
LSD act by antagonising dopamine D2 and serotonin 5HT2A and 5HT7 receptors. It 
also acts as partial agonist at 5HT1A and moderately acting at α receptor. It was 
reported that LSD was not as effective as CLO, OLA, AMI and RISP  in terms of 
improvement of symptoms however it was effective than HALO, QTP, ARI, ZIP and 





BXP was approved in July 2015 by the FDA for its use in schizophrenia and as an 
adjunctive therapy to antidepressants. It acts as a partial agonist at dopamine D2 and 
serotonin 5HT1A receptors. In partial agonism it binds to receptor and activates it in 
condition where dopamine activity is decrease like in depression while it blocks D2 
where high dopamine activity is there like schizophrenia. Animal data showed that 
BXP improved cognitive function by acting on the 5HT1A receptor. Various doses 
have been studied in clinical trials and it was reported in one trial that 2 and 4 mg of 
dose showed statistically significant improvement in PANSS score than placebo. 
Another trial reported 4 mg is efficacious than placebo. The common adverse effects 
related to BXP were reported to be akathisia and weight gain (Scarff, 2016a, Markovic 
et al., 2017). BXP has not been compared in detail with other AAPs. A review by 
Parikh et al reported BXP to cause less akathisia in comparison to Cariprazine (CRP); 
however BXP causes more weight gain than ARI, CPZ and ZIP (Parikh et al., 2017). 
1.9.3.2.13 Cariprazine 
 
CPZ was approved in September 2015 by the FDA. It acts as a partial agonist on D2 
and D3 receptor and serotonin 5HT1A however it acts as antagonist at 5HT2A, 2B, 
2C and 5HT7. There is minimal antagonism at histamine H1 receptors. Various trials 
on CPZ showed that in all doses studied (1.5, 3, 4.5 and 6) there was improvement in 
PANSS score. The most common adverse effects associated with CPZ were akathisia, 
extrapyramidal symptoms and headache. More clinical trials are required to 
characterise the CPZ profile (Scarff, 2016b). 
 
1.9.3.2.14 Long acting Injectable (LAI) antipsychotics 
 
Long acting injectable (LAI) are available for both typical antipsychotics such as 
HALO, Fluphenazine, Flupenthixol and Zuclopenthixol and AAPs such as OLA, ARI, 
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PLP and RISP. The purpose of LAI is to allow the physician to shift to long acting 
when non adherence occur with oral tablets and also to make the treatment easier. 
Meta-analysis showed effectiveness of LAI over oral antipsychotics in terms of 
relapse prevention (Leucht et al., 2011); however other studies showed no change in 
relapse prevention with both routes of administration (Fusar-Poli et al., 2013, 
Kishimoto et al., 2014). In terms of adverse effects, LAI proved to be worse than oral 
formulation. It was reported that LAI of OLA caused worsening of psychosis along 
with weight gain, extrapyramidal side effects and post injection syndrome. These 
adverse effects were also found to be associated with RISP and PLP. The most 
dangerous effect reported was leading to suicide and it was reported to be in patients 
taking RISP (Gentile, 2013). Further studies are required to explore more safety 
profiles of these LAI antipsychotics. 
1.9.4 First generation vs. second generation antipsychotics 
 
For the past few years, research focussed more on AAPs which have better therapeutic 
and less adverse effects compared to typical antipsychotics. Patient severities of 
schizophrenia are assessed by usually 2 scales, Brief Psychiatric Rating Scale (BPRS) 
and Positive And Negative Syndrome Scale (PANSS). Both provide overall 
psychopathology along with severity of positive and negative symptoms. A 
randomized controlled clinical trial reported effectiveness of AAPs over typical 
antipsychotics in terms of positive and negative symptoms. Depression, cognition and 
anxiety were also improved by use of AAPs (Tandon et al., 2008). Various other 
studies also reported effectiveness of AAPs over typical antipsychotics (Davis et al., 
2003, Geddes et al., 2000). Meta-analysis of randomized controlled clinical trials by 
Leucht and colleagues comparing AAPs to HALO (typical antipsychotic) also showed 
effectiveness of all AAPs in improvement of schizophrenic symptoms over HALO 
(Leucht et al., 1999). Due to the greater efficacy and lower risk of motor adverse 
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effects, AAPs is becoming the gold standard for the treatment of schizophrenia 
compared to typical antipsychotics (Tandon and Fleischhacker, 2005). 
1.10 Atypical antipsychotic-induced adverse effects 
Compared to typical antipsychotics, AAPs show less extrapyramidal adverse effects; 
however, long term uses of AAPs are associated with potentially serious metabolic 
adverse effects. AAPs cause weight gain and associated metabolic disorders such as 
insulin resistance, impaired glucose tolerance, dyslipidemia and essential 
hypertension, all risk factors for the development of cardiometabolic disease 



















Table 1.3 Definition of metabolic syndrome (Sulistiowati and Sihombing, 2016, 
Huang, 2009) 
 NCEP-ATP III 
(2005 revised) 
WHO (1998) EGIR (1999) 1DF 
(2005) 
Criteria Any three of the five 
criteria below 
Insulin resistance (IGT, 
IFG,T2D or evidence of IR) 
or diabetes plus  
two of five criteria below 
Hyperinsulinemia 
(plasma insulin >75 
percentile) plus two 
of the four criteria 
below 
Obesity 




Obesity Waist Circumference:  
> 40 inches (M), 
> 35 inches (F) 
Waist/hip ratio: 
 >0.90 (M),                    
>0.85 (F) or  














Insulin resistance Insulin resistance Fasting 
glucose 
≥100mg/dl 
Dyslipidemia TG ≥150mg/dl TG ≥ 150mg/dl or  



















Hypertension >130mmHg systolic 
or  
>85mmHg diastolic 
≥ 140/90 mmHg ≥140/90mmHg >130mmH
g Systolic 
or  
> 85 mmHg 
diastolic 





NCEP-ATP III (National Cholesterol Education Program-adult treatment plan III) 
EGIR: European group for study of insulin resistance  
IDF: International diabetes foundation  
IGT: Impaired glucose tolerance; IFG: impaired fasting glucose: T2D: type 2 diabetes 
 IR: Insulin resistance, M: male; F: female, TG: Triglycerides 
HDL-C: High density lipoprotein-cholesterol 
≥ greater than or equal;  < less than 
 
Numerous studies including systematic reviews and meta-analysis showed that among 
AAPs, CLO and OLA appears to be associated with greater risk; QTP, RISP, ILP and 
PLP intermediate risk; while ARI, AMI and ZIP are associated with smaller risk of 
49 
 
metabolic syndrome (Table 1.4) (Smith et al., 2008, Papanastasiou, 2013, Bak et al., 
2014, De Hert et al., 2007, Newcomer, 2005, Simon et al., 2009). The details of 
various characteristics of metabolic syndrome will be discussed in following sections. 
       Table 1.4 AAPs and risks for common metabolic abnormalities  




CLO + + + + + + + + + 
OLA + + + + + + + + + 
QTP + + + + + + 
RISP + + + + + 
ILP + + + + 
PLP + + + + 
ASP + + + 
ARI ± + + 
AMI ± + + 
LSD ± + + 
ZIP ± + + 
 
+ + +     Strong effect 
+ +        Moderate effect 
+           Less effect 
±           Mixed result 
 
 
1.10.1 AAP-induced weight gain 
According to WHO, a body mass Index (BMI) (measured by weight in kilogram 
divided by square of height in meters) ≥25kg/m2 is considered as overweight while 
≥30kg/m2 BM1 as obese. In the context of abdominal obesity, it is related to waist 
circumference >102 cm in men and >88cm in women. The prevalence of weight gain 
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ranges from 6% to 55%; these studies also suggested OLA as the main drug causing 
obesity (Nasrallah, 2008, Curtis et al., 2011, Tsan et al., 2012). Among AAPs, ZIP is 
considered to be the drug which causes the least weight gain while CLO and OLA are 
considered more likely to cause drug-induced weight gain. Various studies showed 
massive weight gain of 12.4 kg in CLO-treated schizophrenic patients while OLA 
showed 12 kg (Nasrallah, 2008, Nemeroff, 1997, Haddad and Wieck, 2004). A study 
by Haupt and colleagues showed that ZIP caused weight gain of only 1kg while RISP 
and QTP showed 2-3kg in first year of treatment (Haupt, 2006). A study by Nasrallah 
however, showed weight loss by ZIP (Nasrallah, 2008). ARI showed varying results 
of weight gain depending upon the BMI; in patients with a BMI of greater than 
27kg/m2, ARI showed weight loss instead of weight gain (Haddad, 2005). In other 
study in patients with a BMI less than 23kg/m2, ARI showed a weight gain of 2.6kg 
(Nasrallah, 2008) (Figure 1.3). 
 
 
Figure 1.3 One year weight gain data in patients treated with AAPs (modified 




The CATIE Schizophrenia trial which investigated the 10-year risk for coronary heart 
disease (CHD) in various AAP-treated patient groups identified that different AAPs 
confer varying levels of CHD risk with OLA being the most strongly associated with 
increased CHD risk (Swartz et al., 2008). CATIE trial was an 18-month, randomized 
controlled trial and showed comparison of 4 AAPs, OLA, QTP, RISP, ZIP and typical 
antipsychotic, perphenazine in 1493 schizophrenic patients. It showed that OLA, QTP, 
RISP and ZIP were associated with a weight gain/loss of +0.9kg/month, 
0.23kg/month, 0.18kg/month and -0.14kg/month respectively. This showed that 
among the AAPs used, OLA caused the greatest weight gain with most adverse 
metabolic effects while ZIP caused the least adverse effects and weight gain (Swartz 
et al., 2008). Perphenazine no doubt was comparable to AAPs in efficacy but was 
discontinued due to high extrapyramidal adverse effects. However CLO, included in 
phase 2 of CATIE trial, was reported to be more effective drug for schizophrenic 
patients with a poor symptoms response to previous antipsychotic drugs although it 
was also associated with metabolic adverse effects (Swartz et al., 2008). European 
First-Episode Schizophrenia Trial (EUFEST), another 12-month clinical trial, 
conducted in 14 countries in 498 patients aged 18-40 years with first episode 
schizophrenia, compared HALO against AMI, OLA, QTP and ZIP. Patients who 
received OLA gained more weight (1.16kg/month) compared to QTP (0.88kg/month), 
AMI (0.81kg/month) and ZIP (0.4kg/month) (Kahn et al., 2008). CAFÉ (Comparison 
of Atypicals for First Episode) trial, a 52 week comparison of AAPs including OLA, 
QTP and RISP in schizophrenic patients, reported that OLA-treated patients showed 
more weight gain (average 1.76kg per month) compared to RISP (1.28kg per month) 
and QTP (1.29kg per month) (Patel et al., 2009). Several other studies also found CLO 
and OLA to produce the highest degree of metabolic adverse effects while QTP, RISP 
and AMI show intermediate effects; and ARI and ZIP are considered to cause the least 
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adverse effects (Kluge et al., 2009, Wang et al., 2013, Young et al., 2015, Newcomer, 
2007).  
1.10.2 AAP-induced hyperlipidaemia 
The prevalence of hyperlipidaemia among AAP-treated patients was reported to be 
between 15-53% compared to general population (Mackin et al., 2007, Hagg et al., 
2006, Young et al., 2015). Various studies showed that CLO and OLA cause high 
triglyceride and cholesterol levels in schizophrenic patients compared to RISP, AMI 
and ZIP (Ucok and Gaebel, 2008, Wu et al., 2006, Rettenbacher et al., 2006). 
Comprehensive literature review by Newcomer showed increase in cholesterol levels 
in schizophrenic patients after using CLO and OLA (Newcomer, 2005). CATIE trial 
also showed increased lipid levels after using OLA while ZIP produced less effect on 
lipids (McEvoy et al., 2006). Preclinical studies also showed increased lipid levels 
after administration of CLO and OLA (Boyda et al., 2010, Cooper et al., 2008, Minet-
Ringuet et al., 2007). Increase in levels of triglycerides and cholesterols were reported 
in adult female rats after 48hr of single intraperitoneal injection of CLO and OLA 
(Jassim et al., 2012). Kalinichev and colleagues showed increased levels of free fatty 
acids in female rats after administration of OLA (Kalinichev et al., 2005). An 
epidemiological study carried out in Japan reported association of OLA with 
hyperlipidemia in AAP-treated patients compared to RISP, QTP, PLP, CLO and 
Zotepine while ARI was least associated with change in lipid levels (Takeuchi et al., 
2015). Goncalves and colleagues showed that CLO and OLA caused more damage to 
lipid levels followed by RISP and QTP while ZIP and ARI were least associated with 
change in lipid levels (Goncalves et al., 2015). 
1.10.3 AAP-induced hyperglycaemia 
AAPs can increase the risk of hyperglycaemia ultimately leading to diabetes mellitus 
or diabetic ketoacidosis. The prevalence of high glucose in schizophrenic patients 
receiving AAPs is reported to be 24.6% (Ko et al., 2013, Young et al., 2015). A meta-
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analysis by Jin and colleagues showed increased glucose levels developed within 1-3 
months of use of AAPs (Jin et al., 2002); this was supported by Balf et al who also 
found hyperglycaemia to develop  within 3 months use of CLO, OLA, QTP and RISP 
(Balf et al., 2008). Various studies have also associated CLO and OLA with increase 
in glucose levels, glucose intolerance and insulin resistance compared to other AAPs 
(Newcomer et al., 2002, Ober et al., 1999, Goncalves et al., 2015). CLO and OLA 
were also associated with increased risk of diabetic ketoacidosis (DKA) and diabetes 
(Newcomer, 2005). Though DKA usually develop in type 1 diabetes, reports have 
shown incidence of DKA in patients receiving AAPs especially CLO and OLA (Balf 
et al., 2008). FDA adverse event reporting system database (FAERS) mentioned OLA 
as the most notorious drug causing hyperglycaemia among all AAPs (Kato et al., 
2015). Meta-analysis by Rummer-Kluge also showed strong association of CLO and 
OLA in causing hyperglycaemia compared to various other AAPs (Rummel-Kluge et 
al., 2010). Interestingly, various studies have also reported reversal of glucose levels 
to nearly normal level by switching to RISP, ARI or ZIP. In these studies, patients 
with schizophrenia on CLO and OLA showing metabolic adverse effects were 
included. Clinical diagnosis was evaluated using CGI-S and PANSS scale. It was 
reported that switching to RISP, ARI or ZIP for 4-6 months not only decrease body 
weight but also decreased glucose and cholesterol levels to nearly normal levels 
(Montes et al., 2007, Wani et al., 2015, Weiden et al., 2003, Bernardo et al., 2011).  
1.10.4 AAP-induced cardiovascular disease 
The prevalence of CVD in AAP-treated schizophrenic patients is 1.5-2 times higher 
than general population (Kelly et al., 2010). It was reported that AAPs contribute to 
the development of CVD and stroke by increasing the risks such as hyperglycaemia, 
weight gain and hyperlipidaemia. Daumat and colleagues assessed the antipsychotic 
drugs effects used in CATIE on participants’ 10-year coronary heart disease (CHD) 
risk. It was found that risk for CHD differs significantly between antipsychotic agents, 
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with OLA showing the greatest elevation in CHD risk (Daumit et al., 2008). The 
prevalence of hypertension, an independent risk factor for CVD, was reported to be 
16-49% in schizophrenic patients treated with AAPs (Ko et al., 2013, Young et al., 
2015) with CLO the most associated (Henderson et al., 2004, Gupta and 
Rajaprabhakaran, 1994, George and Winther, 1996). Study by Woo and colleagues 
showed CLO but not OLA cause hypertension (Woo et al., 2009). The CATIE trial 
also did not show any change in blood pressure in all of the AAPs used in 
schizophrenic patients (Boden et al., 2013). However, Jerel et al reported ZIP to be 
involved in hypertension (Jerrell et al., 2010). Prolongation of QTc interval is also an 
important adverse effect. It may leads to torsade de pointes; a ventricular arrhythmia 
which if not treated leads to ventricular fibrillation and then cardiac arrest. In CATIE 
trial there was no effect on QTc interval among OLA, RISP, QTP and ZIP. However 
in one clinical trial comparing sertindole and ZIP, QTc was reported to be increased 
by sertindole (Glassman and Bigger, 2001). This contradicts with another trial where 
ZIP was reported to prolong the QTc interval in schizophrenic patients (Wilton et al., 
2001), an observation supported by Khasawneh and Shankar (Khasawneh and 
Shankar, 2014). Myocarditis, a rare adverse effect, was reported to develop in CLO-
treated schizophrenic patients (Khasawneh and Shankar, 2014). The data regarding 
association of AAPs with myocardial infarction (MI) have been inconsistent and 
conflicting. Some studies reported an increased risk of MI associated with AAPs 
(Huang et al., 2017, Enger et al., 2004) whereas others found no association (Jerrell 
and McIntyre, 2007, Nakagawa et al., 2006). Arteriosclerosis is also considered as an 
important risk factor leading to CVD. Hypertension and other diseases like diabetes 
increase the stiffness of arteries. A study by Findikli and colleagues reported increased 
arterial stiffness in AAP-treated schizophrenic patients (Findikli et al., 2016). Risk 
factor such as remnant-like lipoprotein particles cholesterol (RLP-C) also play 
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important role in development of CVD. A study by Nagamine, comparing effects of 
RISP and OLA on RLP-C in schizophrenic patients showed more RLP-C levels by 
OLA compared to RISP. It is suggested that RLP-C may take up by macrophages in 
arterial wall where it form foam cells leading to formation of atherosclerotic plaques 
(Nagamine, 2008). It has already been demonstrated that RLP-C promote 
arteriosclerosis through formation of atherosclerosis plaque due to increased uptake 
by macrophages, impaired vascular endothelial cell function, increased platelet 
aggregation and enhanced monocyte adhesion to vessel endothelium (Tanaka, 2004). 
It was proposed that atherosclerosis in coronary artery might lead to  arteriosclerosis 
leading to CHD (Nagamine, 2008). Because of some confusing results among AAPs 
related to cardiovascular complications, long-term clinical trials are required to 
characterise cardiovascular complications caused by AAPs. 
Other minor adverse effects related to AAPs are increased prolactin secretion, 




1.10.5 Mechanisms behind AAP-induced metabolic toxicity 
  
1.10.5.1 Dyslipidaemia 
The absolute mechanism for causing dyslipidaemia in AAP-treated individuals is not 
fully understood, however, there is clear indication that obesity leads to the 
dyslipidaemia that is characterised by increased triglycerides, cholesterol, LDL and 
decreased HDL levels. One of the mechanisms postulated is a direct effect of AAPs 
on triglycerides. These drugs either stimulate the hepatic triglyceride production and 
secretion or may cause inhibition of the lipoprotein lipase enzyme which is necessary 
for hydrolysis of the triglycerides (Minet-Ringuet et al., 2007). Various studies have 
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suggested a potential role for transcription factor, sterol regulatory element binding 
proteins (SREBPs), which regulates lipids and cholesterol synthesis. It was suggested 
that AAPs upregulate the SREBP-1 gene in liver and adipose tissue and increased the 
synthesis of triglycerides (Minet-Ringuet et al., 2007, Ferno et al., 2009, Jassim et al., 
2012). According to other studies, insulin resistance might play an important role in 
mechanism of dyslipidaemia (Yan et al., 2013, Goncalves et al., 2015). On insulin 
resistance, body naturally act and produce compensatory insulin from pancreas which 
leads to a condition called hyperinsulinemia. Physiologically, insulin regulates the 
processes that take place in triglyceride metabolism. In the liver, insulin blocks 
apolipoprotein (Apo) B release which is an important component of very low density 
lipoprotein (VLDL) and helps in the formation of lipids. Also, it activates SREBP1c 
which increase the transcription of genes necessary for fatty acid and triglyceride 
synthesis (Horton et al., 2002). When insulin resistance develop, there will be more 
release of ApoB which will result in more lipogenesis and, with the help of more 
ApoB, cause increased release of VLDL ultimately leading to increased plasma 
triglyceride levels (Lauressergues et al., 2010). Insulin has blocking action on lipolysis 
by acting on hormone sensitive lipase; therefore insulin resistance results in increased 
lipolysis leading to triglyceride breakdown and release of free fatty acids (FFA) into 
the circulation from adipose tissue. These FFA transport to liver and cause production 
of more VLDL and then the same cycle starts all over again (Adiels et al., 2005). It 
was also proposed that AAPs causes inhibition of enzymes involved in cholesterol 
synthesis leading to compensatory increase in SREBP2 which in turn trigger synthesis 
of genes involved in cholesterol synthesis. This was confirmed in studies where CLO 
and OLA increased the production of cholesterol in liver and adipose tissue (Zhang et 





1.10.5.2 Lipid accumulation  
 
1.10.5.2.1 Neuroreceptors effects 
The molecular mechanism of lipid accumulation by AAPs is not fully understood, 
however various mechanisms has been postulated which are discussed below. 
It was proposed that AAPs act centrally and cause hyperphagia by acting as inhibitor 
at various receptors especially dopamine, histamine and serotonin (Goncalves et al., 
2015). Serotonin receptor functions physiologically in a manner that it regulates food 
intake and increase satiety. By blocking 5HT2C receptor, it prevents satiety and leads 
to hyperphagia. This was confirmed in preclinical models where rodents were given 
5-HT and it decreased intake of food in rodents (Balt et al., 2011). Study by Coccurello 
and Moles also showed that 5HT2C knock out-mice resulted in increased weight gain 
and feeding (Coccurello and Moles, 2010). Various studies mentioned that all AAPs 
have some degree of D2 receptor occupancy however the role of dopamine receptors 
in the context of food regulation is still controversial. Due to varying degree of drug 
effect on dopamine receptors, the result is confusing. However it was reported that D2 
antagonism can affect eating habit (Panariello et al., 2011, Reynolds and Kirk, 2010). 
Preclinical studies on mice also showed involvement of H1 receptor in weight gain. 
Study by Masaki and colleagues showed that HI receptor knock out cause mice to eat 
more. However detailed studies are required to understand the absolute role of H1 
receptor in weight gain (Masaki et al., 2001, Masaki et al., 2004). 
Lipid accumulation and weight gain might occur due to changes in weight regulation 
hormones such as insulin and leptin. Leptin, apart from its peripheral action, acts on 
leptin receptor in hypothalamus and regulate food intake. Hyperleptinemia and leptin 
resistance cause  increased appetite and weight gain (Melkersson and Dahl, 2004). The 
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role of insulin resistance and leptin will be discussed in more detail in their respective 
sections. 
 
1.10.5.2.2 Peripheral effects 
It was reported that weight gain can develop independently of food intake (Vestri et 
al., 2007). The proposed mechanism might be a direct effect of AAPs on the biology 
of peripheral tissues especially adipose tissue. Various in vitro studies have proposed 
an increase in lipogenesis and decrease in lipolysis as a mechanism by which AAPs 
caused lipid accumulation (Minet-Ringuet et al., 2007, Vestri et al., 2007). It was 
reported that CLO and OLA increase the differentiation of the preadipocytes which 
leads to triglyceride accumulation (Hemmrich et al., 2011). Ferno and colleagues 
reported anti-lipolysis as a mechanism causing triglyceride accumulation by AAPs, 
especially CLO, OLA, QTP and RISP (Ferno et al., 2009). Various in vitro 
(preadipocyte cell line (Vestri et al., 2007, Yang et al., 2007, Tsubai et al., 2017) and 
primary human adipocyte (Hemmrich et al., 2006, Pavan et al., 2010, Sertie et al., 
2011)) studies reported that CLO and OLA have stimulating effect on adipogenesis 
which cause weight gain. 
1.10.5.3 Insulin resistance 
Adipose tissue is present in multiple areas throughout the body. Adipose tissue is not 
only considered as an energy storage depot but also act as endocrine organ to release 
various hormones and cytokines which are involved in insulin resistance. The 
adipocytes in adipose tissue store lipids as triglycerides in a large lipid droplet which 
push the nucleus to one side. One of the functions of insulin is to regulate uptake of 
glucose and convert into glycogen and /or triglycerides in muscle and adipose tissue. 
Insulin also increase the activity of lipoprotein lipase in the adipose tissue to get the 
lipoprotein clear from plasma. It also inhibits the function of hormone sensitive lipase 
in adipocytes which block the release of free fatty acids from adipocytes (Goncalves 
59 
 
et al., 2015, Saltiel and Pessin, 2002). Insulin after binding to its receptor, insulin 
receptor (IR), phosphorylates its substrate called insulin receptor substrate (IRS) 
which further phosphorylates several substrates. In the context of glucose regulation, 
phosphorylated IRS activates phosphoinositide 3-kinase (P13K) pathway activating 
the glucose transporter 4 and translocate it to the cell membrane where its function is 
to transport glucose into the cells. Insulin also has modulatory role on the activity of 
glucose metabolism enzymes (pyruvate kinase and hexokinase) (Correll et al., 2011).  
 Shulman and Niswender proposed that increase fatty acid levels may act on 
serine/threonine amino acid residues on IRS which ultimately make P13K unable to 
activate glucose transport. This leads to insulin resistance though production of insulin 
is normal from pancreas (Shulman, 2000, Niswender and Schwartz, 2003). Study by 
Morino and colleagues also reported serine phosphorylation of IRS-1 as a mechanism 
that leads to insulin resistance (Morino et al., 2008). Various in vitro studies carried 
out in neuronal, L6 and 3T3-L1, reported glucose uptake blockade by CLO, RISP and 
fluphenazine proposing that AAPs blocked glucose uptake transporter protein 
resulting in insulin resistance (Goncalves et al., 2015, Vestri et al., 2007). It was also 
reported that AAPs caused decrease in GLUT4 mRNA expression which leads to 
decreased movement of glucose transporter to the cell surface (Jassim et al., 2012). 
Another proposed mechanism is direct action of CLO and OLA on pancreatic beta 
cells; these drugs affect the physiological activity of pancreatic cells leading to 
hyperinsulinemia and insulin resistance (Reynolds and Kirk, 2010, Best et al., 2005, 
Melkersson et al., 2000). Various other studies showed that AAPs especially OLA 
caused increase in insulin secretion but decreased insulin sensitivity in response to 
hyperglycaemia leading to insulin resistance (Caballero, 2003, Almeras et al., 2004, 
Newcomer et al., 2002). Various processes like weight gain, inflammation, oxidative 
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stress, hyperglycaemia and hyperlipidaemia might act indirectly leading to insulin 
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1.10.5.4 Oxidative stress and mitochondrial toxicity 
 
Oxidative stress in cells cause the production of molecules, known as reactive oxygen 
species (ROS) which have important role in the pathology of cells and cause cell injury 
or apoptosis. Preclinical studies using CLO reported decrease in antioxidant enzyme 
levels like superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and 
catalase (CAT) while plasma malondialdehyde (MDA) levels were increased (Zhang 
et al., 2006, Agostinho et al., 2007). Study by Reinke et al  in rats reported association 
of CLO in causing more oxidative damage compared to OLA (Reinke et al., 2004). 
Increased levels of antioxidant enzyme, superoxide dismutase in CLO-treated blood 
samples of patients have also been reported which may suggest that AAPs act by 
increasing ROS in cells causing metabolic toxicity (Contreras-Shannon et al., 2013).  
 Mitochondrial dysfunction is another mechanism suggested to cause metabolic 
adverse effects. Mitochondria play an important role in synthesizing adenosine 
triphosphate (ATP) through electron transport and oxidative phosphorylation. AAPs 
may act by disturbing the key metabolic enzymes of mitochondria. An in vitro study 
using neuroblastoma and lymphoblastic cells from schizophrenic patients reported 
alteration in mitochondrial functions by CLO-induced oxidation of mitochondrial 
proteins. The mitochondrial proteins are important for energy metabolism and 
disturbances in these proteins could result in metabolic toxicity. The oxidized proteins 
which were affected are enzymes such as pyruvate kinase and maleate dehydrogenase 
(Contreras-Shannon et al., 2013, Baig et al., 2010). Preclinical rat and mice brain 
studies also showed changes in mitochondrial functions (dysregulation of ATP and 
metabolism) and protein oxidation on using AAPs (Streck et al., 2007, Ji et al., 2009).  
1.10.5.5 Inflammation  
Mitochondrial dysfunction and ROS might lead to inflammatory state of the tissue. It 
has been documented that ROS may play a role in the production of several pro-
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inflammatory cytokines (Bulua et al., 2011). In diabetic and obese patients, 
inflammatory cytokines like IL-6, IL-1β, monocyte chemoattractant protein (MCP) 
and TNF-α have been found to be elevated in their serum (Salminen et al., 2012, 
Lowell and Shulman, 2005). Contreras and colleagues, using 3T3-L1 preadipocyte 
and monocyte cell lines, reported increased levels of proinflammatory cytokines such 
as IL-2, MCP-1, IL-12p70, granulocyte monocyte colony stimulating factor (GM-
CSF) and IL-6 when treated with CLO (Contreras-Shannon et al., 2013). This was 
further strengthened by another group of researchers who reported increased 
proinflammatory cytokines by AAPs in primary human adipocytes treated with CLO. 
These raised proinflammatory cytokines, especially MCP-1, could infiltrate 
monocytes and macrophages into adipose tissue which further increase the release of 
inflammatory mediators from the adipose tissue (Sarvari et al., 2014). Various clinical 
studies involving AAPs showed increased levels of inflammatory cytokines such as 
IL-10, IL-15, IL-1β, IL-17, IL-18 as well as increased leptin and decreased adiponectin 
secretion (Klemettila et al., 2014, Leonard et al., 2012, Goncalves et al., 2015). An 
important instigator of the inflammatory response to obesity is adipose tissue. It is now 
well recognised that adipose tissue is not only a fat storage depot but also secretes 
hormones, cytokines and chemokines that can function in an endocrine or a paracrine 
fashion. It has been reported that, more than 40% of the total adipose tissue cell content 
from obese rodents and humans may be composed of macrophages. These 
macrophages, on activation released proinflammatory cytokines which can function 
in a paracrine and endocrine fashion to cause decreased insulin sensitivity (Olefsky 






1.11 Role of adipokines in AAP-induced metabolic toxicity 
 
Adipose tissue secretes biologically active adipokines, chemokines and hormone like 
factors. Abnormal function of these adipokines may lead to obesity, weight gain and 
metabolic toxicity (Balistreri et al., 2010). 
1.11.1 Adiponectin 
 
Adiponectin is an important hormone secreted by adipose tissue. Adiponectin also 
called as adipocyte complement-related protein of 30kDa (ACRP30 or AdipoQ). It 
modulates the pathway involving carbohydrate and lipid metabolism. It increases fatty 
acid oxidation while decreasing glucose production (Bartoli et al., 2015a, Shah et al., 
2008a). Adiponectin has insulin sensitizing, anti-atherosclerotic and anti-
inflammatory properties (Yamauchi et al., 2001). It act on its receptors ADIPOR1/2 
and activates adenosine monophosphate (AMP)-dependent protein kinase which 
increase fatty acid oxidation, suppress liver gluconeogenesis and increase glucose 
uptake in liver (Kwon and Pessin, 2013). Arita and colleagues has reported decrease 
adiponectin levels in obese subjects compared to non-obese individuals (Arita et al., 
1999). In a case control study, Lindsay and colleagues showed that individuals with 
less adiponectin levels had less insulin sensitivity and were more prone to develop 
T2DM (Lindsay et al., 2002). Kubota et al reported that adiponectin deficient mice 
showed hyperglycaemia and insulin resistance (Kubota et al., 2002). Maeda and 
colleagues reported insulin resistance with reduced P13 kinase activity in adiponectin 
deficient mice; interestingly, viral mediated adiponectin expression improved the 
insulin resistance and PI3K activity (Maeda et al., 2002). In a recent study, decrease 
in adiponectin levels were showed by CLO in an in vitro preadipocyte 3T3-L1 cell 
model (Tsubai et al., 2017). Meta-analysis by Bartolie and colleagues showed that 
adiponectin levels are linked with metabolic abnormalities. It was reported that 
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schizophrenic patients taking AAPs had lower levels of adiponectin which clearly 
showed correlation of adiponectin with insulin resistance and metabolic abnormality. 
It was further showed by Bartoli and colleagues that CLO and OLA but not RISP 
showed reduced levels of adiponectin (Bartoli et al., 2015b). It was suggested that 
adiponectin might act by directly disturbing hormonal pathways of energy 
homeostasis which could lead to insulin resistance and metabolic toxicity without 
weight gain. Decrease in adiponectin was showed in patients taking CLO and OLA; 
however it was reported that OLA has greater influence on adiponectin secretion 
compared to CLO (Lu et al., 2015). CATIE trial also showed decrease in adiponectin 
levels in schizophrenic patients taking AAPs (Swartz et al., 2008). 
Although absolute mechanism of adiponectin increasing insulin sensitivity is not 
known, it was postulated that adiponectin increased the fatty acid oxidation through 
activation of AMP-activated protein kinase (AMPK) and peroxisome proliferator–
activated receptor (PPAR)-α. This AMPK activation, along with increased effect on 
fatty acid oxidation, triggers a series of reactions which increase the uptake of glucose 
in muscle cells. Muscle cells then convert this glucose into lactate production resulting 
in a reduction in liver gluconeogenesis triggering more uptake of glucose from plasma. 
Decreased gluconeogenesis in liver, decreased glucose levels in plasma and increased 




Leptin is an adipocyte specific hormone released by white adipose tissue. The main 
function of leptin is to regulate energy balance, suppressing food intake leading to 
weight loss by acting on the hypothalamus (Rocha and Folco, 2011). However studies 
showed that leptin is not only involved in appetite control but it is capable to act as a 
metabolic and neuroendocrine hormone (Considine et al., 1996). It regulates glucose 
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metabolism, reproduction, haematopoiesis and immune system (Wauters et al., 2000). 
It is suggested that leptin modulate the release of insulin and thus control its secretion. 
This was reported in a study where leptin was given to normal fed mice which resulted 
in decrease in insulin levels while glucose levels increased (Kulkarni et al., 1997). 
Leptin levels in patients using AAPs is somewhat confusing as various studies showed 
mixed results; some studies mentioned higher levels of leptin  (Hosojima et al., 2006, 
Ak et al., 2013, Potvin et al., 2015) while others showed no change in the levels 
(Kivircik et al., 2003, Tanaka et al., 2008). A study showed increase in leptin levels in 
diet-induced weight gain patients compared to lean individuals (Caro et al., 1996). The 
proposed mechanism could be leptin resistance as normally hyperleptinemia could 
cause decrease in weight gain. Study by Potvin and colleagues reported that serum 
leptin levels showed 318% increase in obese patients compared to non-obese while in 
cerebrospinal fluid (CSF) the concentration was only 30% which  means enough leptin 
couldn’t transport in obese subjects suggesting development of leptin resistance 




IL-6 is a cytokine released by B cells, T cells, adipocytes  and monocytes and are 
involved in inflammatory processes and in metabolic regulation (Scheller et al., 2011). 
It has been postulated that IL-6 has a dual role which depends on the tissue and 
metabolic state. It was proposed that during exercise, skeletal muscle releases IL-6 
which block the TNF-α production which is known to have role in insulin resistance 
and atherosclerosis.  It also helps in the uptake of glucose during exercise in skeletal 
muscle providing glucose to the exercising muscles (Starkie et al., 2003, Makki et al., 
2013). In adipose tissue and liver, IL-6 acts as a proinflammatory factor that causes 
insulin resistance. It was suggested that IL-6 cause insulin resistance by upregulating 
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suppressor of cytokine signalling 3 (SOCS3) which act on IRS1, a mediator of the 
insulin signalling pathway, and blocks its phosphorylation. It was also suggested that 
IL-6 might have role in dysregulation of fatty acid metabolism thereby leading to 
insulin resistance  (Makki et al., 2013). IL-6 levels have been found to be increased in 
obese and diabetic patients having metabolic syndrome and insulin resistance 
(Klemettila et al., 2014, Marques-Vidal et al., 2013). Result from CATIE trial also 
reported elevated levels of IL-6 in patients taking antipsychotic drugs (Mori et al., 
2015). In various clinical studies CLO treatment showed increase in IL-6 levels 
(Klemettila et al., 2014, Kluge et al., 2009, Pollmacher et al., 2000); however some 
studies have also showed a decrease (Sugino et al., 2009, Lu et al., 2004) or no change 
in IL-6 levels (Roge et al., 2012, Hemmrich et al., 2011) in schizophrenic patients. 
 
1.11.4 Tumour Necrosis Factor-alpha 
 
TNF-α was identified as cytotoxic substance in mice serum, which was infected with 
Bacillus Calmette-Guerin, as it induce haemorrhagic necrosis (Carswell et al., 1975). 
TNF-α was produced by monocytes, macrophages, muscle cells and adipocytes. 
Various roles have been documented for TNF-α in growth promotion, cytotoxicity, 
inflammation, metabolism and immune responses (Bradley et al., 2008). Hotamislgil 
and Spiegelman proposed association of TNF-α with obesity and insulin resistance 
(Hotamisligil and Spiegelman, 1994). Various mechanisms have been proposed for 
TNF-α to cause insulin resistance which includes glucose uptake blockade, 
downregulation of GLUT4 mRNA in adipocytes and impairment of insulin receptor 
and IRS-1 phosphorylation (Stephens et al., 1997, Hotamisligil et al., 1994, 
Hotamisligil et al., 1995). Various studies reported increase in TNF-α levels after 
treatment with AAPs showing its association with metabolic toxicity (Victoriano et 




1.11.5 Other Adipokines 
 
 There are other adipokines which are released by adipocytes but their role in AAP 
induced metabolic toxicity is still not clear. These include, resistin, ghrelin, adipsin, 
apelin, visfatin, vaspin, omentin, lipocalin, retinol binding protein, angiopoietin-like 
protein 2, chemerin,  MCP-1 and plasminogen activator inhibitor (PAI)-1 (Balistreri 
et al., 2010, Kwon and Pessin, 2013, Makki et al., 2013). 
 
1.12 Adipose tissue 
 
There are three types of adipose tissue: white adipose tissue (WAT), brown adipose 
tissue (BAT) and, beige adipose tissue. WAT consist of adipocytes with large lipid 
droplet (unilocular cells) which push the other organelles to the periphery. Its major 
function is regulation and storage of energy in the form of triglycerides. BAT consists 
of smaller lipid droplets (multilocular cells) and many mitochondria which give 
brownish colour. Its function is thermogenesis and generation of heat (Seale et al., 
2009). Beige adipocytes are part of WAT which on stimulation acquire phenotype 
similar to brown adipocytes. WAT are present mostly in adults, where majority is 
present under the skin called as subcutaneous adipose tissue while the other is 
deposited around viscera such as mesenteric, perirenal, omental, mediastinal and 
pericardial while BAT is present mostly in infants but evidence showed existence of 
BAT in adults as well. They are present mainly in supraclavicular, suprarenal, 
interscapular and  around aorta  (Nedergaard et al., 2007). Adipose tissue consist of 
preadipocytes, adipocytes, fibroblasts, inflammatory cells and mesenchymal stem 
cells (Gustafson et al., 2007). Adipogenesis involves a highly complex but organised 
system of gene expression. Understanding of complexity of adipogenesis is very 
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important which also help in development of new strategies for improving adipose 
tissue related diseases such as metabolic toxicity (Lowe et al., 2011). 
1.12.1 Adipocyte stem cells 
 
Green and Kehinde established immortal fibroblast cell lines that differentiated in to 
mature adipocytes on hormonal inducers. These known as 3T3-L1 and 3T3-F442A; 
isolated from non-clonal swiss mouse 3T3 cells which are widely used for in vitro 
experiment. Later on, detailed research resulted in development of other preadipocyte 
cell lines like 1246, Ob1771, TA1 and 30A5 though there were little differences in 
their differentiation condition but they act similar as 3T3-L1 and 3T3-F442A (Rosen 
et al., 2000, Ntambi and Young-Cheul, 2000). Adipocytes can now be developed from 
pluripotent mesenchymal stem cells (MSCs) which can be isolated from adipose tissue 
and muscle. These MSC can be differentiated into cell types like adipocytes, 
chondrocytes, myocytes and osteoblast. Further research also separated stem cells 
from adipose stromal vascular  fraction but their capacity to develop into adipocytes 
are found to be variable both in vitro as well as in vivo (Lowe et al., 2011, Rodeheffer 
et al., 2008). Also cell surface markers has been proposed to contain stromal cells that 
differentiate into adipocytes in vivo which include CD34+, CD24+, a7, Scal+, PDGFR 
alpha+ but these cells show limited adipogenic activity which need to be further 
explored (Tang et al., 2008, Rodeheffer et al., 2008). Various cellular  models, which 
are sources of adipocytes have been presented in diagram below (Rosen and 








Figure 1.5 Various models used to study adipogenesis (adopted from (Rosen and 
MacDougald, 2006). a) Embryonic stem (ES) cells  differentiated directly into adipocytes, 
under influence of retinoic acid and pro-adipogenic hormones. (b) Mouse embryonic 
fibroblasts (MEFs), which can be isolated after disaggregation of embryos at embryonic day 
(E)12–14, can be differentiated to adipocytes (c) or can be immortalized by serial passaging 
or introduction of the SV40 large T antigen prior to differentiation. Most immortalized MEF 
lines do not differentiate unless a pro-adipogenic transcription factor such as proliferator-
activated receptor γ (PPARγ) or CCAAT-enhancer-binding protein α (C/EBPα) is introduced. 
(d) Brown-adipose stromal cells from newborn mice can be immortalized using SV40 large T 
antigen, and differentiate efficiently on hormonal treatment. (e) Multipotent precursor cells 
isolated from several adult tissues including adipose tissue, skeletal muscle and bone marrow 
provide another source of that has been isolated from bone marrow cells, which are 






1.12.2 Adipogenesis  
Better understanding of adipogenesis could contribute towards the development of 
potential therapeutic strategies for metabolic diseases such as obesity and metabolic 
syndrome. Improvement in adipocyte functions and replacement of poorly functioning 
adipocytes could be beneficial in metabolic disease (Lowe et al., 2011). Adipogenesis 
comprises of various stages involving transcription factors, cell cycle proteins and 
gene expression regulation which leads to development of mature adipocyte 
(Lefterova and Lazar, 2009). Adipogenesis comprises of two main phases: 
Determination phase:  In this phase multipotent MSC converted into preadipocytes 
which then go through growth phase followed by growth arrest and clonal expansion. 
In growth arrest, preadipocytes withdraw from cell cycle before undergoing adipose 
conversion. This is necessary for adipocyte differentiation. In clonal expansion, 
preadipocytes goes through one or more cycle of mitosis before entering into terminal 
differentiation phase. 
Terminal differentiation phase: In this phase, the preadipocyte takes on the 
characteristic of mature adipocyte ready to perform its physiological actions. It 
acquires the machinery which is necessary for insulin action, lipid transport and 
synthesis and the secretion of adipocyte-specific proteins (Umek et al., 1991, Lane et 
al., 1999, Ntambi and Young-Cheul, 2000, Spiegelman et al., 1983). These phases are 
controlled by complex network of factors and genes which are briefly described below.  
Various signals played role in the initiation of adipogenesis from conversion of stem 
cells to adipocytes. These include fibroblast growth factor, interleukin 17, insulin, 
insulin like growth factor 1 (IGF-1), transforming growth factor, thyroid hormones, 
glucocorticoids, mineralocorticoids, PPARγ  and bone morphogenetic proteins (Lowe 
et al., 2011). Insulin has promising effect on adipogenesis. Downstream component of 
the insulin/IGF-1 signalling cascade are important for adipogenesis. Downstream 
effectors of insulin action cascade, such as PI3K and protein kinase B (PKB) have 
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been reported  to be involved in adipogenesis (Kim and Chen, 2004). Glucocorticoids 
(GC) are also potent inducers of adipogenesis. GC receptors are present in human 
preadipocytes and it activates the expression of C/EBPδ and PPARγ (Wu et al., 1996). 
Some fibroblast growth factors such as FGF1, 2 and 10 showed adipogenic activity on 
human preadipocytes and, their neutralization inhibits adipogenesis (Hutley et al., 
2004). 
A variety of cytokines including TNF-1, IL-1 and many proinflammatory molecules  
have been found to inhibit adipogenesis in most cultured preadipocyte lines (Ohsumi 
et al., 1994). In addition several growth factors are potent inhibitors of adipogenesis, 
including platelet- derived growth factor and endothelial-derived growth factor 
(Hauner et al., 1995). The inhibitory effect is supposed to be mediated by activation 
of mitogen-activated protein kinases (MAPK). These kinases phosphorylate PPARγ2 
at Ser112 in the amino-terminal domain and inhibit its adipogenic activity (Rosen et 
al., 2000). 
Signalling pathways also play an important role in adipogenesis. One of them is WNT 
signalling, the suppression of which is necessary for adipogenesis (Prestwich and 
Macdougald, 2007). Another signalling pathway, called as hedgehog (HH) which 
inhibits adipogenesis, has been proposed to have a role in adipogenesis (Pospisilik et 
al., 2010). The absolute mechanism involved is not clear however role of HH and 
WNT signalling receptors has been proposed. It was suggested that HH and WNT 
signalling receptors, present on the primary cilia in differentiating adipocytes, become 
impaired during adipogenesis steps which leads to over expression of PPARγ gene. 
This over expression resulted in increased adipogenesis which might end up to obese 
phenotype (Marion et al., 2009). Other pathways which have been reported to be 
involved in adipogenesis are SMAD signalling (Tan et al., 2011, Marchildon et al., 
2010), ribosomal protein S6 kinase 1(S6K1) (Carnevalli et al., 2010), the Janus kinase-
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signal transducer and activator of transcription 3 pathway (JAK-STAT3) (Zhang et 
al., 2011), glutathione, AKT and inositol pyrophosphate pathway (Chakraborty et al., 
2010). It was also reported that transcriptional regulators like retinoblastoma protein 
(RB), p53, zinc-finger protein 423 and proto-oncoprotein MAF are controlled by the 
above mentioned pathways (Molchadsky et al., 2008, Nishikawa et al., 2010, Calo et 
al., 2010, Gupta et al., 2010). Any imbalance disturbs the pathways which ultimately 
halt process of adipogenesis. Some studies suggested cell shape as a factor influencing 
adipogenesis. It has been shown those rounded mesenchymal stem cells are more 
likely to become adipocytes (Kilian et al., 2010, Feng et al., 2010).  Role of 
extracellular remodelling has also been postulated in adipogenesis which showed that 
impairment of membrane-bound matrix metalloproteinase (MMP14) leads to 
defective adipogenesis (Chun et al., 2006). 
1.12.2.1 Role of Transcriptional factors during adipogenesis 
Adipocyte differentiation involves a regulated set of gene expression events and 
understanding the transcriptional network is of fundamental importance. Once the 
adipogenesis process started, it over expressed adipogenic early key regulators 
CAAT/enhancer-binding proteins (C/EBP) β and δ. These factors target the genes 
encoding PPARγ, considered as master regulator of adipogenesis, CEBP α and 
SREBP1 which regulates lipogenic genes (Rosen and MacDougald, 2006, Payne et 
al., 2009). PPARγ then activates genes encoding C/EBPα through positive feedback 
mechanism. PPARγ and C/EBPα then over express genes which have a role in 
lipogenesis, lipolysis and insulin sensitivity including fatty acid binding protein 
(FABP4), lipoprotein lipase (LPL), GLUT 4, perilipin, lipin, leptin and adiponectin.  
PPARγ, a member of the nuclear hormone receptor superfamily, heterodimerize with 
retinoid X receptor to bind DNA and be transcriptionally active. PPARγ has 2 isoforms 
generated by alternative splicing. PPARγ2 is more abundant in fat cells compared to 
PPARγ1 which is abundant in colonic epithelium and macrophages (Mansen et al., 
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1996).PPARγ is not only important for adipogenesis but is also required for 
maintenance of differentiated adipocytes. Adenoviral gene transfer of a dominant-
negative PPARγ into mature 3T3-L1 adipocytes resulted in decrease in cell size and 
expression of adipocyte markers (Tamori et al., 2002). In vivo knock down of PPARγ 
in differentiated adipocytes resulted in adipocyte death followed by generation of new 
adipocytes (Imai et al., 2004).   
Several C/EBPs including C/EBPα, β, γ, and δ are expressed in adipocytes. Regulated 
expression has been observed for C/EBP family during adipogenesis and studies 
indicated that these proteins have profound impact on development of adipocytes 
(Rosen et al., 2000, Lowe et al., 2011). It has been reported that C/EBP β and δ are 
involved in early differentiation of adipocytes while C/EBPα is induced later, slightly 
preceding the induction of adipocytes end-product genes. It was also proposed that 
C/EBP β and δ promote adipogenesis by inducing C/EBPα and PPARγ (Darlington et 
al., 1998). 
SREBP1c is a pro-adipogenic basic helix-loop-helix (bHLH) transcription factor that 
induce PPARγ expression. SREBP1c role in adipogenesis was proposed by the 
observation that the mRNA expression of SREBP1c was induced dramatically as 3T3-
L1 preadipocyte cell line was stimulated to undergo differentiation. SREBP1c 
overexpression in the presence of hormonal inducers of differentiation resulted in 
increased adipocyte marker expression and lipid accumulation in 3T3-L1 cells 
compared to control cells (Kim et al., 1998b). It was proposed that SREBP1c produced 
some factors that enhances PPARγ activity (Kim et al., 1998b). Others proposed that 
SREBP1c itself activated PPARγ and then mutually acted together to increase 
adipogenesis (Fajas et al., 1999, Kim et al., 1998a). SREBP1c also regulate various 
genes linked to fatty acid and triglyceride metabolism that include acetyl-CoA 
carboxylase, fatty acid synthase and glycerophosphate acyltransferase (Rosen et al., 
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2000). Other transcription factors that are linked to adipogenesis  are orphan nuclear 
receptor, nuclear factor of activated T cells (NFAT), high-mobility group proteins and 
cyclic AMP response element binding protein (Rosen et al., 2000). 
There have been factors reported to act as adipogenic as well as anti-adipogenic at 
different stage of adipogenesis to regulate this highly complex network. One of the  
example is nuclear receptor, chicken ovalbumin upstream promoter-transcription 
factor 11(COUP-TF11) which promote preadipocyte lineage by blocking WNT 
signalling, however it was reported to be act as inhibitor of C/EBPα  and PPARγ  thus 
inhibit adipogenesis (Xu et al., 2008, Li et al., 2009). It has also been reported that the 
factors which regulate adipogenesis also affect its activity during adipogenesis. To 
explain this, it has been reported that Sirtuin (SIRT2) act on forkhead box O1 
(FOXO1) and blocked its acetylation and phosphorylation which ultimately increase 
its nuclear localization. This increase in FOXO1 blocked genes encoding PPARγ thus 
inhibits PPARγ leading to impaired adipogenesis. Another example of PPARγ 
inhibitor is retinol binding protein1 (RBP1) (Zizola et al., 2010, Jing et al., 2007, 
Picard et al., 2004). Phosphorylation has also been reported to be another factor which 
regulates adipogenesis. One of such example is CDK5 which phosphorylate Ser273 
of PPARγ gene leading to decrease expression of its target genes in adipocytes (Choi 
et al., 2010). Others excitatory regulators includes early growth response-2 (EGR2) 
(White and Stephens, 2010), early B cell factor 1 (EBF1) (Jimenez et al., 2007), 
kruppel like factor 4) (KLF4) (Birsoy et al., 2008) while inhibitory factors include 
KLF3, C terminal binding protein 1 and 2 (CTBP) (Sue et al., 2008), interferon 
regulatory factor (IRF) 3 and  4 (Eguchi et al., 2008) and globin transcription factor 2 
and 3 (GATA 2 and 3) (Tong et al., 2005). 
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Figure 1.6   Stages of Adipogenesis 
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1.13 AAPs induced gene dysregulation in adipocytes 
 
Various transcriptional factors play role in differentiation of preadipocytes. Three 
most important transcriptional factors are PPARγ, C/EBPα and SREBP (Yang et al., 
2009, Rosen et al., 2000). SREBP plays an important role in fatty acid metabolism and 
also regulates genes involved in lipid synthesis. Upregulation of SREBP has great 
effect on downstream genes and differentiation markers and increases their expression 
such as PPARγ, C/EBP α, FABP4 and fatty acid synthase (FAS). Various studies 
reported increased expression of SREBP, PPARγ and C/EBPα along with lipid 
accumulation by AAPs showing role of these transcription factors in metabolic 
toxicity (Hu et al., 2010, Yang et al., 2007). This was also showed in a study by Li and 
colleagues reported increase expression of SREBP and downstream genes by OLA (Li 
et al., 2016). Study by Yang and colleagues showed that CLO had no effect on PPARγ 
and C/EBPα however they proposed SREBP as the main transcription factor which 
played role in lipid accumulation and weight gain (Yang et al., 2009).  In vitro study 
by Raeder and colleagues reported increase expression of SREBP by CLO while ZIP 
did not show any change in SREBP expression which showed the association of 
SREBP gene in metabolic toxicity caused by AAPs (Raeder et al., 2006). However in 
vitro primary human adipocytes study by Sarvari and colleagues showed changes in 
various genes including INSR, PPARα, LEP, ADIPOQ and SIRT1 after giving AAPs 
suggesting involvement of many genes in metabolic toxicity. Their study also reported 
that CLO increased PPARγ expression while ZIP showed no change. AAPs also did 
not show any change in SREBP1 expression in a study by Sarvari and colleagues 
(Sarvari et al., 2014). Change in Inflammatory genes might have role in metabolic 
toxicity. It has been shown that AAPs caused increase expression of nuclear factor 
kappa (NF-KB1) and proinflammatory cytokines such as TNF-α, IL-1β, IL-8 and 
MCP-1. This increase may cause macrophages to infiltrate to adipose tissue and cause 
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inflammation which leads to metabolic toxicity (Sarvari et al., 2014). This 
involvement was also showed in another study where OLA caused increased 
expression of TNF-α (Victoriano et al., 2010). It was proposed that increasing TNF-α 
expression or secretion might have effect on GLUT4 transporter and IRS1 leading to 
reduce insulin activity resulted in insulin resistance (Sarvari et al., 2014).  
Lipin (LPIN) gene might have important role in metabolic toxicity. The LPIN gene 
encodes three proteins, 1, 2, and 3. It was first isolated from fatty liver dystrophy 
mutant mouse strain. LPIN1 is abundant in adipose tissue, skeletal muscle and testis 
while it is also found in kidney, brain, heart and liver. During triglyceride synthesis, 
LPIN1 act by converting phosphatadate into 1, 2-diaacylglycerol (Reue, 2009). The 
LPIN1 is essential for development of adipocytes.                        
LPIN1 gene is a late adipogenic differentiation marker without which adipocytes 
cannot fully differentiate and mature as well. It was proved by knock down of LPIN1 
gene in 3T3-L1 preadipocytes which inhibited adipocyte differentiation whereas 
increased expression induced adipocyte differentiation. It has been reported that 
LPIN1 worked as co-activator of PPARγ2 and regulates the network between PPARγ2 
and C/EBPα activating the genes required for adipogenesis. Various preclinical studies 
on animals showed that lack of LPIN1 gene in mice, resulted in failure to develop 
mature adipocytes leading to lipodystrophy and fatty liver while transgenic mice with 
increased LPIN1 expression resulted in hypertrophic adipocytes (Koh et al., 2008, 
Reue and Zhang, 2008, van Harmelen et al., 2007). However in human, the 
relationship of LPIN1 expression with respect to obesity and insulin sensitivity is 
complex. Various studies have shown the downregulation of LPIN1 gene in obese and 
diabetes mellitus 2 subjects (van Harmelen et al., 2007, Yao-Borengasser et al., 2006) 
while other studies showed no correlation between LPIN1 and insulin sensitivity 
(Miranda et al., 2010). The mechanism of decreased LPIN1 expression in obese 
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patients is not known however various factors have been proposed which might affect 
the expression of lipin1 which include environmental factor, genetic factors, effect of 
drugs, abnormal adipocyte function and posttranslational modification (Yao-
Borengasser et al., 2006).  
1.14 Genetic predisposition related to AAP-induced metabolic toxicity 
Genetic factors are considered to be strongest risk factors for AAP-induced metabolic 
toxicity. Several studies have suggested association between genetic variants and 
AAP-induced metabolic toxicity (Devlin and Panagiotopoulos, 2015, Muller et al., 
2012, Ujike et al., 2008). Pharmacokinetically, AAPs are metabolized by cytochrome 
(CYP) 450 isoenzymes. This means poor activity of CYP450 leads to more levels of 
AAPs causing more adverse effects. Study by Lett and colleagues showed that 
polymorphisms in CYP P450 2D6 gene (CYP2D6) might be involved in AAP-induced 
weight gain. This gene is involved in RISP metabolism and it was reported that the T-
allele carrier of the 188C/T variant have decreased CYP2D6 function (Lett et al., 
2012). Study by Lane and colleagues on Chinese schizophrenic patients undergoing 
RISP treatment also showed association of 188T allele of CYP2D6 with increased 
weight gain (Lane et al., 2006). The efficacy of pharmacokinetics in AAPs-induced 
weight gain still undetermined and more research is needed in this part. 
Pharmacodynamically, serotonin receptor gene HTR2C was studied most to 
understand the mechanism behind AAPs-induced metabolic toxicity. Various studies 
showed association of rs3813929 (C/T) promoter SNP (-759C/T) of the HTR2C gene 
with increase weight gain (Ryu et al., 2007, Laika et al., 2010, Lane et al., 2006). 
Another SNP in HT2RC gene (rs1414334) was also reported to be associated with 
metabolic syndrome in patients taking CLO and RISP (Mulder et al., 2009). Various 
studies also reported association of polymorphism in HTR2A gene with weight gain 
in patients treated with OLA and RISP (Ujike et al., 2008, Lane et al., 2006). 
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Polymorphism in dopamine receptor gene also showed association with weight gain. 
It was reported that SNPs (rs4436578, rs1799732 and rs1079598) of DRD2 gene 
showed association in schizophrenic patients using CLO, OLA and RISP (Lane et al., 
2006). Numerous studies showed association of various genes, their SNPs and alleles 
with AAPs-induced weight gain which include; MTHFR and its SNP (rs1801133) 
(Srisawat et al., 2014, Shams and Muller, 2014);  leptin gene and its SNP (rs7799039) 
(Nurmi et al., 2013, Brandl et al., 2012); glucagon like peptide GLP-1 gene (rs3799707 
and rs13429709) (Brandl et al., 2014a) and Melanocortin-4 receptor (MC4R) and its 
SNP (rs17782313 and rs11872992). Study by Gonclaves and colleagues showed 
association of mitochondrial genes with AAPs-induced weight gain and metabolic 
toxicity. Their study reported significant association between rs6435326, rs1053517 
and rs1801318 in NADH: Ubiquinone Oxidoreductase Core Subunit S1 (NDUFS1) 
gene and weight gain (Goncalves et al., 2014).  
However some studies did not show any gene association with AAPs induced weight 
gain. Godlewsky and colleagues showed no association of histamine H receptor 
(HIHR) gene with AAPs-induced weight gain. Their group studied five SNPs, 
rs2067466, rs2067467, rs2067469, rs2067468 and rs2067470 but no association was 
found between these SNPs and OLA induced weight gain (Godlewska et al., 2013). 
Study by Lett et al also reported no association of rs3813929 SNP in HTR2C gene 
(Lett et al., 2012). Controversial results are also reported with various genes as some 
study showed association with weight gain while other did not show association with 
the same gene. These include adiponectin (ADIPOQ) and PPARγ. Herken and 
colleagues showed association of PPARγ with weight gain while Brandl and 
colleagues reported no association of PPARγ and ADIPOQ gene with weight gain 
(Kohlrausch, 2013, Herken et al., 2009, Brandl et al., 2014b).   
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Genome wide association studies (GWAS) showed association of many genes 
including HTR2C, leptin, fat mass and obesity-associated (FTO), DRD2, TNFα, 
Synaptosomal-associated protein 25 (SNAP-25), MC4R, and INSIG2 in metabolic 
toxicity caused by antipsychotic drugs.  The top finding emerge to be association of 
SNP (rs1568679) of Meis homeobox2 (MEIS2) gene for increase in waist and hip 
circumference in patients given RISP. This gene is important for the development and 
function of pancreas which might have link between adiposity and diabetes. This 
GWAS also reported association of SNP (rs13224682) of protein kinase cyclic 
adenosine monophosphate-dependent regulatory type 11 beta (PRKAR2B) gene with 
triglyceride increase in CLO-treated patients. This gene controls the cellular effects of 
cAMP so it regulates many signalling pathways (Adkins et al., 2011, Correll et al., 
2011). Further studies are required to validate these genes and their association with 
metabolic toxicity so that physician can apply personalised medicines (AAPs) to 
schizophrenic patients (Gressier et al., 2016, Lett et al., 2012). 
1.15 Aim of the thesis 
 
AAPs are the mainstay of treatment in schizophrenia however their use is impeded by 
the high frequency of metabolic adverse effects like insulin resistance, weight gain 
with abdominal obesity, diabetes mellitus, dyslipidaemia and essential hypertension 
observed in these patients. AAPs lead to cardiovascular complications which badly 
affect the quality of life resulting in greater mortality rate compared to general 
population (Scigliano and Ronchetti, 2013). Various mechanisms have been proposed 
for the metabolic toxicity caused by AAPs; these include direct effect on adipose 
tissue, insulin resistance, inflammation, oxidative stress, hormonal effect and CNS 
receptor effects. But none of the mechanisms have shown the role of any specific 
system involved in metabolic toxicity. The main purpose of this work is to improve 
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our understanding of AAP-induced metabolic toxicity using in vitro adipocyte models 
and to test therapeutic strategies than can arrest or reverse AAP-induced metabolic 
toxicity. Specific aims of this study are to understand the role of AAPs in causing 
metabolic toxicity by: 
1) Characterisation of the effect of specific AAPs on adipogenesis and adipokines 
using in vitro murine adipocyte models and primary human adipocytes. 
2) Understanding the molecular mechanisms that are responsible for AAPs-induced 
metabolic toxicity.  
3) Investigation of the adjuvant drugs potential to reverse the adipotoxicity caused by 
AAPs. 
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AAPs are second-generation antipsychotics commonly prescribed for the treatment of 
psychiatric disorders including schizophrenia and psychosis (Sarvari et al., 2014). As 
compared to first-generation antipsychotics, AAPs show fewer extrapyramidal 
adverse effects. However, the long-term use of these drugs is associated with 
potentially serious metabolic adverse effects. The major side effects of AAPs are 
weight gain and associated metabolic disorders such as insulin resistance, obesity, 
impaired glucose tolerance, T2DM, dyslipidemia and essential hypertension. These 
metabolic abnormalities lead to the development of cardiometabolic disease 
(Nasrallah, 2008). The risk of metabolic toxicity differs between different AAPs. It 
was concluded that CLO and OLA constitute the highest metabolic risk; QTP, RISP, 
and AMI intermediate; while ARI and ZIP were considered to pose a lower risk (Wang 
et al., 2013). The exact mechanism behind AAP-induced metabolic adverse effects is 
not yet known however it is believed that these drugs cause these effects by acting 
centrally and peripherally. Various studies showed that AAPs disturbed histamine, 
serotonin and noradrenergic signalling targeting central nervous system pathways 
involved in food intake. This suppresses satiety leading to increasing eating habits 
which lead to weight gain and its complications (Balf et al., 2008, Coccurello and 
Moles, 2010, Masaki et al., 2004). One of the suggested mechanism is the direct effect 
of AAPs on adipocytes.  White adipose tissue is an important endocrine organ with 
important functions. The major constituent of adipose tissue is the adipocyte. The main 
function of fat cells is to maintain glucose and lipid homeostasis and store and release 
energy when required.  Surplus energy is stored as triglycerides in the form of lipid 
droplets (Lefterova and Lazar, 2009). Some studies mentioned the involvement of 
subcutaneous adipose tissue as a key organ to affect metabolic hormones. It was 
proposed that AAPs act directly on the adipose tissue increasing adipogenesis which 
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ultimately leads to increased lipid accumulation and weight gain (Minet-Ringuet et 
al., 2007, Hemmrich et al., 2011). However another study showed no direct effect of 
AAPs on fat cell formation and highlighted the central role of AAPs in causing 
metabolic toxicity (Hauner et al., 2003). Other proposed mechanisms include adipose 
mitochondrial dysfunction which disturbs electron transport chain pathway (Ji et al., 
2009, Streck et al., 2007), increased production of reactive oxygen species (Miljevic 
et al., 2010) or genetic factors (Lett et al., 2012). Other researchers reported the role 
of inflammation in AAP-induced metabolic adverse effects. According to these 
studies, AAPs caused metabolic toxicity by increasing the release of proinflammatory 
cytokines like IL-6 and TNF-α which caused phosphorylation of insulin receptors  
leading  to insulin resistance; one of the major features of metabolic toxicity (Makki 
et al., 2013, Klemettila et al., 2014, Pollmacher et al., 2000). Various clinical trials 
found CLO and OLA to increase TNF-α and IL-6 levels after AAP treatment which 
further implicates their role in metabolic adverse reactions (Klemettila et al., 2014, 
Kluge et al., 2009). Adipose tissue also secretes adiponectin, an adipose-derived 
hormone which modulates the pathway involving carbohydrate and lipid metabolism. 
In obesity, adipokine secretion and expression is disturbed along with dysregulation 
of glucose and lipid metabolism leading to metabolic abnormalities. Meta-analysis of 
plasma adiponectin levels in schizophrenic patients showed decrease in adiponectin 
levels by CLO and OLA. Decreased adiponectin levels may lead to obesity, insulin 
resistance and T2DM (Bartoli et al., 2015c).The exact mechanism causing decreased 
adiponectin levels are not fully explored however the role of adiponectin has been 
proposed as a link in metabolic abnormality (Bartoli et al., 2015b, Wang et al., 2013). 
During adipogenesis, preadipocytes, a fibroblast-like cell, differentiates into mature 
adipocytes. This process takes various stages which involve various transcriptional 
factors which includes PPARγ, C/EBPs, SREBP and LPIN1 (Yang et al., 2009). 
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PPARγ, a master regulator of adipogenesis develops and maintain fat cells and their 
capacity to store lipids (Medina-Gomez et al., 2007). The importance of PPARγ was 
demonstrated by targeted gene knockout strategy in mice; this resulted in the failure 
of development of adipose tissue (Evans et al., 2004). It has been shown that AAPs 
caused a stimulatory effect on PPARγ; this might have a link with AAP-induced 
weight gain and AAP-mediated increase in adipocyte lipid accumulation (Sarvari et 
al., 2014). However, another study showed no role of PPARγ in weight gain (Brandl 
et al., 2014a). Another important transcription factor required for normal adipocyte 
differentiation is lipin 1. LPIN1 gene knockdown resulted in inhibition of adipocyte 
differentiation and it increases the function of PPARγ2 through direct interaction with 
and activation of PPARγ2 (Kim et al., 2013, Koh et al., 2008, Yao-Borengasser et al., 
2006). The relationship of LPIN1 expression with obesity or metabolic syndrome is 
complex. Some studies have shown downregulation of LPIN1 gene in obese and 
T2DM subjects (van Harmelen et al., 2007, Yao-Borengasser et al., 2006) while others 
have showed no relation between LPIN1 and metabolic syndrome (Miranda et al., 
2010). Under normal conditions, adipocytes store excess triglycerides while in obese 
subjects, adipocytes may reach maximum capacity of their fat storage. Due to this, 
lipid may be stored in ectopic sites such as liver, skeletal muscle, and heart which 
disturb their physiological functions, ultimately leading to insulin resistance. 
Increased lipolysis from excess triglycerides in adipose tissue resulted in higher levels 
of FFA (Schenk et al., 2008). This FFA then caused glucose intolerance resulting in 
insulin resistance. This was further supported by Boden and Kelly’s study showing 





2.1.1 Rationale for the study 
 
Various mechanisms, some of which are contradictory, have been postulated for the 
pathogenesis of AAP-induced metabolic toxicity so far. CLO and OLA has been 
suggested to cause metabolic adverse effects compared to other AAPs (Swartz et al., 
2008, Kluge et al., 2009, Young et al., 2015); this could be as a result of their effects 
on adipogenesis (Hemmrich et al., 2011, Hu et al., 2010); or their effect on 
inflammatory cytokines (Pollmacher et al., 2000, Makki et al., 2013); or other 
adipokines such as adiponectin (Wang et al., 2013, Bartoli et al., 2015b); or a mixture 
of these effects. Our study used a 3T3-F442A murine preadipocyte cell line model to 
investigate the effect of AAPs on lipid accumulation, adipogenic transcription 
markers, and adipocytokine release. This study primarily focussed on three AAPs: 
CLO and OLA, which are considered to result in metabolic adverse effects; and ARI, 

























The hypotheses tested in this chapter were; 
1) AAPs cause lipid accumulation by a direct effect on adipogenesis and thereby lead 
to weight gain and ultimately metabolic toxicity. 
2) AAPs upregulate the expression of adipogenic transcription factor PPARγ and other 
important transcription factors such as LPIN1.  
3) AAPs cause changes in the release of adipocytokines which could be 
mechanistically important in the development of insulin resistance and metabolic 
adverse effects. 
 
2.1.3 Aims and objectives 
 
The aims and objectives were; 
1) To investigate AAP-induced metabolic toxicity using an in vitro murine adipocyte 
model by the assessment of: 
a. adipocyte function and gene transcription; 
b. adipocyte-secreted markers and 














AAPs, CLO and OLA were purchased from Sigma-Aldrich, St. Louis, MO, USA 
while ARI and lopinavir (LPV) were purchased from Santa Cruz Biotechnology, 
Texas (TX), USA. Methanol, ethanol, dimethyl sulfoxide (DMSO), trypsin, 
dimethylformamide, (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide) (MTT), insulin from bovine pancreas, radioimmunoprecipitation (RIPA) 
lysis buffer, sodium dodecyl sulphate (SDS), Ethylenediaminetetraacetic acid 
(EDTA), chloroform and Oil Red O stain were purchased from Sigma-Aldrich, St. 
Louis, MO, USA. Fetal bovine serum (FBS), Dulbecco’s modified eagle’s medium 
(DMEM), Hank’s balanced salt solution (HBSS), rat tail collagen I, reverse 
transcription kit, Tri Reagent solution for RNA, FAM labelled PPARγ and lipin1, VIC 
labelled β-actin TaqMan gene expression assays, TaqMan gene expression master 
mix, isopropanol, enzyme-linked immunosorbent assay (ELISA) kits for adiponectin, 
IL-6 and TNF-α were purchased from Thermo Fisher Scientific, TX, USA. PPARγ 
(catalogue number: 2443) antibody was purchased from Cell signalling technology, 
Massachusetts (MA), USA, lipin1 (catalogue number: sc-98450) and β-actin 
(catalogue number sc-47778) were purchased from Santa Cruz Biotechnology, TX, 
USA. FFA assay kit, detergent compatible (DC) protein assay kit and Simple Western 
assays were purchased from Abcam, Cambridge, UK, Bio-Rad, California (CA), USA 
and ProteinSimple, CA, USA respectively. 12 well and 6 well polystyrene plates, 
T175, T75 flasks and other cell culture materials were purchased from Thermo Fisher 
Scientific, TX, USA. 3T3-F442A murine preadipocyte cell line was available in-house 
in the Wolfson centre for Personalised Medicine, Department of Molecular and 
Clinical Pharmacology, University of Liverpool, UK.  
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2.2.2 Cell Culture 
 
Preadipocytes were cultured and maintained in T75 flasks in DMEM containing 10% 
FBS. Once confluent (75-80%), cell culture media was discarded and cells were 
washed carefully with HBSS. After washing, 5ml of trypsin was added to the flasks 
and incubated for 5 minutes to dislodge the cells from the surface of the flasks. After 
incubation at 37 ᴼC for 5 minutes, the cells were detached by gentle tapping of the 
bottom of the flask. The cell suspension was poured into a universal tube containing 
10ml of DMEM to neutralise the trypsin. The tubes were centrifuged at 1000rpm for 
5 minutes at room temperature to obtain the cell pellet. The supernatant was discarded 
once centrifugation finished and the cell pellet was suspended in 3-5ml of DMEM 
depending upon the size of the pellet. Cell counting was done by mixing 10µl of the 
cell suspension with 10µl of trypan blue dye. Then 10µl mixture of cells and dye was 
loaded into a Countess Cell chamber slide (Thermo Fisher Scientific, TX, USA) which 
was then counted by using a Countess Cell counter (Thermo Fisher Scientific, TX, 
USA). One million cells were suspended in adequate amount of media and sub-
cultured in new T75 flasks for maintenance of cell line. The remaining cells were 
either frozen or cultured in collagen- coated plates as required. 
2.2.2.1 Freezing of cells 
 
Once the required number of cells were separated for maintenance in a T75 flask or 
collagen-coated plates, the universal tube containing media with cells was centrifuged 
at 1000rpm for 5 minutes to obtain the pellet. The supernatant was discarded and 
freezing medium was added according to the cell number (1 ml freezing medium per 
1 million cells). After mixing, this mixture was added into cryovials. These cryovials 
were then kept in Mr Frosty, a container which freeze at the rate of 1 ᴼC per every 
minute and kept in a -80 ᴼC refrigerator until required.  
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2.2.2.2 Drug incubations 
 
6 well plates were coated with rat tail collagen (Thermo Fisher Scientific, TX, USA) 
before the culture of the cells. Stock collagen was diluted with distilled water (Sigma-
Aldrich, Dorset, UK) and pour into plates so that the final concentration of collagen 
in well plates was 100µg/µl. Plates were kept in centrifuge for 1 hr for coating, after 
which the diluted collagen was discarded and plates were washed with HBSS to 
remove all the remaining collagen floating in the plates. For drug incubations, 20,000 
cells/well were cultured in collagen-coated 6 well plates. After two days of incubation 
in the incubator, the DMEM cell culture media was replaced by differentiating media 
containing 10mg/ml of insulin in all wells except the preadipocyte wells. The day of 
addition of insulin (start of differentiation process) was considered as day 0 of 
differentiation (Table 1). After 48 hours of differentiation, all media were discarded 
and replaced with fresh preadipocyte or differentiation media as the case may be. The 
differentiation media was replenished every 48 hours till day 10 when adipocytes were 
fully differentiated. Cells were treated with either vehicle (the solvent in which the 
drug was dissolved) or increasing doses of the drugs. Drug addition was conducted 
from day 2 to day 8 (total 4 drug additions) at every 48 hour intervals. This resembles 
the chronic toxicity model which was used to study chronic drug accumulation effects 
on various parameters. As metabolic toxic effects occur due to chronic exposure of 
drugs in humans so we used multiple drug exposure to cells to resemble our model 
more clinically. On day 10, supernatants and cell lysates were collected to measure 
adipokine levels and gene and protein expression respectively. Every experiment was 





CLO (1µM, 2µM, 20μM), OLA (0.2µM, 2µM, 20μM) and ARI (0.2µM, 1µM, 20μM) 
were used in the current study. The upper and lower concentrations of the therapeutic 
range were used for each drug. We also used an additional higher dose (20uM) to 
understand the effect of higher concentrations of AAPs which may be achieved as a 
result of accumulation within the adipose tissue. Different vehicles were used for each 
drug depending upon their solubility (CLO/LPV: methanol; OLA: DMSO; ARI: 
ethanol). Lopinavir (LPV) (20μM), an anti-HIV drug with known deleterious effects 
on adipocyte function was used as a comparator. All the drug’s effect were compared 
with their respective vehicles.  
 
Table 2.1  Drug treatment time line. Differentiating Medium (DM) 
 
 
2.2.3 Measurement of Cell Viability 
 
Cell viability was assessed in both preadipocytes and differentiated adipocytes by 
MTT assay. Preadipocytes were seeded in flat bottom 96-well plates at a density of 
10,000 cells per well and incubated for 24 hr. A range of CLO, OLA and ARI 
concentrations (1-100µM) were added, with each concentration having 3 sets of 
quadruplicate wells and were incubated for 4 days. For differentiating adipocytes, cells 
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drugs. After 4 days all wells (both preadipocytes and differentiated adipocytes) 
received 20µl of MTT solution followed by incubation at 37°C for 2 hr. After 2 hrs, 
100µl lysis buffer, prepared by adding 20% (w/v) SDS in dimethylformamide solution 
was added to all wells and incubated overnight. The absorbance of the plates was read 
at 595nm using a multimode detector (Beckman Coulter, CA, USA).  
 The MTT assay is based on the conversion of the tetrazolium salt MTT into a 
coloured and water-soluble formazan. The dehydrogenase enzymes of the viable cells 
reduce the yellow MTT solution to a purple colour at 37 °C. Therefore, the amount of 
formazan produced is directly proportional to the number of living cells providing a 
good indication of cell viability. 
2.2.4 Lipid Accumulation 
 
Two days after last drug addition, cells were washed with 2 ml/well of HBSS. Cells 
were then fixed in 2ml of formaldehyde (10% formaldehyde in HBSS) for 1 hr. After 
fixing, plates were washed with HBSS twice and 1.5ml filtered Oil Red O solution 
was added. Oil Red O stock solution was prepared by dissolving 0.5 g of Oil Red O 
powder in 100 ml of isopropanol. The working solution consisted of a mixture of 3 
parts of Oil Red O stock solution and 2 parts of distilled water. The plates were placed 
on a shaker and left for 1 hr. Excess Oil Red O solution was then washed off with cold 
tap water and images were taken under a microscope. To quantify lipid accumulation, 
1ml of 70 % isopropanol was added to each well to dissolve the lipid-bound Oil Red 
O stain and plates were put on a shaker for half an hour. 200µl isopropanol with stain 
was then transferred to a 96-well plate and absorbance was read using a multimode 




2.2.5 Measurement of secreted adipokines 
2.2.5.1 Adiponectin 
 
Adiponectin secretion was measured by solid phase sandwich ELISA kit. Supernatants 
were collected from the 6-well plates into Eppendorf tubes. Dilutions were prepared 
both for samples (1:1000) and standards. 100µl of diluted drug-treated samples and 
controls were added to the antibody coated 96-well plate. The plate was then covered 
and incubated for 1 hr at 37 ᴼC. After 1 hr, solution was aspirated and all wells were 
washed 3 times with wash buffer. 100µl 1x detection antibody solution was added and 
incubated for 1 hr at 37 O C. After aspiration of the solution, all wells were then washed 
with wash buffer 3 times and 100µl 1x horseradish peroxidase-(HRP) was added to all 
wells. The plate was again incubated for 1 hr at 37 ᴼC. After 1 hr, solution was 
aspirated and wells were washed 5 times with wash buffer. 100 µl substrate solution 
was added to all wells followed by an incubation period of 20min in the dark at room 
temperature. After the last incubation period, 100µl of stop solution was added to all 
of the wells and readings were made using a plate reader at 450nm. Adiponectin 
concentration in each sample was calculated as per manufacturer’s instructions. 
2.2.5.2 IL-6 
 
100µl of standards and samples were added to the antibody-coated 96-well plate. The 
plate was covered with plate cover and incubated for 2 hr at room temperature. The 
solution was aspirated after incubation and wells were washed 4 times with wash 
buffer. 100µl of IL-6 biotin conjugate solution was added and incubated for 30 min at 
room temperature. After incubation, solution was aspirated and all wells were washed 
4 times with wash buffer. Streptavidin-HRP (100µl) was added and 30min incubation 
was done at room temperature. After aspiration and washing wells, 4 times with wash 
buffer 100µl stabilised chromogen was added to each well. The plate was then allowed 
to incubate for 30min in dark at room temperature. In last step 100µl of stop solution 
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was added to all of the wells and readings were measured using a plate reader at 




After adding 100µl of standard and samples in appropriate well to the antibody-coated 
96-well plate, 50µl of TNF-α biotin conjugate solution was added in all wells. Plate 
was covered and incubated for 90 min at room temperature. The solution was aspirated 
and wells were washed 4 times with wash buffer. 100µl of Streptavidin-HRP solution 
was added in each well and plate was incubated for 30 min at room temperature. After 
incubation solution was aspirated and wells were washed 4 times with wash buffer. 
After washing, 100µl of stabilised chromogen was added to each well and incubated 
for 30 min at room temperature in the dark. After last incubation 100µl of stop solution 
was added to each well and readings were measured using a plate reader at 450nm. 




Cell culture supernatants were used to assess the FFA secretion by adipocytes. 50µl 
of standard dilutions and samples were added to 96 well plate followed by 2µl of Acyl-
CoA Synthetase (ACS) reagent in each well. The plate was then incubated for 30 min 
at 37 ᴼC. 50µl reaction mix (Table 2.2) was added to each well and incubated for 
30min at 37 ᴼC. The absorbance was then immediately measured using a plate reader 
at 570nm. FFA concentration in each sample was calculated as mentioned in the user 
manual. 
 
Table 2.2  Reaction Mix for one reaction: FFA colorimetric assay 
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Component Reaction Mix (µl) 
Assay  buffer 44 
Fatty acid Probe 2 




2.2.6 Isolation of mRNA 
 
After aspirating the supernatant, cells were washed twice with HBSS. Cells were lysed 
by adding 500µl of Tri Reagent solution in each well. The lysates were transferred to 
autoclaved Eppendorf tubes. The lysates were mixed with 100µl of chloroform and 
the tubes were shaken vigorously for 15 seconds to get a homogenised mixture. The 
tubes were incubated at room temperature for 10 minutes. Afterwards, the tubes were 
centrifuged at 14000rpm for 15 minutes at 4 °C result in in the separation of  a lower 
red (containing proteins), an interphase (containing DNA) and a colourless upper 
aqueous solution (containing RNA). The aqueous solution containing RNA was 
transferred carefully to a fresh tube and remaining solution was discarded. 25µl of 
isopropanol was added to each tube followed by brief mixing with vortex and 
incubation at room temperature for 10 minutes. After that, tubes were centrifuged at 
12000 rpm for 10 minutes at 4 °C. The supernatants were then transferred to new tubes 
leaving any impurities at the bottom. 225µl of isopropanol was added to each tube 
followed by brief mixing with vortex and incubation at room temperature for 10 
minutes. All tubes were centrifuged at 14000 rpm for 10 minutes at 4 °C. RNA 
precipitate in the form of white pellet at the bottom of the tube. The supernatant was 
discarded without disturbing pellet. 100µl of 75% ethanol was added and all the tubes 
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were centrifuged at 14000 rpm for 10 minutes at 4 °C. The supernatant was discarded 
without disturbing pellet. The RNA pellet was then air-dried for 10-15 minutes to 
remove all ethanol. 15µl of RNAase/DNAase free water was added and mixed gently 
by pipetting up and down. The quality and quantity of RNA extracted were checked 
using a Nanodrop 8000 Spectrophotometer (Thermo Fisher Scientific, TX, USA). All 
samples were stored at -20°C until used for reverse transcription.  
2.2.7 Reverse transcription of total RNA 
 
2µg of total RNA for each sample was added to reverse transcription reagents as 
shown in table 2.3.  
      Table 2.3. Components of reverse transcription reaction  
Reagents Quantity (µl) 
Magnesium Chloride (MgCl2) 5.5 
Random Hexamer 1.25 
dNTP Mixture 5 
MultiScribeTM Reverse Transcriptase 0.875 
Reverse Transcription Buffer 2.5 
RNAase Inhibitor 0.5 
Total 15.625 
 
RNAase/DNAase free water was added to a tube containing total RNA and reverse 
transcription reagents making a total volume of 25µl in each tube. The tubes were 
mixed gently and then placed on a heating block of Veriti thermo-cycler from Applied 
Biosystems, Warrington, UK. The thermo-cycler was run according to reaction 
cycling parameter as shown in Table 2.4. On finishing reaction, the samples were 
mixed by vortex and centrifuged at maximum speed for few seconds. The cDNA 
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obtained was quantified using Nanodrop to check the quality and quantity of cDNA. 
This cDNA was further normalised to 20 ng/µl using RNAase/DNAase free water. 
            Table 2.4. Reaction cycling parameter in Thermal Cycler 
Temperature Time 
25°C 10 min 
48°C 30 min 
95°C 5 min 
4°C Indefinitely 
 
2.2.8 Gene expression by Real-time PCR 
 
Gene expression was carried out using 7900HT Fast Real-Time PCR system (Applied 
Biosystems, CA, USA). TaqMan gene expression assays (Target gene - FAM labelled; 
Endogenous control -VIC labelled)  and TaqMan gene expression master mix were 
used to perform duplex real-time PCR reactions to assess the levels of mRNA 
expression of target  genes relative to mRNA levels of β-actin (housekeeping gene). 
Table 2.5 show the reaction components used. All reactions were performed in a 384-
well plate (Thermo Fisher Scientific, TX, USA) using standard cycling parameters 
(Table 2.6). The mRNA expression was calculated using the comparative CT method 
according to the manufacturer’s protocol. The fold expression of the gene of interest 
was expressed as 2^-(∆∆CT). 
 
         
 
 




 Table 2. 5. Reaction components for Real-time PCR 
Reagents Quantity (µl) 
TaqMan gene expression Assay 
(20x FAM dye-labelled) 
1 
TaqMan gene expression Assay 
(20x VIC dye-labelled) 
1 
TaqMan gene expression Master Mix 10 
cDNA (1-100ng) 4 




      Table 2.6. Reaction cycling (40 cycles) parameter for Real-time PCR 
Temperature Time 
50 °C 2 min 
95 °C 10 min 
95 °C 15 sec 
60 °C 1 min 
 
 
2.2.9 Protein extraction  
 
Protein lysates were prepared using RIPA lysis buffer. After discarding the 
supernatant, cells were gently washed in ice-cold HBSS. 100µl RIPA buffer was added 
and a scraper was used to collect the cell lysates in Eppendorf tubes. Cells were then 
allowed to lyse on ice for 30min. After lysing, the Eppendorf tubes were centrifuged 
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to spin down insoluble materials for 30min at maximum speed at 4°C. The supernatant 
was collected containing the total cell protein. 
2.2.10 Protein quantitation 
 
Protein in lysates was quantitated by DC Protein Assay Kit. In this protocol, 20µl of 
reagent S was added to 1ml of reagent A which was considered as working reagent A. 
5µl of protein standards and samples were added to the 96-well flat bottom plate. 25µl 
of working reagent A was added to all the wells followed by addition of 200µl of 
reagent B in all wells. The reagents were mixed by keeping the plate on a shaker for 1 
min followed by 15 min incubation at room temperature. The readings were measured 
using a plate reader at 550nm. Protein concentration in each sample was calculated as 
mentioned in the user manual. 1-5 µg of protein was used for each sample for target 
protein expression. 
2.2.11 Simple Western Assay  
 
For quantitative analysis of protein expression, Simple Western System (WES, 
ProteinSimple, CA, USA) was used. Simple Western is a gel-free, blot free, film free 
and Western blot-like substitute technique. The WES machine performs size-based 
separation, immunoprobing, washing, detecting and analysis of the data (Chen et al., 
2015). A duplex approach was applied in which both target protein antibody and 
endogenous control antibody were loaded in same wells. The biotinylated ladder was 
used for molecular weight determination. Protein lysates were mixed with 5x 
fluorescent master mix in a microcentrifuge tube to obtain final concentration between 
0.2mg/ml to 0.8mg/ml. The samples and ladder were then denatured at 95 ᴼC for 5 
minutes. All the samples, ladder, primary and secondary antibodies, wash buffers and 
chemiluminescence substrate were loaded in the Simple WES plate in appropriate 
wells. The plate was centrifuged at 2500 rpm for 10 min. After that, the plate was 
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loaded in the WES machine for a period of 3 hrs. The resulting digital image was 
analysed using Compass software (Protein simple, CA, USA) as instructed in the user 
manual. The target protein was normalized against β-actin in the analysis. The 
following dilutions were used; PPARγ: 1: 25, lipin1: 1:50 and β-actin: 1:25. 
2.3 Statistical Analysis 
 
All experiments were done in triplicates. All statistical comparisons were made using 
unpaired t tests on Stat Direct software version 2.7.9. Differences were considered 
significant at p≤ 0.05.The result was shown as mean ± SD. 
2.4 Results 
 





None of the concentrations used for OLA and ARI showed any cell inhibition 
(Inhibitory concentrations (IC) 50= >100). However CLO showed cell inhibition only 
at higher concentrations (IC50=81.37µM) (Fig.2.1A). However all of our experiments 
were on differentiating adipocytes. 
 
2.4.1.2 Differentiating Adipocytes 
None of the concentrations used for OLA and ARI showed cell inhibition as IC50, is 
greater than 100 (IC50= >100). However CLO showed cell inhibition at higher 
concentrations (IC50= 60.57 µM). The maximum concentration we tested in 
subsequent experiments was 20uM, a concentration which had no appreciable cell 




 Figure 2.1 A.  The percentage cell death caused by CLO, OLA and ARI (0.01-100 µM) on 3T3-
F442A preadipocytes determined by MTT assay. Cells were treated with AAPs for 4 days followed 
by incubation with MTT solution for 2hr. Lysis buffer was added followed by overnight incubation. 
Absorbance was then measured by multimode detector. All experiments were done in triplicates. CLO: 




Figure 2.1 B. The percentage cell death caused by CLO, OLA and ARI (0.01-100 µM) on 3T3-
F442A differentiating adipocytes determined by MTT assay. Cells were treated with AAPs for 4 
days followed by incubation with MTT solution for 2hr. Lysis buffer was added followed by overnight 
incubation. Absorbance was then measured by multimode detector. All experiments were done in 





























































2.4.2 Effect of AAPs on lipid accumulation and adipogenesis 
 
In differentiating adipocytes, a dose dependent significant increase in lipid 
accumulation was observed with CLO compared to vehicle-treated cells (1uM CLO: 
1.22 absorbance units (AU) ±0.011; p=0.01, 2µM:1.35±0.017; p=0.001, 
20µM:1.56±0.097; p=0.001, Vehicle: 1.05±0.06). OLA showed trend in increase in 
lipid droplets but this was not statistically significant (0.2μM:1.49±0.17; p=non-
significant (ns), 2μM:1.53±0.15; p=ns, 20μM:1.57±0.14; p=ns). ARI, on the other 
hand did not show any change in lipid accumulation in any of the dose used. LPV, an 
anti-HIV drug which was used as comparator, showed significant reduction as 
compared to the vehicle as expected (0.86±0.043; p=0.01) (Fig. 2.2 A). This was also 
evident from the photomicrographs taken following Oil Red O staining (Fig 2.2 B). 
 
Figure 2.2.A. Quantitation of lipid bound stain. 1ml of 70 % isopropanol was added to each well to 
dissolve the lipid-bound Oil Red O stain and plates were put on a shaker for half an hour. 200µl 
isopropanol with stain was then transferred to a 96-well plate and absorbance was read using a 
multimode detector. Graph showing effect of various concentrations of CLO, OLA and ARI on 
differentiated adipocytes. All experiments were done in triplicates. Data was shown as Mean ±SD; 
p≤0.05. * VEH M vs LPV/CLO. VEH M Vehicle. Methanol, VEH E: Vehicle Ethanol, VEH D: Vehicle 






























































Figure 2.2 B. Photomicrographs (20x magnification) showing Oil Red O staining of 3T3-F442A adipocytes on 
10th day post differentiation treated with various concentration of CLO, OLA and ARI. CLO: Clozapine 
OLA: Olanzapine, ARI: Aripiprazole: LPV: Lopinavir  
Vehicle 
0.2μM OLA 2μM OLA 20μM OLA 
LPV 
1μM CLO 2μM CLO 20μM CLO 
0.2μM ARI 20μM ARI 1μM ARI 
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2.4.3 Effect of AAPs on adipocytokine secretions 
 
2.4.3.1 Adiponectin secretion 
 
Treatment with CLO showed dose dependent significant increase in adiponectin 
secretion as compared to vehicle (1µM:555.28ng/ml±51.70; p=0.005, 
2µM:661.07±69.20; p=0.002, 20µM:736.77±66.06; p=0.001, vehicle: 323.16±53.07). 
However both OLA (2µM: 1115.82±16.26; p=0.003, 20µM:990.70±6.08; p=0.0002, 
vehicle: 1243.51±31.03) and ARI (1µM:347.73±7.74; p=0.001, 20µM:322.40±4.31; 
p=0.0003, vehicle: 408.59±12.07) showed significant reduction in adiponectin 
secretion. LPV showed significant reduction in adiponectin secretion compared to 
vehicle as expected (114.52± 42.52; p=0.006) (Fig 2.3 A).  
 
Figure 2.3 A. Effect of AAPs on Adiponectin secretion. Differentiated adipocytes were treated with 
increasing doses of CLO, OLA and ARI over a period of 10 days. Supernatants were collected on day 
10 and adiponectin secretion was measured by solid phase sandwich ELISA as described by 
manufacturer’s instructions.  All experiments were done in triplicates. Data represent mean ± SD; p ≤ 
0.05. * VEH M vs LPV/CLO, # VEH D vs OLA,  † VEH E vs ARI. AAPs: Atypical antipsychotics, 
VEH M: Vehicle Methanol, VEH E: Vehicle Ethanol, VEH D: Vehicle DMSO, LPV: Lopinavir, CLO: 











































2.4.3.2 IL-6 secretion 
 
None of the concentrations used for CLO (1uM: 19.30±3.91; p=ns, 2µM:19.73±3.61; 
p=ns, 20µM:22.84±3.96; p=ns, Vehicle: 21.03±3.35) and OLA (0.2uM: 24.80±1.24; 
p=ns, 2µM:24.88±0.80; p=ns, 20µM:24.97±1.93; p=ns, Vehicle: 22.26±0.40) showed 
any change in secreted IL-6. ARI showed increase in IL-6 secretion only at the higher 
dose (20µM:74.49±2.44; p=0.0004, Vehicle: 12.28±0.41). LPV showed significant 
increase in IL-6 secretion as expected (75.59± 3.35; p=0.0002) (Fig 2.3B). 
 
2.4.3.3 TNF-α secretion 
 
CLO showed dose dependent significant increase in TNF-α secretion compared to 
vehicle (1uM: 37.10±0.16; p=0.0004, 2µM:43.17±0.34; p=<0.0001, 
20µM:45.24±0.16; p=<0.0001, Vehicle: 32.89 ±0.34). However none of the doses of 
OLA (0.2uM: 21.33±0.29; p=ns, 2µM:21.12±0.30; p=ns, 20µM:20.95±0.31; p=ns, 
Vehicle: 21.69 ±0.45) and ARI (0.2uM:21.67±0.12; p=ns, 1µM:21.43±0.10; p=ns, 
20µM:21.28±0.08; p=ns, Vehicle: 21.91±0.09) showed any change in secretion while 










































Figure 2.3B.  Effect of AAPs on IL-6 secretion. Differentiated adipocytes were treated with 
increasing doses of CLO, OLA and ARI over a period of 10 days. Supernatants were collected on day 
10 and IL-6 secretion was measured by solid phase sandwich ELISA as described by manufacturer’s 
instructions.. All experiments were done in triplicates. Data represent mean ± SD; p ≤ 0.05 *VEH M 
vs LPV,   # VEH E vs ARI. AAPs: Atypical antipsychotics, VEH M: Vehicle Methanol, VEH E: Vehicle 























Figure 2.3C. Effect of AAPs on TNF-α secretion. Differentiated adipocytes were treated with 
increasing doses of CLO, OLA and ARI over a period of 10 days. Supernatants were collected on day 
10 and TNF-α secretion was measured by solid phase sandwich ELISA as described by manufacturer’s 
instructions. All experiments were done in triplicates. Data represent mean ± SD; p ≤ 0.05 *VEH M vs 
LPV/CLO. AAPs: Atypical antipsychotics, VEH M: Vehicle Methanol, VEH E: Vehicle Ethanol, VEH 































2.4.3.4 Free Fatty Acid Secretion 
 
FFA was significantly and dose dependently increased by CLO as compared to the 
vehicle (1uM: 0.119±0.001; p=0.0003, 2µM:0.124±0.002; p=0.001, 
20µM:0.131±0.004; p=0.007, Vehicle: 0.105 ±0.0009). However OLA increased FFA 
secretion only at therapeutic concentration (0.2µM:0.114±0.003; p=<0.0001, Vehicle: 
0.100±0.002) and not at other concentrations (2µM:0.103±0.004; p=ns, 
20µM:0.099±0.002; p=ns).  On the other hand, ARI did not show any change in FFA 
at therapeutic doses (0.2µM:0.113±0.0005; p=ns, 1µM:0.117±0.0009; p=ns) but 
increased at the higher dose (20µM: 0.137 ±0.001, p=0.0002, Vehicle: 0.115±0.0007). 
LPV, as expected, showed a significant increase in FFA secretion (0.116±0.0007; 
p=<0.0001) (Fig 2.3 D).  
 
 
Figure 2.3D. Effect of AAPs on FFA secretion. Differentiated adipocytes were treated with 
increasing doses of CLO, OLA and ARI over a period of 10 days. Supernatants were collected on day 
10 and FFA secretion was measured by colorimetric method as described by manufacturer’s 
instructions. All experiments were done in triplicates. Data represent mean ± SD; p ≤ 0.05 *VEH M vs 
LPV/CLO, # VEH D vs OLA, † VEH E vs ARI. AAPs: Atypical antipsychotics, VEH M: Vehicle 
Methanol, VEH E: Vehicle Ethanol, VEH D: Vehicle DMSO, LPV: Lopinavir, CLO: Clozapine, OLA: 





























































2.4.4 Effect of AAPs on Adipogenic gene and protein expression 
 
2.4.4.1 Adiponectin mRNA expression 
 
Adiponectin (adipoQ) gene showed a significant dose dependent increase in 
expression following treatment with CLO (1uM: 1.69±0.17; p=0.03, 2µM:2.06±0.07; 
p=0.006, 20µM:2.62±0.35; p=<0.0001). However none of the OLA (0.2uM: 
1.07±0.04; p=ns, 2µM:0.99±0.03; p=ns, 20µM:0.93±0.03; p=ns) and ARI (0.2uM: 
0.94±0.04; p=ns, 1µM:0.99±0.05; p=ns, 20µM:1.03±0.06; p=ns) concentrations tested 
showed any change in adiponectin expression. LPV showed significant decrease in 
adiponectin gene expression as expected (0.69±0.14; p=0.04) (Fig 2.4 A). 
 
Figure 2.4A.  Effect of AAPs on adipoQ mRNA expression. Differentiated adipocytes were treated 
with increasing doses of CLO, OLA and ARI over a period of 10 days. RNA extracted and  adipoQ 
mRNA was assessed using RT-PCR. β-actin was used as endogenous control. All experiments were 
done in triplicates. Data represent mean fold change ± SD; p ≤ 0.05  * VEH M vs LPV/CLO. AAPs: 
Atypical antipsychotics, VEH M: Vehicle Methanol, VEH E: Vehicle Ethanol, VEH D: Vehicle DMSO, 

































2.4.4.2 ppar-γ mRNA expression 
 
After treatment with CLO and ARI, ppar-γ showed significant dose dependent (2μM 
CLO; 2.79±0.43; p<0.0001, 20 μM CLO: 3.58±0.38; p<0.0001, 1μM ARI: 1.55±0.10; 
p=0.03, 20 μM ARI:1.87 ±0.15,p=0.0003) increase in mRNA expression as compared 
to vehicle while OLA showed an increase in expression only at 0.2µM (1.08±0.01, 
p=0.04). LPV (0.78±0.07,p=0.04) showed significant decrease in ppar-γ  expression 
compared to the vehicle (Fig 2.4B). 
 
2.4.4.3 PPARγ protein expression  
 
Two concentrations (therapeutic and higher dose) for each of the drug was used to 
investigate drugs effect on PPARγ and lipin1 (LPIN1) protein expression. 
CLO treatment showed dose dependent (1μM:176.53±7.84; p=0.002, 
20μM:307.34±26.30; p=0.0001) significant increase in PPARγ expression as 
compared to the vehicle while OLA did not show any change (0.2μM:105.38±2.54; 
p=ns, 20μM:90.22±3.56; p=ns). Treatment with ARI showed a significant increase in 
PPARγ expression only at the highest dose used (0.2μM: 85.15±7.33; p=ns, 20μ M: 
261.68±48.46, p=0.02).LPV showed trend to decrease but the result was non-














Figure 2.4B. Effect of AAPs on pparγ mRNA expression. Differentiated adipocytes were treated with 
increasing doses of CLO, OLA and ARI over a period of 10days. RNA extracted and pparγ mRNA was 
assessed using RT-PCR. β actin was used as endogenous control. All experiments were done in 
triplicates. Data represent mean fold change ± SD; p ≤ 0.05 * VEH M vs CLO, #VEH D vs OLA, † 
VEH-E vs ARI. AAPs: Atypical antipsychotics, VEH M: Vehicle Methanol, VEH E:  Vehicle Ethanol, 
























Figure 2.4C. Effect of AAPs on PPARγ protein expression. Differentiated adipocytes were treated 
with increasing doses of CLO, OLA and ARI over a period of 10 days. Protein isolated and PPARγ 
expression was assessed by western blotting. β-actin was used as endogenous control. Data represent 
mean ± SD; p ≤ 0.05  *VEH M  vs CLO,  # VEH E vs ARI. AAPs: Atypical antipsychotics, VEH M: 
Vehicle Methanol, VEH E: Vehicle Ethanol, VEH D: Vehicle DMSO, LPV: Lopinavir, CLO: 



































2.4.4.4. Lipin1 mRNA expression 
 
CLO treatment showed significant increase in lpin1 mRNA expression 
(2µM:1.66±0.08, p=0.005, 20µM:1.94±0.10, p=0.004) as compared to vehicle. OLA 
caused decrease in expression only at higher dose (20µM:0.92±0.03, p=0.05) while 
ARI showed decrease only at therapeutic doses (0.2µM:0.78±0.02, p=0.004, 
1µM:0.88±0.03, p=0.004). LPV showed significant decreased as compared to vehicle 
(0.64± 0.11, p=0.03) (Fig.2.4D). 
 
2.4.4.5 Lipin1 protein expression  
 
CLO treatment showed significant increase in LPIN1 expression only at higher dose 
(20μM:213.46±26.43, p=0.02) compared to vehicle while both OLA 
(0.2µM:110.02±9.38, p=ns, 20µM:92.44±14.62,p=ns) and ARI 
(0.2µM:94.62±20.51,p=ns, 20µM:107.08±31.07,p=ns) did not show any change in 
any of the concentration used. Treatment with LPV showed significant decreased 












Figure 2.4D. Effect of AAPs on lipin1 mRNA expression. Differentiated adipocytes were treated 
with increasing doses of CLO, OLA and ARI over a period of 10days. RNA extracted and lipin1 mRNA 
was assessed using RT-PCR. β-actin was used as endogenous control. All experiments were done in 
triplicates. Data represent mean fold change ± SD; p ≤ 0.05 * VEH M vs CLO, #VEH D vs OLA, † 
VEH-E vs ARI. AAPs: Atypical antipsychotics, VEH M: Vehicle Methanol, VEH E: Vehicle Ethanol, 







































  β-actin (Kda-48) 
Figure 2.4E. Effect of AAPs on Lipin1 protein expression. Differentiated adipocytes were treated with increasing 
doses of CLO, OLA and ARI over a period of 10 days. Protein isolated and Lipin1 expression was assessed by western 
blotting. β-actin was used as endogenous control. Data represent mean ± SD; p ≤ 0.05 *VEH M vs LPV/CLO. AAPs: 
Atypical antipsychotics, VEH M: Vehicle Methanol, VEH E: Vehicle Ethanol, VEH D: Vehicle DMSO, LPV: Lopinavir, 





AAPs are the drug of choice for treatment of schizophrenia due to less risk of 
extrapyramidal side effects. However, it causes metabolic adverse effects such as 
weight gain, insulin resistance, and dyslipidemia. Various mechanisms ranging from 
central receptor effects to the peripheral inflammatory, oxidative stress, insulin 
resistance, and lipid accumulation has been proposed but none of them have been 
declared as an absolute mechanism (Hu et al., 2010). We used 3T3-F442A 
preadipocyte cell line as a murine in vitro model to characterise the underlying 
mechanism. We preferred to use this cell line model compared to other 3T3, such as 
3T3-L1, OP9 or C3H10T1/2 as 3T3-F442A has more ability to accumulate fat and 
showed more advanced commitment towards adipocyte differentiation (Ruiz-Ojeda et 
al., 2016). Schizophrenic patients took AAPs for long period of time leading to 
accumulation of drugs in the body which cause metabolic adverse effects. To mimic 
this condition, an in vitro chronic toxicity model approach was applied in which drugs 
were given multiple times, to study the effect of drugs on lipid accumulation and 
various adipogenic parameters. Previous studies have proposed increased lipid 
accumulation and increased adipogenesis as a mechanism of weight gain leading to 
insulin resistance and metabolic syndrome caused by AAPs (Vestri et al., 2007, Yang 
et al., 2007, Hemmrich et al., 2011). Our result showed an increase in lipid 
accumulation by CLO and OLA but not ARI. This is consistent with Hu and colleagues 
study which showed an increase in adipogenesis by CLO (Hu et al., 2010). Our result 
is also consistent with recently published data reported dose-dependent increase by 
CLO in lipid droplets using 3T3-L1 as a model (Tsubai et al., 2017). Our results also 
coincide with Hemmrich and colleagues research (Hemmrich et al., 2011) which 
showed increased lipid accumulation by CLO while OLA marginally increases it. 
Hemmrich study also showed a decrease in lipid accumulation by ARI which was not 
observed in our study. Our data clearly depicted that CLO and OLA cause 
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accumulation of excess body fat compared to ARI. This showed CLO and to some 
extent OLA, poses a potential risk to cause weight gain, obesity and metabolic 
syndrome. Our study showed a comparison in terms of lipid accumulation among 
AAPs, which was not showed in previous studies, which clearly showed role of CLO 
and OLA in causing weight gain, obesity and metabolic adverse effects. This also links 
to published clinical data, span over 20 years on psychiatric schizophrenic patients 
treated with AAPs, which reported 52.3 percent patients to be associated with weight 
gain after using CLO and OLA compared to ARI treated group (Francesco and 
Cervone, 2014). Obesity is characterised by increased size and accumulation of lipid 
droplets so we can suggest from our data that CLO and OLA directly affect the cells 
and increased adipogenesis leading to deposition of excess fat, which might be one of 
the mechanisms by which AAPs cause weight gain. However, there are also 
contradictory results related to the effect of AAPs on adipogenesis. A study by Sertie 
and colleagues showed that lipid droplet accumulation did not change significantly 
even at the higher dose of CLO (30μM) and OLA (100μM) (Sertie et al., 2011). Also, 
Hauner and colleagues reported no direct effect of CLO on fat cell formation (Hauner 
et al., 2003) but in their study, CLO was given only for 24hr which might not show 
effect while our study spans around 10 days with multiple drug additions leading to 
chromic accumulation of drugs which produced its deleterious effects by increasing 
adipogenesis  and lipid accumulation.  
Adipogenesis triggers important transcriptional changes in adipocytes without which 
adipocytes cannot be mature. Most important is the increased expression of PPARγ, 
considered as a master regulator of adipogenesis. Previous studies showed an increase 
in PPARγ mRNA expression by CLO (Sertie et al., 2011, Sarvari et al., 2014)  while 
OLA did not show any change  (Sarvari et al., 2014, Hu et al., 2010, Sertie et al., 
2011). Our study is consistent with these findings. Our results also showed no effect 
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on PPARγ mRNA expression by therapeutic concentrations of ARI which coincides 
with Sarvari and colleagues’ study (Sarvari et al., 2014). These previous results and 
our results showed the importance of transcriptional factor such as PPARγ in 
adipogenesis without which adipocytes cannot be mature and perform physiological 
and molecular functions. It is quite possible that AAPs, increased adipogenesis by 
activating PPARγ which caused increased formation of lipid droplets and lipid 
accumulation leading to weight gain. However, there are studies which contradict with 
these results. Nimura et al reported no change in PPARγ and adiponectin gene by the 
higher dose of OLA (Nimura et al., 2015). Another study by Brandl et al on 216 
schizophrenic patients who received antipsychotics for 14 weeks, showed that neither 
PPARγ nor adiponectin gene variants had any association with antipsychotic-induced 
weight gain (Brandl et al., 2014b). In the current study, CLO but not OLA or ARI 
showed an increase in lipin1 gene and protein expression. Hence, there is a possibility 
that AAPs such as CLO cause metabolic adverse effects by affecting adipogenesis 
through lipin1 by increasing adipogenesis, leading to weight gain and obesity. This is 
the first study to investigate the expression of lipin1 when treated with AAPs; our 
results showed increase in lipin1 expression by CLO while OLA and ARI did not show 
any noticeable effect. Lipin1 worked as co-activator of PPARγ2 and regulates the 
network between PPARγ2 and C/EBPα activating the genes required for adipogenesis. 
Studies showed that lack of lipin1 gene in mice, resulted in failure to develop mature 
adipocytes leading to lipodystrophy and fatty liver while transgenic mice with 
increased lipin1 expression resulted in hypertrophic adipocytes (Koh et al., 2008, Reue 
and Zhang, 2008, van Harmelen et al., 2007).This suggest that lipin1 can be potential 
transcriptional factor, which might be affected by AAP resulted in lipid accumulation, 
obesity and weight gain. However in human, the relationship of lipin1 expression with 
obesity and insulin sensitivity is complex. Various studies have shown the 
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downregulation of lipin1 gene in obese and diabetes mellitus 2 subjects (van Harmelen 
et al., 2007, Yao-Borengasser et al., 2006) while other studies showed no correlation 
between lipin1 and insulin sensitivity (Miranda et al., 2010). The mechanism of 
decreased lipin1 expression in obese patients is still unknown. Future studies are 
required to characterise the role of lipin1 in AAPs induced metabolic adverse effects.  
 Lower adiponectin levels have been associated with insulin resistance and diabetes 
mellitus (Richards et al., 2006). Many previous clinical studies have shown decreased 
adiponectin secretion in patients treated with AAPs (Klemettila et al., 2014, Hanssens 
et al., 2008). Our results show increase in adiponectin secretion by CLO which 
contradict with recently published data showing a decrease in adiponectin secretion 
by CLO (Tsubai et al., 2017). Our study also contradicts with the clinical results which 
reported a decrease in adiponectin secretion by CLO and OLA (Wampers et al., 2012, 
Sugai et al., 2012, Klemettila et al., 2014, Hanssens et al., 2008). We performed CLO 
accumulation assay (explained in chapter 3) to find the cause of discrepancy between 
our model and other published data. It was found that less CLO was accumulated 
inside the 3T3-F442A adipocytes compared to control which might play role in 
contradictory data of adiponectin secretion. This experiment suggest involvement of 
adipocyte membrane transporter or receptor which block the entry of drugs  into  the 
cells however  more research is required to find the exact cause.  
Another factor associated with antipsychotic-induced metabolic toxicity is the role of 
inflammation (Sarvari et al., 2014). The inflammatory markers like IL-6 and TNF-α 
can act on insulin receptor and block its phosphorylation or might affect fatty acid 
metabolism which leads to insulin resistance (Makki et al., 2013). Our result did not 
show any change in IL-6 secretion by CLO and OLA however, ARI showed an 
increase but only at a higher dose. Our in vitro results contradict with published 
clinical data that showed an increase in IL-6 levels after CLO treatment (Leonard et 
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al., 2012, Klemettila et al., 2014). However it should be noted that clinical studies 
showed an inconsistent result with OLA; Hori et al (Hori et al., 2007) showed no effect 
while Kluge et al (Kluge et al., 2009) showed a decrease in IL-6 levels. Sobis and 
colleagues’ research showed decrease IL-6 secretion by ARI which also contradict 
with our results (Sobis et al., 2015). The contradictory result showed by our model 
might be associated with decreased accumulation of CLO inside the cell as mentioned 
earlier. Also our study span around 10 days which might not produce the required 
effect, due to short duration of study in which drug was not accumulated enough to 
produce effect,  compared to schizophrenic patients taking AAPs for longer period of 
time . 
In the context of TNF-α levels, our result correlates with Sarvari and colleagues study 
in terms of only OLA and ARI which did not show any change.  However, our data 
showed increased TNF-α levels by CLO which contradict with Sarvari et al study 
showing no change (Sarvari et al., 2014). Clinically, TNF-α level was increased by 
CLO and OLA (Pollmacher et al., 2000, Kluge et al., 2009) and decreased by ARI 
(Sobis et al., 2015). However, our data correlate clinically only with CLO, suggesting 
its potential is causing metabolic adverse effects. TNF-α could be a potential factor to 
study as it has been reported  to be associated with insulin resistance (Guilherme et 
al., 2008). It has been proposed that TNF-α  suppress insulin signalling leading to 
insulin resistance (Guilherme et al., 2008). Changes in TNF-α levels by AAP 
especially CLO suggests that these drugs induced inflammation in adipose tissue 
activating a cascade of factors and events which not only affect physiological 
functions of adipose tissue but also affect other organs leading to insulin resistance.  
FFA also play an important role in metabolic syndrome. Insulin creates a balance 
between lipogenesis and lipolysis however during insulin resistance there is an 
increase lipolysis which increases the release of FFA. This FFA is either stored in the 
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adipose tissue leading to obesity or goes to the liver causing increased production of 
triglycerides resulting in hepatic steatosis. FFA also cause glucose intolerance by 
decreasing glucose intake by the muscle leading to diabetes (Adiels et al., 2005). 
Previous studies showed increased levels of FFA by CLO whereas OLA decreased the 
levels and ARI cause no change (Kaddurah-Daouk et al., 2007, Canfran-Duque et al., 
2013, Jassim et al., 2012). Our study coincides with published CLO and ARI data 
except OLA which showed decreased levels in other studies while our study did not 
show any change in FFA levels (Jassim et al., 2012, Kaddurah-Daouk et al., 2007). 
Our data showed role of AAP especially CLO in causing lipolysis releasing excess 
FFA which then stored in peripheral tissues, disturbing their physiological functions 
either causing steatosis or glucose intolerance which ultimately lead to insulin 
resistance. It is possible that increase in FFA levels might be one of the mechanisms 
causing metabolic adverse effects, however, more studies required to characterise its 
role in metabolic syndrome.  
In summary, the data presented here correlates with some of the published literature, 
but also contradicts with some studies. Of the AAPs studied, CLO caused the greatest 
amount of metabolic toxicity. Contrary to expectations and the published literature, it 
caused an increase in adiponectin levels. In next chapter, we have used another model 
(primary human adipocytes) to validate the murine data but also to explain the 
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There are three types of adipose tissue in the human body; white adipose tissue 
(WAT), brown adipose tissue (BAT) and beige adipose tissue. Beige adipocytes reside 
in WAT and on stimulation, acquire a thermogenic phenotype similar to brown 
adipocytes (Kiefer, 2017). The human body has abundant WAT which consist of 
mostly white adipocytes with a single large cytoplasmic lipid droplet and a nucleus 
which is located to the side of the cell. Along with white adipocytes, adipose tissue 
also contains immune cells, fibroblasts, endothelial cells and neuronal cells 
(Cristancho and Lazar, 2011). Adipogenesis comprises of a complex process involving 
the determination of preadipocytes from stem cells, and their terminal differentiation 
into mature adipocytes. Adipogenesis is mediated by several transcription factors 
which play an important role in the maturation of adipocytes. The most important 
regulator of adipogenesis is considered to be PPARγ. There are 2 isoforms of PPARγ, 
1 and 2, which exist due to alternative splicing. PPARγ2 is mainly expressed in the 
adipose tissue. It has been found that overexpression of PPARγ induces adipocyte 
differentiation and adipogenesis while cells lacking PPARγ resulted in failure of the 
cells to become mature adipocytes. PPARγ also induce expression of genes, LPIN1, 
SREBP, GLUT 4, ADIPOQ and LPL (lipoprotein lipase), all of which play important 
role in lipogenesis and glucose metabolism (Rosen and MacDougald, 2006, Tontonoz 
and Spiegelman, 2008). It has been reported that subcutaneous adipose tissue which 
has the highest lipid accumulation capability showed the highest expression of PPARγ 
and C/EBP-α compared to abdominal mesenteric and omental adipose tissue 
(Tchkonia et al., 2002). The previous study has reported the connection between 
PPARγ and lipin1 proposing that it reinforces the interaction between C/EBPα and 
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PPARγ2 thus increase the production of adipocyte-specific genes necessary for 








Leptin and adiponectin are considered to be the two most important hormones released 
by WAT. Leptin suppresses satiety factor that suppresses food intake. There is a 
positive correlation between plasma levels of leptin and WAT mass (Potvin et al., 
2015). Adiponectin is considered to be an important biomarker for indicating insulin 
sensitivity. There has been an inverse relationship between adiponectin levels and 
WAT mass. It also secretes proinflammatory factors, important ones are IL-6 and 
TNF-α (Pollmacher et al., 2000).  
AAPs are considered to be the gold standard for schizophrenia; however, these drugs 
result in metabolic adverse effects which include weight gain, insulin resistance, 
glucose intolerance and dyslipidemia, all of which are risk factors for metabolic 
complications such as obesity, diabetes mellitus, and cardiovascular disease. Various 
clinical trials have showed that among various AAPs prescribed, CLO and OLA are 
considered to be the worst in causing metabolic adverse effects; QTP, RISP and AMI 
are moderately implicated; and, ARI and ZIP are the lowest in causing metabolic 
adverse effects (Tandon et al., 2008, Naber and Lambert, 2009). Various mechanisms 
have been proposed for AAP-induced metabolic toxicity. According to various in vitro 
C/EBP α PPARγ2 
Adipocyte Specific genes 




Figure 3.1. Interaction between Lipin1 and PPARγ 
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studies (primary human and rat adipocytes) (Himmerich et al., 2011, Boyda et al., 
2010, Nimura et al., 2015, Pavan et al., 2010, Loffler et al., 2016) and clinical studies 
(Haupt, 2006, Haddad, 2005, Swartz et al., 2008, Kahn et al., 2008, Francesco and 
Cervone, 2014), lipid accumulation leading to weight gain and obesity is considered 
to be one factor causing metabolic adverse effects. It has been shown that hypertrophy 
and hyperplasia of adipocytes resulted in the accumulation of the fats. This was 
considered to be the main pathway leading to lipid accumulation and obesity 
(Landgraf et al., 2015). However, there is also evidence of metabolic disturbances by 
CLO without weight gain. It was shown that CLO cause diabetes, dyslipidemia and 
impaired glucose tolerance in the absence of weight gain (Steffenhagen et al., 2012, 
Zimmermann et al., 2003). Another mechanism proposed is the direct effect of AAPs 
on insulin action causing its impairment which badly affects glucose transport and 
balance between lipogenesis and lipolysis (Vestri et al., 2007).Various clinical trials 
in schizophrenic patients taking CLO and OLA also showed a decrease in adiponectin 
levels which depicts the relationship of decreased adiponectin levels with insulin 
resistance  proposing its mechanistic role in metabolic toxicity (Lu et al., 2015, Bartoli 
et al., 2015b, Swartz et al., 2008). Leptin not only decreases appetite leading to weight 
loss but also involved in regulation of glucose metabolism and immune system. 
Various clinical studies showed a mixed result with some studies showing an increase 
in leptin levels (Potvin et al., 2015) by AAPs whereas others showed no change 
(Tanaka et al., 2008). It was suggested that leptin resistance might be the reason 
causing weight gain in schizophrenic patients taking AAPs (Caro et al., 1996, Potvin 
et al., 2015). Inflammation might be involved in causing metabolic toxicity by AAPs. 
It was suggested that pro-inflammatory marker levels especially IL-6 and TNF-α were 
increased in schizophrenic patients taking AAPs. These markers blocked IRS1 
phosphorylation resulting in insulin resistance (Hotamisligil et al., 1995, Makki et al., 
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2013). The other proposed mechanism was related to TNF-α which act on adipocytes 
and cause increase in lipolysis and decrease triglyceride synthesis. This resulted in 
increasing levels of FFA in the plasma. These FFA cause accumulation of triglycerides 
and other activated lipids in peripheral tissues like liver, pancreas and beta cells. This 
accumulation disrupts the normal metabolic function of these tissues leading to insulin 
resistance (Guilherme et al., 2008). Previous studies showed an increase in IL-6 and 
TNF-α levels in schizophrenic patients taking AAPs (Mori et al., 2015, Klemettila et 
al., 2014, Victoriano et al., 2010, Pollmacher et al., 2000). Other proposed mechanisms 
by which AAPs caused metabolic toxicity include, effects on neuroreceptors 
(serotonin, dopamine, histamine) leading to weight gain (Balt et al., 2011, Masaki et 
al., 2004, Reynolds and Kirk, 2010), impairment of mitochondrial functions (Ji et al., 
2009) and production of reactive oxygen species (Miljevic et al., 2013). 
    The absolute mechanism causing AAPs-induced metabolic adverse effects is 
unknown. This chapter investigate the effect of AAPs on adipogenesis using primary 
human adipocytes as a model and attempt validation of the results obtained in Chapter 
2 using a murine 3T3-F442A model. 
 
3.1.1 Rationale for the study 
 
Several mechanisms have been proposed which are thought to be mechanistically 
involved in metabolic adverse effects caused by AAPs so far. Among AAPs, CLO and 
OLA has been suggested to cause metabolic adverse effects compared to other AAPs 
(Nasrallah, 2008). This could be due to their effects on adipogenesis (Loffler et al., 
2016, Francesco and Cervone, 2014); or changes in their transcription factors (Sertie 
et al., 2011); or inflammatory cytokines (Guilherme et al., 2008); or adipokines such 
as adiponectin and leptin (Bartoli et al., 2015a, Potvin et al., 2015); or combination of 
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these effects. Our adiponectin secretion data for murine 3T3-F442A adipocyte model 
showed contradictory result (as discussed in chapter 2) compared to what showed 
clinically (Paredes et al., 2014, Pollmacher et al., 2000), which inclined us to use 
primary human adipocyte as a model to validate the effect of AAPs on lipid 
accumulation, adipogenic transcription markers, and adipocytokine release.  
3.1.2 Hypothesis 
 
This chapter tested the hypothesis that AAPs directly interfere with adipogenesis and 
adipocyte function which in turn result in AAP-induced weight gain and metabolic 
dysfunction. 
 
3.1.3 Aims and objectives 
 
The aims and objectives were; 
1) To characterise AAP-induced metabolic toxicity in vitro using primary human 
adipocytes. 
2) To investigate the mechanisms behind AAP-induced metabolic toxicity in primary 
human adipocytes by assessment of: 
a. adipocyte lipid accumulation and gene transcription; 
b. adipocyte-secreted protein markers and 
c. adipocyte secreted inflammatory cytokines 
3) To correlate the findings from Chapter 2 (3T3-F442A) with those generated using 









CLO and OLA were purchased from Sigma-Aldrich, MO, USA while ARI and LPV 
were obtained from Santa Cruz Biotechnology, TX, USA.  Preadipocyte growth 
medium (supplemented with fetal calf serum [0.05ml/ml], endothelial cell growth 
supplement [0.004ml/ml], epidermal growth factor [10ng/ml], hydrocortisone 
[1µg/ml] and heparin [90µg/ml]), Differentiated growth medium (supplemented with 
insulin [0.5µg/ml], d-biotin [8µg/ml], d-dexamethasone [400ng/ml], 3-isobutyl-1-
methylxanthine (IBMX) [44µg/ml], L-Thyroxine [9ng/ml] and ciglitazone [3µg/ml]), 
Nutritional  growth medium (supplemented with fetal calf serum [0.03ml/ml], insulin 
[0.5µg/ml], d-biotin [8µg/ml] and d-dexamethasone [400ng/ml]), detach kit 
(containing HEPES  (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), trypsin 
and trypsin neutralising solution), and freezing medium were purchased from 
PromoCell, Heidelberg, Germany. DMSO, RIPA lysis buffer, chloroform and Oil Red 
O dye were purchased from Sigma-Aldrich, MO, USA. HBSS, phosphate-buffered 
saline (PBS), pre-cast gels for western blot, LDS sample buffer, sample reducing 
agent, enhanced chemiluminescent substrate, reverse transcription kit, Tri Reagent 
solution for RNA, FAM labelled PPARγ and lipin1, VIC labelled β- actin TaqMan 
gene expression assays, TaqMan gene expression master mix, isopropanol, human 
ELISA kits for adiponectin, IL-6, TNF-α, and leptin were purchased from Thermo 
Fisher Scientific, TX, USA. The nitrocellulose membrane was purchased from Gene 
Flow, Staffordshire, UK. All other cell culture materials were purchased from Thermo 





3.2.2 Cell Culture 
 
Preadipocytes from abdominal subcutaneous adipose tissue obtained from healthy 
controls (n=3; Caucasian; age range: 31-43 years; Gender: female; BMI: 21-25kg/m2) 
were obtained commercially from PromoCell, Heidelberg, Germany. The 
preadipocytes were cultured and maintained in a T75 flask in preadipocyte growth 
medium. Once confluent (75-80%), cell culture media was discarded and cells were 
washed carefully with 5ml of HEPES solution. 5ml of trypsin was added to the flask 
and incubated for 5 minutes at room temperature to dislodge the cells from the surface 
of the flask. After incubation cells were detached by gentle tapping of the bottom of 
the flask. 5ml of trypsin neutralization solution was added to neutralize trypsin. This 
mixture was then poured into a universal tube and centrifuged at 220g for 3 minutes 
at room temperature to obtain the cell pellet. The supernatant was discarded once 
centrifugation was finished and the cell pellet was suspended in 3-5ml of preadipocyte 
growth medium depending upon the size of the pellet. Cell counting was done by 
mixing 10µl of the cell containing media with 10µl of trypan blue dye. Then 10µl 
mixture of cells and dye was loaded into a Countess Cell chamber slide, and cell 
counting was performed using Cell Counter, Thermo Fisher Scientific, TX, USA. One 
million cells were then sub-cultured in a new T75 flask for maintenance of cell cohort. 
The remaining cells were either frozen or cultured in 6-well plates. 
75,000 cells/well were seeded in 6-well plates containing preadipocyte growth 
medium. Once 70% confluent (usually take 3-5 days depending on the population 
doubling time for individual donor cells), differentiation was induced by replacing the 
basal medium with the differentiation medium (Counted as day 0 of differentiation).  
After 3 days, the differentiated media was replaced by adipocyte nutrition medium. 
The nutrition media was changed every 48hours for the next 10 days. Cells were 
treated with either vehicle or different doses of AAPs starting from day 3 to day 11 
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(total 5 drug additions). On day 13, 48 hrs after the last drug addition, conditioned 
media and cell lysates were collected to study adipocytokine levels, and gene and 
protein expression respectively. In our experiment, we used 3 donors to check the 
reproducibility of the results and for statistical purposes. 
CLO (1µM, 20μM), OLA (0.2µM, 20μM) and ARI (0.2µM, 10μM) were used in the 
study. We focused primarily on two doses for each drug; one was a therapeutically 
used dose and the other was a higher dose (20uM) based on the assumption that AAPs 
might accumulate in the adipose tissue. LPV (20μM), an anti-HIV drug with known 
deleterious effects on adipocyte function was used as a comparator.   
Cell death was minimal with a 20µM dose of CLO and OLA; however, 20µM ARI 
caused significant amount of cell death. The deleterious effect of 20µM ARI dose was 
also reported by Himmerich and colleagues (Himmerich et al., 2011) in their primary 
human adipocyte model. Because of this, we reduced the maximum concentration of 
ARI to 10μM. 
Table 3.1. Drug treatment timeline 
DM: Differentiating media 
 
 
3.2.3 Lipid Accumulation 
 










Adipocyte Nutrition Media 



































3.2.4 Measurement of Adipocytokine secretions 
 
Adiponectin, IL-6, TNF-α and leptin secretion were measured according to 
manufacturer’s protocol as described in section 2.2.5.   
3.2.5 Gene and protein expression 
 
Isolation of mRNA, reverse transcription, gene expression, and protein isolation and 
quantitation were measured by methodology as described in section 2.2.6 and 2.2.9  
3.2.6 Western blotting 
 
20µg protein was mixed with 5µl of a mixture of LDS sample buffer and sample 
reducing agent. This mixture was prepared by mixing 70µl of LDS sample buffer and 
30µl of sample reducing agent. Samples were heated at 95°C for 5 min. All samples 
were centrifuged and kept on ice for further 5 min. Pre-cast gels were used for loading 
of the samples. Ladder and samples were loaded in their respective wells. The gel was 
run at 80 volts in running buffer until samples run past the stacking gel for 15 min and 
then 170 volts for 1-1.5 hr before the samples reach the ridge at the bottom of the 
cassette. The gel was then blotted in transfer buffer at 100V for 1hr during which 
proteins were transferred to nitrocellulose membrane. The membrane was blocked in 
10% milk/TBST (Tris buffer saline-tween) solution for 1 hr to avoid non-specific 
binding of the antibodies. The primary antibody was diluted in 5% milk/TBST and the 
membrane was incubated with primary antibody overnight at 4 °C. After incubation, 
the nitrocellulose membrane was washed with TBST 6 times with repeated washes 
after every 5 minutes. After washing, the membrane was incubated with secondary 
antibody in 5% milk/TBST at room temperature for 1hr. The membrane was again 
washed 6 times with repeated washes after every 5 minutes.  Enhanced 
chemiluminescent substrate was then applied and western blot was developed by using 
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ChemiDoc Touch Imaging system and quantitated by Image Lab software (Bio-Rad, 
CA, USA). The antibodies used were PPARγ (1:1000 dilution, catalogue number: 
2443; Cell Signalling Technology, MA, USA), Anti-rabbit secondary antibody 
(1:2000 dilution: catalogue number 7074S: Cell Signalling Technology, MA, USA) 
and beta-actin (1:1000 dilution, catalogue number sc-47778: Santa Cruz 
Biotechnology, TX, USA). 
3.2.7 Simple Western Assay  
 
Simple Western was performed by methodology as described in section 2.2.11.  
3.2.8 Clozapine Accumulation Assay 
 
Both murine and human subcutaneous preadipocytes were cultured in 6 well plates. 
After reaching fully differentiated stage, (Cells kept in differentiating media, murine 
adipocytes: 10 days; primary human adipocytes: 3 days in differentiating media and 
then 10 days in adipocyte nutrition media), cells were washed two times with pre-
warmed HBSS. Then 1ml/well pre-warmed master mix was added to each well. 
Master Mix was prepared which consist of transport buffer (HBSS supplemented with 
25mM HEPES and 0.1% BSA; pH: 7.4) and 0.1μCi/ml tritium-labelled CLO with 
sufficient non-radiolabelled drug. A separate master mix was used for the non-specific 
transporter inhibitor, Verapamil which was used at a concentration of 100μM.The 
plates were incubated for 30min at 37°C. After incubation, cells were washed three 
times with ice-cold HBSS and then solubilised with 10% SDS for 30min.The lysates 
were finally transferred to scintillation tubes having 4ml scintillation cocktail and 
radioactivity was measured through Tri-Carb 1500 Time-Resolved Liquid 




3.3 Statistical Analysis 
 
All statistical comparisons (3 donors) were made using t-test on Stats Direct software 
version 2.7.9. Two-way repeated measure Analysis of variance (ANOVA) was 
conducted by Statistical Package for Social Sciences (SPSS) version 24. Differences 
were considered significant at p≤0.05.The result was shown as mean ± SD.  
We have presented data relative to measured variables observed with the vehicle 
control. The following points have been deduced by going through all the data 
processed by two-way repeated measures ANOVA.  
In all of our data, Mauchly’s test of Sphericity indicated that the assumption of 
sphericity had not been violated for the one-way effects of treatment and dose or the 
interaction of the two (p=NS). Sphericity is the statistical condition where the 
variances of the differences between all combinations of related groups are equal. If it 
is not equal then there is a violation of sphericity. However, if data does not violate 
the assumption of sphericity then there is no need to modify degrees of freedom. Not 
violating this assumption means that the F-statistic that has been calculated is valid 
and can be used to determine statistical significance 
(https://statistics.laerd.com)(https://statistics.laerd.com/statistical-guides/sphericity-
statistical-guide.php). 
In all of our parameters, a test of between-subject effects showed that there is a 
statistically significant difference between the responses of the three donors in the 
study (p≤0.05). This indicates a high inter-individual variability. This showed that 
experiment itself worked fine with respect to drug effect on individual donor; however 
because of variability between donors (adipose tissue donors), we observed marked 
differences in the magnitude of the effect.  
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In two-way repeated measures ANOVA, we also performed comparison between 
therapeutic and high dose. 
 Overall, due to high inter-individual variability the results based on three samples 
should be utilised as indicators for further study as opposed to drawing a conclusion 
about the biology of the individual.  
In conclusion, we can say that two-way repeated measures ANOVA analysis provide 
us detail information about our data and comparison which clearly indicated that the 
drug is producing some trend or change however due to inter-individual variability, 
most of the outcome became non-significant.  
In result section, we will highlight our result along with two-way repeated measures 
ANOVA description separately for each parameter. 
3.4 Results 
 
3.4.1 Effect of AAPs on adipocyte lipid accumulation  
 
We expressed lipid accumulation data for each drug and dose as a percentage of what 
was observed with the vehicle; this showed that CLO at therapeutic dose (1µM) 
resulted in significantly increased accumulation of lipids in differentiating adipocytes 
on day 13 (CLO; p=0.04) while therapeutic doses for OLA (0.2µM) and ARI (0.2µM) 
did not show any change. However, high doses of CLO (20µM) and OLA (20µM) but 
not ARI (10µM), showed a trend to increase lipid accumulation although it was not 
statistically significant (Fig.3.2A).  
The two-way repeated measures ANOVA further confirmed the above results; 
statistically significant difference in the mean treatment response for lipid 
accumulation between treatments (F (2, 4) = 7.07, p = 0.04) was observed (The test 
statistic used for ANOVA is the F-statistic and is calculated by taking the Mean Square 
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(MS) for the variable divided by the MS of the error. This F-statistic is a ratio of the 
variability between groups compared to the variability within the groups). However, 
the difference in lipid accumulation between the high dose and therapeutic dose for all 
treatments were not statistically significant (F (1, 2) =0.431, p=0.5) (Fig.3.2B). The 
analysis also showed that the interaction between treatment and dose was statistically 
non-significant (F (2, 4) =1.882, p=0.2).  
Two-way repeated measures ANOVA also showed that there was significant 
difference between subjects studied in this experiment (p=0.001). However, individual 
donor response for lipid accumulation followed a similar trend for all the drugs tested 
(Fig.3.2C). Post hoc tests using the Bonferroni correction revealed that the therapeutic 
vs high dose effect elicited average 3% change in lipid accumulation, which was 
statistically non-significant (95% confidence Interval (CI) [18%, 25%], p =0.5).  
Oil Red O staining of primary human adipocytes also showed that CLO and OLA, at 























































Figure 3.2: A) Quantitation of lipid-bound dye extracted by isopropanol showing the effect of various concentrations of CLO, OLA, and ARI on differentiated adipocytes. 
All experiments were done in adipocytes cultured from 3 individual donors. Data was shown as Mean ±SD; p≤0.05. * Vehicle vs CLO;  B) Dose and Treatment Plot profile 
for lipid accumulation with AAPs. Dose 1(blue): therapeutic dose; Dose 2 (green): higher dose; Treatment 1: CLO, 2: OLA, 3: ARI; C) Change in lipid accumulation 




































ARI 10µM OLA 20µM 
OLA 0.2µM 
Figure 3.3. Photomicrographs (20x magnification) showing Oil Red O staining of cultured primary 








3.4.2 Effect of AAPs on adipocytokines 
 
3.4.2.1 Adiponectin  
 
We expressed adiponectin levels for each drug and dose as a percentage of what was 
observed with the vehicle; this showed that both CLO and OLA at higher doses 
(20uM) resulted in significantly reduced secretion of adiponectin from the 
differentiating adipocytes on day 13 (CLO; p=0.03, OLA; p=0.01). However, there 
was no change in adiponectin secretion with the therapeutic doses of CLO or OLA. 
Both doses of ARI showed a trend to increase adiponectin although this was not 
statistically significant (Fig.3.4A). 
The two-way repeated measures ANOVA further confirmed the above results; 
statistically significant difference in the mean treatment response for adiponectin 
secretion between treatments (F (2, 4) = 10.16, p = 0.03) was observed. There was also 
a statistically significant difference between high and therapeutic dose of all 
treatments (F (1, 2) = 40.90, p = 0.02) (Fig.3.4B). The analysis also showed that the 
interaction between treatment and dose was statistically significant (F (2, 4) =20.45, 
p=0.01). 
Two-way repeated measures ANOVA also showed that there was significant 
difference between subjects studied in this experiment (p=0.003).  However, 
individual donor response for adiponectin followed a similar trend for all the drugs 
tested (Fig.3.4C). Post hoc tests using the Bonferroni correction revealed that there 
was a 31% average change in adiponectin secretion between the therapeutic and high 










































































Figure 3.4: A) Adiponectin secretion showing the effect of various concentrations of CLO, OLA and ARI on differentiated adipocytes. All experiments were done 
in adipocytes cultured from 3 individual donors. Data was shown as Mean ± SD; p ≤ 0.05. * VEH vs CLO/OLA;  B) Dose and Treatment Plot profile for adiponectin 
secretion with AAPs. Dose 1(blue): therapeutic dose; Dose 2(green): higher dose; Treatment 1: CLO, 2: OLA, 3: ARI; C) Change in adiponectin secretion observed 







3.4.2.2 Leptin  
 
We expressed leptin levels for each drug and dose as a percentage of what was 
observed with the vehicle; this showed that CLO but not OLA resulted in significantly 
increased secretion of leptin from the differentiating adipocytes on day 13 (1µM CLO; 
p=0.04, 20µM CLO; p=0.01). Both doses of ARI showed a trend to decrease leptin 
secretions although this was not statistically significant (Fig.3.5A).  
The two-way repeated measures ANOVA further confirmed the above results; 
statistically significant difference in the mean treatment response for leptin secretion 
between treatments (F (2, 4) =18.09, p=0.01) was observed. However, the difference 
between high and therapeutic dose for all treatments were not statistically significant 
(F (1, 2)=0.449, p=0.5) (Fig.3.5B). The analysis also showed that the interaction 
between treatment and dose was statistically non-significant (F (2, 4)=1.794, p=0.3).  
Two-way repeated measures ANOVA also showed that there was significant 
difference between subjects studied in this experiment (p=0.001).  However, 
individual donor response for leptin followed a similar trend for all the drugs tested 
(Fig.3.5C). Post hoc tests using the Bonferroni correction revealed that there was only 
a 0.8% average change in leptin secretion between therapeutic and high dose used for 






































































Figure 3.5: A) Leptin secretion showing the effect of various concentrations of CLO, OLA and ARI on differentiated adipocytes. All experiments were done in 
adipocytes cultured from 3 individual donors. Data was shown as Mean ±SD; p≤0.05. * Vehicle vs CLO;  B) Dose and Treatment Plot profile for leptin secretion 
with AAPs. Dose 1(blue): therapeutic dose; Dose 2(green): higher dose; Treatment 1: CLO, 2: OLA, 3: ARI;  C) Change in leptin secretion observed in individual 
donors with various concentrations of CLO, OLA and ARI. 





3.4.2.3 IL-6  
 
We expressed IL-6 levels for each drug and dose as a percentage of what was observed 
with the vehicle; this showed that the therapeutic doses of CLO, OLA and ARI did not 
show any change in IL-6 levels. However, high doses of both CLO and OLA but not 
ARI showed a trend to increase IL-6 secretion although this was not statistically 
significant (Fig.3.6A).  
The two-way repeated measures ANOVA further confirmed the above results; no 
statistically significant difference in the mean treatment response for IL-6 secretion 
between treatments (F (2, 4) = 1.67, p = 0.29) was observed.  The difference in IL-6 
secretion between high and therapeutic dose for all treatments were also statistically 
non-significant (F (1, 2) =1.99, p=0.5). (Fig.3.6B). The analysis also showed that the 
interaction between treatment and dose was statistically non-significant (F (2, 4)=4.29, 
p=0.6).  
Two-way repeated measures ANOVA also showed that there was significant 
difference between subjects studied in this experiment (p=0.005).  However, 
individual donor response for IL-6 followed a similar trend for all the drugs tested 
(Fig.3.6C). Post hoc tests using the Bonferroni correction revealed that there was a 6% 
average change in IL-6 secretion between the therapeutic and high dose tested for each 




We did not detect TNF-α level in our samples despite using a high-sensitive TNF-α 







































































Figure 3.6: A) IL-6 secretion showing the effect of various concentrations of CLO, OLA and ARI on differentiated adipocytes. All experiments were done in 
adipocytes cultured from 3 individual donors. Data was shown as Mean ±SD; p≤0.05; B) Dose and Treatment Plot profile for IL-6 secretion with AAPs. Dose 1(blue): 
therapeutic dose; Dose 2(green): higher dose; Treatment 1: CLO, 2: OLA, 3: ARI; C) Change in IL-6 secretion observed in individual donors with various 




3.4.3 Effect of AAPs on PPARγ and lipin1 gene and protein expression  
 
3.4.3.1 PPARγ gene 
 
We expressed PPARγ mRNA expression for each drug and dose as a percentage of 
what was observed with the vehicle; this showed that neither CLO nor OLA showed 
any change in expression. ARI, on the other hand, showed a trend to increase PPARγ 
expression at therapeutic dose but this was statistically non-significant. There was no 
change in PPARγ gene expression at 10µM of ARI (Fig.3.7A).  
The two-way repeated measures ANOVA further confirmed the above results; no 
statistically significant difference in the mean treatment response for PPARγ gene 
expression between treatments (F (2, 4) = 0.286, p = 0.7) was observed. No difference 
in PPARγ expression was observed between high and therapeutic dose for all 
treatments (F (1, 2) =0.50, p=0.5) (Fig.3.7B). The analysis also showed that the 
interaction between treatment and dose was statistically non-significant (F (2, 
4)=0.382, p=0.7).  
Two-way repeated measures ANOVA also showed that there was significant 
difference between subjects studied in this experiment (p=0.04).  However, individual 
donor response for expression followed a similar trend for all the drugs tested 
(Fig.3.7C). Post hoc tests using the Bonferroni correction revealed that there was a 
15% average change in PPARγ gene expression between the therapeutic and  high 
dose tested for AAPs; however, this was statistically non- significant (95% CI, [79%, 
110%], p =0.5).  
 
3.4.3.2 PPARγ protein expression  
We expressed PPARγ protein expression for each drug and dose as a percentage of 
what was observed with the vehicle; this showed that although both doses of CLO and 
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the high dose of OLA showed a trend to increase PPARγ protein expression, this was 
not statistically significant. Neither dose of ARI showed any difference in PPARγ 
expression (Fig.3.8A).  
The two-way repeated measures ANOVA further confirmed the above results; no 
statistically significant difference in the mean treatment response for PPARγ protein 
expression between treatments (F (2, 4) = 0.456, p = 0.6) was observed. Also, there 
was no difference between high and therapeutic dose for all treatments (F (1, 2) 
=0.313, p=0.6) (Fig.3.8B). The analysis also showed that the interaction between 
treatment and dose was statistically non-significant (F (2, 4)=0.155, p=0.6).  
Two-way repeated measures ANOVA also showed that there was significant 
difference between subjects studied in this experiment (p=0.03).  However, individual 
donor response for expression followed a similar trend for all the drugs tested 
(Fig.3.8C). Post hoc tests using the Bonferroni correction revealed that the therapeutic 
vs high dose effect elicited on average 7% change in expression, which was 




























































Figure 3.7: A) PPARγ gene expression showing the effect of various concentrations of CLO, OLA and ARI on differentiated adipocytes. All experiments were 
done in adipocytes cultured from 3 individual donors. Data was shown as Mean ±SD; p≤0.05; B) Dose and Treatment Plot profile for PPARγ gene expression with 
AAPs. Dose 1(blue): therapeutic dose; Dose 2(green): higher dose; Treatment 1: CLO, 2: OLA, 3: ARI; C) Change in PPARγ gene expression observed in individual 
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Figure 3.8: A) PPARγ protein expression showing the effect of various concentrations of CLO, OLA and ARI on differentiated adipocytes. All experiments were 
done in adipocytes cultured from 3 individual donors. Data was shown as Mean ±SD; p≤0.05; B) Dose and Treatment Plot profile for PPARγ protein expression 
with AAPs. Dose 1(blue): therapeutic dose; Dose 2(green): higher dose; Treatment 1: CLO, 2: OLA, 3: ARI; C) Change in PPARγ protein expression observed in 





























































3.4.3.3 LPIN1 gene expression  
 
We expressed LPIN1 mRNA expression for each drug and dose as a percentage of 
what was observed with the vehicle; this showed that therapeutic doses of all three 
AAPs showed no change in expression. Interestingly, higher dose of all AAPs showed 
a trend to decrease LPIN1 mRNA expression however this was not statistically 
significant (Fig.3.9A).  
The two-way repeated measures ANOVA further confirmed the above results; no 
statistically significant difference in the mean treatment response for LPIN1 gene 
expression between treatments (F (2, 4) = 0.068, p = 0.9) was observed. No difference 
was observed between high and therapeutic dose for all treatments (F (1, 2) =0.55, 
p=0.4) (Fig.3.9B). The analysis also showed that the interaction between treatment 
and dose was statistically non-significant (F (2, 4)=1.049, p=0.4).  
Two-way repeated measures ANOVA also showed that there was significant 
difference between subjects studied in this experiment (p=0.001).  However, 
individual donor response for expression followed a similar trend for all the drugs 
tested (Fig.3.9C). Post hoc tests using the Bonferroni correction revealed that the 
therapeutic vs high dose effect elicited on average 31% change in expression, which 
was statistically significant (95% CI, [13%, 49%], p =0.01).  
 
3.4.3.4 LPIN1 protein expression  
We expressed LPIN1 protein expression for each drug and dose as a percentage of 
what was observed with the vehicle. Although there were some trends to 
increase/decrease LPIN1 protein expression between the doses tested, none of the 
changes observed were statistically significant (Fig.3.10A).  
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The two-way repeated measures ANOVA further confirmed the above results; no 
statistically significant difference in the mean treatment response for LPIN1 protein 
expression between treatments (F (2, 4) = 5.95, p = 0.06) was observed; No difference 
was observed between high and therapeutic dose for all treatments (F (1, 2) =1.38, 
p=0.3) (Fig.3.10B). The analysis also showed that the interaction between treatment 
and dose was statistically non-significant (F (2, 4)=0.954, p=0.4).  
Two-way repeated measures ANOVA also showed that there was significant 
difference between subjects studied in this experiment (p=0.02).  However, individual 
donor response for expression followed a similar trend for all the drugs tested 
(Fig.3.10C). Post hoc tests using the Bonferroni correction revealed that the 
therapeutic vs high dose effect elicited on average 27% change in expression, which 



























































Figure 3.9: A) LPIN1 gene expression showing the effect of various concentrations of CLO, OLA and ARI on differentiated adipocytes. All experiments were 
done in adipocytes cultured from 3 individual donors. Data was shown as Mean ±SD; p≤0.05; B) Dose and Treatment Plot profile for LPIN1 gene expression with 
AAPs. Dose 1(blue): therapeutic dose; Dose 2(green): higher dose; Treatment 1: CLO, 2: OLA, 3: ARI; C) Change in LPIN1 gene expression observed in individual 





























































Figure 3.10: A) LPIN1 protein expression showing the effect of various concentrations of CLO, OLA and ARI on differentiated adipocytes. All experiments were 
done in adipocytes cultured from 3 individual donors. Data was shown as Mean ±SD; p≤0.05; B) Dose and Treatment Plot profile for LPIN1 protein expression with 
AAPs. Dose 1(blue): therapeutic dose; Dose 2(green): higher dose; Treatment 1: CLO, 2: OLA, 3: ARI; C) Change in LPIN1 protein expression observed in 
individual donors with various concentrations of CLO, OLA and ARI. 
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3.4.4 Clozapine accumulation Assay 
 
 
We observed an increase in adiponectin secretion by CLO in our experiment on 3T3-
F442A murine adipocytes (discussed in Chapter 2). This contradicted with already 
published in vitro data (Tsubai et al., 2017) as well as clinical data (Sugai et al., 2012, 
Klemettila et al., 2014) which reported decrease adiponectin levels by CLO. To 
investigate this discrepancy, we used primary human adipocyte as another model to 
study the effect of CLO on adiponectin. We compared the accumulation of CLO in 
murine and primary human adipocytes to investigate whether there was any change in 
the uptake of the drug between these two cell models.  
Our results showed that CLO accumulated 20-fold more in primary human adipocytes 
compared to the 3T3-F442A murine adipocytes (Fig.3.11 A). On adding verapamil, a 
nonspecific multitransporter inhibitor, there was a significant decrease in the 
accumulation of CLO (593±158.01; p=0.006) in primary subcutaneous human 
adipocytes compared to the control (1293.4±170.56) (Fig. 3.11B) whereas in 3T3-
F442A adipocytes there was no change (45.63±26.96; p=ns) compared to control 
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B 
A 
Fig 3.11: A) Accumulation of CLO in 3T3-F442A differentiated adipocytes and subcutaneous human 
adipocytes. Cells were incubated for 30min in the master mix with 1μM of CLO (H3) in the presence 
or absence of transport inhibitor (100μM Verapamil); B) Accumulation of CLO in adipocytes cultured 
from 3 individual donors; C)  Accumulation of CLO in 3T3-F442A differentiated adipocytes which was 






Various mechanisms have been highlighted to be involved in AAP-induced metabolic 
adverse effects however; there is a need to address the exact mechanisms by which 
this toxicity happens. This is important as it will guide therapeutic decisions and also 
lead to the development of new drugs with minimal adverse effects. Various studies 
have proposed a direct effect of AAPs on the adipose tissue leading to an increase in 
lipid accumulation. This increase is considered as one of the mechanisms causing 
metabolic toxicity (Minet-Ringuet et al., 2007, Pavan et al., 2010, Hemmrich et al., 
2006). Our data showed a significant increase in lipid accumulation by CLO at a 
therapeutic dose (1µM) while higher doses of both CLO and OLA, even though a trend 
to increase was observed, the result was non-significant. On the other hand, ARI 
showed a trend to decrease or no change. Our findings with CLO and OLA are 
consistent with the previous studies which showed an increase in lipid accumulation 
with CLO in human adipocytes isolated from subcutaneous adipose tissue (Hemmrich 
et al., 2006, Pavan et al., 2010) and non-significant increase in lipid accumulation 
observed with OLA in adipose-derived stem cells isolated from abdominal 
subcutaneous adipose tissue (Sertie et al., 2011). Hemmrich and colleagues reported a 
decrease in lipid accumulation with ARI in primary human adipocytes (Hemmrich et 
al., 2011); our own results are in agreement with these results. Increase in lipid 
accumulation observed in our study with CLO particularly may suggest that this could 
be one of the mechanisms by which CLO (and to certain extent, OLA) result in 
increased weight gain. However it must be highlighted that there are other studies 
which has failed to show any effect by CLO on adipogenesis (Hauner et al., 2003). 
Hauner’s study used mammary-derived adipose tissue rather than subcutaneous 
adipose tissue; regiospecific differences in the way adipose tissue respond to drugs has 
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been shown before and could be one of the reason for differences observed between 
this study and Hauner’s study. Also, Hauner et al exposed the cells to CLO only for 
24hrs; this study utilised a chronic dosing pattern with long term drug incubations 
(drug exposure once every 48 hrs for a period of 10 days) to mimic the clinical model. 
This could also be the reason for the discrepancy in results.  
Adipogenesis is driven by several transcription factors and their downstream target 
genes which are important for glucose and lipid metabolism. Some of these factors are 
also important for maturation and maintenance of adipocytes. Among these, the most 
important are PPARγ and lipin1. Even though we observed a trend to increase for 
PPARγ and lipin1 proteins, we encountered high in-between variability in response 
between our biological replicates and therefore these results were not statistically 
significant. We only used 3 biological replicates because of i) limitations in the 
availability of adipocytes from donors who met our inclusion criteria, and, ii) logistics 
of performing a chronic toxicity experiment in a larger number of replicates. It may 
be that an increased sample size could have resulted in reduced variability. However, 
when individual samples are analysed in isolation, the trend observed in expression of 
PPARγ and lipin1 protein (increased expression with higher dose of CLO and OLA 
while ARI reduced it) was consistent between all 3 biological replicates. In addition, 
our results on PPARγ gene tallies with previous studies which showed no change in 
PPARγ with therapeutic dose of CLO. Our data also coincides with previous studies 
where OLA (Nimura et al., 2015, Sertie et al., 2011) and ARI (Sarvari et al., 2014) 
showed no change in PPARγ mRNA expression. This suggests a role for other 
mechanisms involved in AAP-induced metabolic adverse effects. We have for the first 
time investigated the expression of cellular lipin1 and whether it change with AAPs. 
However, unlike PPARγ, the results varied between the biological replicates for 
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individual doses of AAPs and it was difficult conclude how lipin1 expression changes 
with AAPs. Future studies with an increased sample size are required to explore this 
transcription factor as it is important for maturation and maintenance of adipocytes 
and functions as a co-factor between PPARγ and CEBP-α to produce target genes 
necessary for the maintenance of adipocytes (Reue and Zhang, 2008). Adiponectin is 
an insulin-sensitizing cytokine, the lower levels of which caused insulin resistance. 
Our data showed a decrease in adiponectin secretion by CLO and OLA but not ARI. 
This coincides with clinical studies which have reported reduction in adiponectin 
levels with CLO and OLA but not with ARI (Paredes et al., 2014, Pollmacher et al., 
2000, Klemettila et al., 2014, Hanssens et al., 2008). Human studies showed negative 
correlation between adiponectin and insulin sensitivity. It has been observed that 
adiponectin levels were decreased in subjects having insulin resistance in condition 
like T2DM or obesity (Weyer et al., 2001, Jin et al., 2008). It has also been showed 
that treatments given to improve insulin sensitivity also improved circulating 
adiponectin levels (Arita et al., 1999, Wang et al., 2006). This suggests that CLO and 
OLA may act directly on adipocytes and decrease the secretion of adiponectin which 
ultimately cause insulin resistance. Leptin is another important adipokine which has 
been suggested to play a role in metabolic disease. Leptin has a role in energy balance 
and suppresses food intake and thereby cause weight loss (Lu et al., 2015). Our leptin 
results showed a significant increase in secretion by CLO but not OLA. However, ARI 
showed a trend to decrease. Our data coincides with clinical data in terms of CLO and 
ARI (Paredes et al., 2014, Jin et al., 2008); however, it did not show a significant 
increase in leptin levels with OLA as suggested by previous studies (Potvin et al., 
2015). This could be because of a variety of reasons. Firstly, our data comes from only 
3 donors and therefore does not fully represent the wider population. Secondly, it has 
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been proposed that some individuals might be resistant to drug effect on leptin or vary 
in sensitivity for leptin metabolism. Increase in concentration of leptin without food 
reduction in obese patients had been reported suggesting the development of leptin 
resistance in these patients (Potvin et al., 2015). This showed that AAPs could 
exacerbate leptin resistance condition. This resistance could generate metabolic 
condition which leads to weight gain.  
Another important mechanism suggested for the development of drug-induced 
metabolic toxicity is inflammation within the adipose tissue. It has been suggested that 
proinflammatory cytokines like IL-6 or TNF-α upregulate the suppressor of cytokine 
signalling 3 (SOCS3) which act on IRS1 and block its phosphorylation leading to 
insulin resistance (Makki et al., 2013). IL-6 levels showed a trend to increase with 
both CLO and OLA (particularly for the higher doses) but not ARI although these 
were statistically non-significant. Our results are consistent with what is observed with 
clinical studies (Leonard et al., 2012, Sobis et al., 2015). This might suggest 
inflammation as one of the main potential mechanisms by which CLO and OLA cause 
insulin resistance leading to metabolic toxicity. We did not detect any TNF-α in our 
conditioned media despite using a high-sensitive TNF-α assay kit. This might suggest 
that only negligible amounts of TNF-α was present in the conditioned media. However 
this contradict with clinical results which showed increased levels of TNF-α in AAP-
treated schizophrenic patients (Klemettila et al., 2014, Pollmacher et al., 2000). 
However in vitro study on isolated subcutaneous human adipocytes by Sarvari et al 
showed, despite detection of TNF-α level, no significant change in levels by CLO, 
OLA and ARI. One possibility of contradictory data in our study might be less 
exposure of cells to drugs compare to Sarvari et al methodology where they add drugs 
continuously for 11 days and changed conditioned media daily while we exposed cells 
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to drugs for only 5 times with change of conditioned media after every 48hr. Clinically 
AAPs were also used for long period of time due to which TNF-α levels were easily 
detected.  
Overall, our model showed results which broadly coincided with clinical studies 
performed previously as well as results from other in vitro data. Whilst we saw a trend 
to change for various markers tested, we were unable to show a concrete change in 
some of the markers largely due to variability observed with our 3 biological 
replicates. Our results clearly show that AAPs produce a direct effect on adipocytes 
and interfere with adipocyte lipid accumulation and secretion of adiponectin and 
leptin. Higher doses of CLO and OLA also result in changes in PPARγ and lipin1 
protein expression. Importantly our results show that there is a distinct difference 
between the metabolically high risk AAPs (CLO and OLA) and ARI, an AAP which 
is not associated with metabolic toxicity.  
Our data also showed high variability between adipocytes obtained from individual 
donors.  However, if we consider each donor separately, it can be observed clearly that 
the patterns of gene and protein changes elicited by AAPs are almost similar.  The 
variability between individuals may be due to various factors such as age, gender, 
hormonal changes and difference in receptor distribution between adipocytes 
obtained. Variability could also be there in the amount of drug metabolising enzymes 
between individuals.  The variability was also seen in preclinical experiments where 
most studies (Choi et al., 2007, Davoodi et al., 2009, Boyda et al., 2010, Kalinichev et 
al., 2005, Lykkegaard et al., 2008, Ota et al., 2002, Park et al., 2008, Patel et al., 2009, 
Raskind et al., 2007, Sondhi et al., 2006) reported significant increase in weight gain, 
while few showed no effect (Amamoto et al., 2006, Baptista et al., 2002, Fell et al., 
2008, Fell et al., 2005, Lacruz et al., 2000, Minet-Ringuet et al., 2007) or minimal 
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change (Cooper et al., 2007, Cooper et al., 2008, Lin et al., 2006, Pouzet et al., 2003). 
A gender specific difference was observed in rats when tested with OLA; female rats 
showed weight gain but this was not observed with male rats. On the other hand, CLO 
generally showed a negative result in both genders in rats showing gender-dependent 
effects as well (Panariello et al., 2011). Covell et al study on schizophrenic patients 
reported that AAPs especially CLO and OLA cause more weight gain in female 
patients than male showing gender specific differences (Covell et al., 2004). 
Our findings also coincided with other researchers who used less number of donors 
and reported higher variation in their result which clearly depicts that variation could 
be due to donor itself and not due to experimental errors (Sarvari et al., 2014, Sertie et 
al., 2011). 
We obtained contradictory results for adiponectin secretion for the murine and primary 
human adipocyte models. This prompted us to measure the uptake of CLO as an 
exemplar AAPs into both these cell types.  Our CLO accumulation assay data showed 
20-fold more accumulation of CLO in primary human adipocytes than the murine 
adipocytes. This would mean that the murine adipocytes were only getting exposed to 
a very low concentration of the drug despite addition of the same concentration of 
CLO to both murine and primary human adipocyte cultures. The contradictory result 
we found for adiponectin could be potentially explained on the basis of this. This might 
suggest differences in the uptake of AAPs by different type of cells (murine and human 
adipocytes); this may include differences in both transporter-dependent and non-
dependent mechanisms which should be carefully considered before selecting an in 
vitro model.   
In summary, our data demonstrated high inter-individual variability between the 3 
adipocyte donors which limits statistical significance of the results, and the 
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conclusions that can be drawn. In future studies a large number of donors may decrease 
the variability. Our data also suggest that the primary human adipocyte is a better 
translational model than the murine 3T3-F442A preadipocyte model. 
The primary human adipocytes data coincided with the clinical data observed for 
adiponectin; this made us to choose primary human adipocytes as the preferred model 
























  Chapter 4 
 
Therapeutic strategies to reverse 
AAP-induced metabolic adverse 












AAPs cause various metabolic adverse effects, including weight gain and insulin 
resistance, which are often difficult to treat. However various therapeutic strategies 
have been suggested as an option to reverse these metabolic adverse effects. There is 
little data available regarding the use of adjunctive drugs to reverse AAP-induced 
metabolic adverse effects (Mizuno et al., 2014). Schizophrenia treatment guidelines 
recommend antipsychotic monotherapy, but suggest polypharmacy as the last option 
to control metabolic adverse effects. Many combinations have been used to reduce 
psychotic symptoms plus  metabolic adverse effects (Fleischhacker and Uchida, 
2014). The most common combination used has been CLO and OLA with other AAPs 
or with other drug groups which include nizatidine, amantadine, reboxetine, 
topiramate (TOPI), sibutramine, metformin (MET), rosiglitazone (ROSI), ARI, 
phenylpropanolamine, modafinil, fenfluramine and atomoxetine. Data from various 
randomised clinical trials showed better results or improvements in metabolic adverse 
effects when AAPs were used together with MET, ARI, TOPI and ROSI (Zimbron et 
al., 2016). A review conducted by Faulkner et al showed improvement in  metabolic 
adverse effects after using reboxetine and TOPI as an adjunctive, but showed mixed 
results for amantadine, nizatidine and sibutramine (Faulkner et al., 2007). They also 
proposed that adjunctive therapies should be applied to antipsychotic patients who 
followed non-pharmacological approaches, like physical activity and diet restriction 
for managing AAP-induced metabolic adverse effects. Their studies also highlighted 
some limitations due to small sample size, short duration of the study, the variability 
of the interventions, failure to study the adverse effects of add-on drugs, 
pharmacokinetic effects and failure to study specific mechanism by which drugs 
reduced  metabolic adverse effects (Faulkner et al., 2007). Another review by Maayan 
and colleagues showed significant improvement in metabolic adverse effects, 
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especially body weight, by using concomitant medications which included 
sibutramine, TOPI, reboxetine, MET and D-fenfluramine. They found that, among all 
the drugs used, MET showed the strongest effect on weight and other metabolic 
parameters. However, their study could not find sufficient evidence to make 
recommendations for broad clinical use due to the small sample size, short study 
duration and the non-availability of data on the adverse effects caused by adjunctive 
drugs (Maayan et al., 2010). The research by Mizuno and colleagues also favoured 
MET as more effective in reducing weight in CLO and OLA-treated schizophrenic 
patients compared to TOPI, ARI, sibutramine, and reboxetine. It was also reported that 
MET and ROSI improved insulin resistance, while ARI, MET and sibutramine 
decreased cholesterol and triglyceride levels more effectively than all the other drugs 
used (Mizuno et al., 2014). From this report, we can surmise that MET seems to be 
the first choice to use as an add-on medication in AAP-treated schizophrenic patients 
as it showed improved effects on body weight, lipids and insulin resistance. However, 
a meta-analysis by Choi suggested that TOPI, ARI and sibutramine are more 
efficacious than MET or reboxetine in reducing weight and  metabolic adverse effects 
(Choi, 2015), showing conflicting results across various studies. As mentioned earlier, 
the difference in sample size, study duration, adjunctive drugs pharmacokinetics and 
the patient response might have affected the results. The study by Fernandez and 
colleagues also suggested genetic involvement in drug response. It was reported that 
a polymorphism in leptin receptor gene resulted in a blunted response in CLO-treated 
patients taking MET (Fernandez et al., 2010), raising the possibility of the 
involvement of genetic factor in drug response. Table 4.1 shows a summary of the 
adjunctive drugs used in schizophrenic patients who were prescribed CLO and OLA 




Table 4.1. Summary of various add-on drugs used concomitantly with CLO and 
OLA in schizophrenic patients (modified from (Mizuno et al., 2014). 
 
Adjunctive Drugs  AAPs Effects on, 
Amantadine OLA Body weight 
Aripiprazole OLA, CLO Bodyweight, lipids, 
glucose metabolism 
Atomoxetine OLA, CLO Body weight 
Famotidine OLA Body weight 
Fluoxetine OLA Body weight 
Intranasal insulin OLA Body composition 
Metformin OLA, CLO Body weight, glucose, 
insulin, lipids, HOMA-IR 
Modafinil OLA, CLO Body weight 
Nizatidine OLA bodyweight 
Orlistat OLA, CLO Body weight 
Phenylpropanolamine CLO Body weight 
Reboxetine OLA Body weight 
Rosiglitazone OLA, CLO Body weight, glucose, 
insulin, lipids, HOMA-IR 
Sibutramine OLA, CLO Body weight 




Zonisamide OLA, CLO Body weight 
Naltrexone OLA Body weight 





4.1.1 Selection of drugs and variables 
Our data on primary human adipocytes (discussed in Chapter 3) showed deleterious 
changes in adiponectin secretion and PPARγ protein expression by CLO compared to 
OLA. Because of this we used CLO as an exemplar in our experiment to see the effect 
of adjunctive drugs on CLO-treated primary human adipocytes; we used adiponectin 
secretion and PPARγ protein expression as the key markers of any metabolic effect. 
Also, both adiponectin and PPARγ are considered as important factors which not only 
maintain normal function of adipocyte, but also play a role in the improvement of 
insulin sensitivity in metabolic toxic conditions. Various studies showed the use of 
numerous drugs as an add-on with CLO. However, we selected drugs (Table 4.2) 
which showed improved insulin sensitivity in patients with metabolic adverse effects 
such as obesity and T2DM; or had previously shown promising effects on adiponectin 
and PPARγ. Clinically relevant therapeutic doses were used for adjunctive drugs while 
ROSI, a known PPARγ agonist was used as positive control. 
 
 
Table 4.2: Concomitant drugs used in CLO-treated primary human adipocytes 
Adjunctive Drugs with 





Telmisartan 5µM, 10µM 
 







MET is a first-line treatment option in T2DM. Studies with MET in non-psychotic 
patients with metabolic syndrome showed a reduction in weight gain and improvement 
in lipid profiles (Rado and von Ammon Cavanaugh, 2016, Chen et al., 2008, Carrizo 
et al., 2009, Klein et al., 2006). Recently it was reported that schizophrenic patients 
taking AAPs experience less weight gain if MET is used as an adjunctive drug in the 
early part of their treatment (Hendrick et al., 2017). MET is a biguanide which has an 
antiphyperglycaemic effect; it decreases both basal and postprandial glucose. 
However, it has no direct effect on insulin secretion, so does not cause hypoglycaemia. 
Various RCT and meta-analysis studies, using MET as an adjunctive drug in AAP-
treated schizophrenic patients, showed significant decreases in BMI, waist 
circumference, triglycerides and glucose levels and increased HDL levels (Zimbron et 
al., 2016, Carrizo et al., 2009, Chen et al., 2008, Hebrani et al., 2015, Siskind et al., 
2016). The proposed mechanism of MET in reversing metabolic parameters may be 
due to its antagonising effect on glucagon suppressing gluconeogenesis and 
glycogenolysis, which improves insulin sensitivity (Wiernsperger and Bailey, 1999). 
It has been reported that CLO-treated patients having the minor allele carrier of the 
TransMembrane protein (TMEM) 18 (rs6548238) and Glucosamine-6-Phosphate 
Deaminase (GNPDA2) (rs10938397) showed a significant decrease in body weight 
after using MET as an adjunctive drug (Chen et al., 2015). TMEM18 is encoded by 
TMEM18 gene and GWAS studies have shown the association of genetic variants in 
the vicinity of TMEM18 with obesity (Larder et al., 2017). The previous study showed 
that TMEM18 is essential for adipogenesis (Bernhard et al., 2013); so it was proposed 
that MET might reverse metabolic adverse effects through the regulation of 




Among all the AAPs, ARI is considered to cause the fewest metabolic adverse effects 
(Wang et al., 2013). The study by Karunakaran et al showed an average weight loss 
of 5.1kg in CLO-treated schizophrenic patients using ARI as an adjunctive drug 
(Karunakaran et al., 2007). Other studies using ARI also showed a significant decrease 
in weight, BMI and triglycerides levels in AAP-treated schizophrenic patients (Choi, 
2015, Wang et al., 2013). However, the study by Henderson et al did not show any 
change in total serum cholesterol, HDL and LDL-cholesterol after administering ARI 
concomitantly with OLA-treated patients (Henderson et al., 2009). Choi’s meta-
analysis reported that on concomitant use of ARI, there was no significant change in 
PANSS score between groups, but it showed a beneficial effect in the improvement of 
metabolic adverse effects. The proposed mechanisms of ARI in improving the AAP-
mediated adverse metabolic effects might be through improvement in adiponectin 
secretion. The study by Wang and colleagues showed a significant increase in 
adiponectin levels in OLA-treated schizophrenic patients given ARI as an adjunctive 
drug (Wang et al., 2013).  
 
4.1.1.3 Rosiglitazone 
ROSI, approved by the FDA in 1999, metabolises glucose and lipids, resulting in 
improvements in blood glucose levels without producing hypoglycaemia. It activates 
the PPARγ transcription factor in cells which regulate glucose and lipid metabolism. 
The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone 
Medication) study showed a reversal of insulin resistance to approximately 70% 
normal by ROSI compared to placebo (Zimbron et al., 2016). However, a double-blind 
placebo-controlled ROSI trial by Henderson and colleagues showed a non-significant 
increase in weight gain, BMI and waist circumference with significant improvement 
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in insulin sensitivity, glucose utilisation and LDL-cholesterol levels (Henderson et al., 
2009). ROSI, through its PPARγ agonistic activity, has various physiological actions 
which include inhibition of pro-inflammatory products, positive effect on insulin 
sensitivity, decreased inflammation and neural tissue protection from inflammatory 
products (Yi et al., 2012). However, some studies reported the incidence of myocardial 
infarction and mortality due to cardiovascular complications caused by ROSI (Nissen 
and Wolski, 2007, Singh et al., 2007), owing to which its use was withdrawn from the 
UK and India in 2010 and from NewZealand and South Africa in 2011. However, it is 
still in use in the USA as FDA initially put restrictions from 2011 to 2013 but later 
lifted the restrictions after reviewing the 2009 clinical trial results, which showed no 
association of cardiovascular complications with ROSI (McCarthy, 2013). We have 
used this drug as a positive control in our experiment as ROSI show beneficial effects 
on the adipocyte.     
 
4.1.1.4 Telmisartan 
Our study was the first of its kind to use TEL in CLO-treated primary human 
adipocytes. Telmisartan is an angiotensin II type-1 receptor blocker and is used widely 
in patients as an anti-hypertensive. A study by Derosa and colleagues showed 
improvement in insulin resistance by TEL in patients with metabolic syndrome 
(Derosa et al., 2007). Telmisartan acts as a partial agonist on PPARγ and activates it 
maximally compared to other angiotensin receptor blockers (ARB). Various in vitro 
and preclinical studies also showed improved insulin resistance after using TEL, 
proposing its action through PPARγ activation (Pushpakom et al., 2017, Benndorf et 
al., 2006, Foryst-Ludwig et al., 2010, Souza-Mello et al., 2010). TEL has also shown 
an established effect on adiponectin, a marker for insulin sensitiser, by increasing its 
concentration. Studies showed that TEL decreased body weight and increased 
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adiponectin levels in glucose intolerant patients (Makita et al., 2008). A meta-analysis 
of TEL use in metabolic syndrome patients by Takagi et al reported a significant 
increase in adiponectin levels and decrease in insulin resistance, depicting TEL 
efficacy in  metabolic adverse effects (Takagi et al., 2013). Pushpakom et al is 
currently undertaking a clinical trial of TEL in HIV-positive patients to investigate 
whether TEL can reverse the antiretroviral-induced metabolic toxicity observed in 
HIV disease (Pushpakom et al., 2015).  
 
4.1.2 Rationale for the work conducted 
Cardiometabolic adverse effects, such as obesity, weight gain, diabetes mellitus and 
metabolic syndrome, are associated with AAPs. It is necessary to find ways to reverse 
these metabolic adverse effects. Though non-pharmacological approaches (physical 
activity, caloric restriction and nutritional plan) have been utilised earlier, due to poor 
rates of uptake, there is a barrier for the effectiveness of these interventions. This has 
diverted the interest of clinicians to pharmacological interventions to combat the 
metabolic adverse effects associated with AAPs (Siskind et al., 2016). Various drugs 
have been used as adjunctive therapy along with AAPs already in the clinic to address 
AAP-induced metabolic disease. Our rationale was to identify the beneficial effect of 
selected drugs (MET, ARI, ROSI and TEL) in vitro when incubated together with 
CLO. We also attempted characterisation of potential mechanisms by which they 








This part of the PhD tested the hypothesis that adjuvant drugs reverse AAP-induced 
metabolic adverse effects directly by acting on adipocytes. 
 
4.1.4 Aims and Objectives 
1) To characterise potential therapeutic strategies that can reverse AAP-induced 
metabolic adverse effects in primary human adipocytes. 
2) To see the effect of these therapeutic strategies on AAP-mediated changes in 
adipokine secretion and PPARγ protein expression. 
3) To investigate the mechanisms behind the reversal of AAP-induced metabolic 
adverse effects using primary human adipocytes by assessment of: 
a. adiponectin secretion and, 
















The materials were similar as described in section 3.2.1. Regarding drugs, CLO, MET 
and TEL were purchased from Sigma-Aldrich, MO, USA while ARI and ROSI were 
from Santa Cruz Biotechnology, TX, USA.  
4.2.2 Cell culture 
Cell culture was performed as described in section 3.2.2. Cells were treated with CLO 
and different doses of adjuvant drugs starting from day 3 to day 11 (total 5 drug 
additions). On day 13, 48 hrs after the last drug addition, conditioned media and cell 
lysates were collected to study adiponectin levels, and PPARγ protein expression 
respectively. In our experiment, we used 3 donors to check the reproducibility of the 
results and for statistical purposes. 
 
4.2.3 Measurement of Adiponectin secretion by ELISA 
Adiponectin secretion was measured by ELISA as described in section 2.2.5.  
4.2.4 Western blotting  
Protein isolation, quantitation and western blotting were performed by methodology 
as described in section 2.2.9.  
4.3 Statistical Analysis 
All statistical comparisons (3 donors) were made using t-test on StatsDirect software 
version 2.7.9. Differences were considered significant at p≤0.05.The result was shown 
as mean ± SD.  
4.4 Results 
We have compared the effect of each adjuvant drug (MET, ARI, ROSI and TEL) 
against both therapeutic (1µM) and high dose (20µM) of CLO. 
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4.4.1 Effect of adjunctive drugs on adiponectin secretion in CLO-treated primary 
human adipocytes  
 
We have shown adiponectin levels measured when two different doses (therapeutic 
dose [1µM] and higher dose [20µM]) of CLO were co-incubated with each adjuvant 
drug. When co-incubated with 1µM CLO, ARI significantly reversed the CLO-
mediated reduction in secretion of adiponectin from the differentiating adipocytes on 
day 13 (CLO; p=0.04). ROSI, MET and TEL, also showed reversal of CLO-mediated 
effect on adiponectin secretion, but this was not statistically significant (Fig.4.1A).   
 
For 20µM CLO, all four adjuvant therapeutic strategies showed a trend to reverse 
CLO-mediated reduction in adiponectin secretion but were not statistically significant 
(Fig 4.1B). 
As discussed in Chapter 3, we believe the lack of statistical significance could once 
again be an indicator of variability between individual subjects (adipose tissue 
donors). This would suggest that experiment itself worked fine with respect to 
individual drug effects; however, because of the variability between donors, we 

































































Figure 4.1: Effect of co-incubation of various adjuvant drugs (ARI, ROSI, MET, TEL) on A) CLO (1µM) and B) CLO 20µM-mediated reduction in secreted adiponectin 
in differentiating primary human adipocytes.  All experiments were done in adipocytes cultured from 3 individual donors. Data was shown as mean ± SD; p ≤ 0.05. * 
1µM CLO vs 1µM CLO+ARI, # VEH  vs 20µM CLO. 
Fig 4.1 A 























































































Figure 4.1: C) Change in adiponectin secretion observed in individual donors (n=3) with 1µM CLO alone and when co-incubated with adjuvant drugs (ARI, ROSI, 
MET, TEL); D) Change in adiponectin secretion observed in individual donors (n=3) with 20µM CLO alone and when co-incubated with adjuvant drugs.  
Fig 4.1 D 
Fig 4.1 C 
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4.4.2 Effect of adjunctive drugs on PPARγ protein expression in CLO-treated primary 
human adipocytes 
 
Our data showed that therapeutic dose of CLO (1µM) cause significantly increased (p=0.04) 
PPARγ expression. The higher dose of CLO (20µM) showed a trend to increase PPARγ 
expression but was statistically non-significant (Fig. 4.2A). 
 
We have shown PPARγ expression levels when therapeutic and higher dose of CLO were co-
incubated with each adjuvant drug. When co-incubated with 1µM CLO, ARI, MET and TEL 
(5µM) resulted in a trend to further increase PPARγ expression compared to 1µM CLO alone; 
however this was not statistically significant. TEL (10µM) co-incubation with 1µM CLO 
resulted in significantly decreased expression of PPARγ as compared to 1µM CLO alone 
(p=0.03). On the other hand, ROSI when co-incubated with 1µM CLO showed a further 
significant increase in PPARγ expression (p=0.01) (Fig 4.2B). 
 
For 20µM CLO, only ROSI showed a further increase in expression which was statistically 
significant (p=0.01). All other drugs (ARI, MET and TEL, 5µM) did not affect the 20µM CLO-
mediated increase in PPARγ expression. However co-incubation of 10µM TEL with 20µM 
CLO showed a significant decrease in the expression of PPARγ as compared to 20µM CLO 
alone (p=0.03) (Fig. 4.2C).  
The lack of statistical significance could be an indicator of variability between individual 
subjects (adipose tissue donors). This would suggest that experiment itself worked fine with 
respect to individual drug effects; however, because of the variability between donors, we 





















































































Fig 4.2 A 
Fig 4.2 B: 1µM CLO plus Adjuvant drugs 
PPARγ (Kda 57) 
β-actin (Kda 43) 
PPARγ (Kda 57) 
β-actin (Kda 43) 
Figure 4.2: A) PPARγ protein expression showing the effect of various concentrations of CLO on differentiated adipocytes. Effect of co-incubation of various adjuvant drugs (ARI, ROSI, 
MET, TEL) on B) CLO (1µM) and C) CLO 20µM-mediated increase in PPARγ protein expression in differentiating primary human adipocytes.  All experiments were done in adipocytes 
cultured from 3 individual donors. Data was shown as mean ± SD; p ≤ 0.05. * VEH vs 1µM CLO, #1µM/20µM CLO vs ROSI,  Ϯ 1µM/20µM CLO vs TEL 10µM.  
 
 









































































Fig 4.2 E 
Fig 4.2 D 
Figure 4.2: D) Change in  PPARγ protein expression observed in individual donors (n=3) with 1µM CLO alone and when co-incubated with adjuvant drugs (ARI, 




4.5 Discussion  
Various clinical trials that investigated the use of adjuvant drugs with AAPs have 
showed efficacy in the reversal of AAP-induced metabolic adverse effects. Some 
studies proposed MET to be used as first line adjuvant therapy to reverse AAP-induced 
weight gain and metabolic adverse effects, while others proposed TOPI and ARI as 
preferred adjunctive drugs (Whitney et al., 2015, Mizuno et al., 2014, Maayan et al., 
2010). The differences between these individual trials may be due to differences in the 
study design, duration and effect of drugs or related to the pharmacokinetic or 
pharmacodynamic properties of adjuvant drugs and their interactions with 
antipsychotic drugs (Cipriani et al., 2009, Zimbron et al., 2016, Choi, 2015). We used 
3 adjunctive drugs (ARI, MET, TEL) plus one drug, ROSI, as a positive control, to 
see their effects on CLO-induced changes in adiponectin secretion and PPARγ 
expression as it has been suggested that these parameters play an important role in 
adipogenesis and in regulating insulin sensitivity. The adjunctive drugs used in our 
experiment show beneficial metabolic effects and have previously shown a promising 
effect on insulin sensitivity and other important metabolic parameters such as weight 
gain, lipids and adipocytokines. However, the mechanistic effects of these drugs on 
adiponectin secretion and PPARγ expression when used alongside AAPs in an in vitro 
primary human adipocyte model have not been reported before. 
Our in vitro studies showed ARI significantly reversed CLO-mediated reduction in 
adiponectin secretion. ARI was effective when used along with both therapeutically 
relevant and a higher concentration of CLO. Our result is consistent with the study by 
Wang et al (Wang et al., 2013) showing increase in adiponectin secretion after giving 
ARI as an adjunctive drug to schizophrenic patients using AAPs. This suggests the 
mechanistic role of ARI in reversing metabolic adverse effects through adiponectin. 
Adiponectin acts as an insulin sensitiser and its levels have been documented to 
177 
 
decrease in patients having insulin resistance in conditions like obesity or T2DM (Jin 
et al., 2008). It has been postulated that adiponectin activates the AMPK kinase 
pathway which activates a series of reactions leading to increased fatty acid oxidation, 
decreased gluconeogenesis in the liver and decreased plasma glucose levels, 
ultimately resulting in improved peripheral insulin sensitivity (Gil-Campos et al., 
2004). This suggests that ARI reverses insulin resistance in metabolic toxic conditions 
by increasing the secretion of adiponectin, which may thereby improve insulin 
sensitivity. However, most of the adjunct studies of CLO and ARI were focused on 
other metabolic parameters and weight gain. Henderson and colleagues reported a 
significant decrease in body weight, BMI, serum cholesterol and serum triglycerides 
on concomitant use of ARI with CLO in schizophrenic patients (Henderson et al., 
2006). Fleischhacker et al also reported reduction in body weight, BMI and waist 
circumference in schizophrenic patients; though there was no improvement in PANSS 
scores, but the clinical global impression (CGI) scale showed some improvement in 
the treatment group (Fleischhacker et al., 2010). However, there are also some studies 
which showed improvement in PANSS score after administering ARI concomitantly 
with CLO in schizophrenic patients (Galling et al., 2017, Srisurapanont et al., 2015). 
This may suggest the involvement of multiple factors other than just adiponectin in 
reversing the AAP-induced metabolic adverse effects. Along with improvement in 
schizophrenic symptoms, there has been a report of akathisia as an adverse effect when 
ARI was given concomitantly with CLO, therefore monitoring is required when both 
drugs are given together (Choi, 2015). Although we observed a reversal in CLO-
mediated effect on adiponectin secretion, our data also showed high variability 
between the 3 donors (this resulted in ARI’s effect on 20µM CLO to be statistically 
non-significant).  This is because of using only 3 biological replicates due to 
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limitations in the availability of adipocytes from donors, and managing a chronic 
toxicity experiment in large number of replicates. However, all our 3 biological 
replicates showed a similar trend in adiponectin secretion (increased secretion) when 
analysed individually. Our data also showed a trend to further increase PPARγ 
expression by ARI when used concomitantly with therapeutic doses of CLO, 
suggesting a mechanistic role of PPARγ in a reversal of metabolic adverse effects. 
Both the increase in adiponectin and PPARγ may suggest that ARI activates PPARγ, 
which is a regulator of adiponectin, resulting in an improvement in insulin sensitivity. 
This shows a strong interaction between PPARγ and adiponectin. As PPARγ is 
considered the master regulator of adipogenesis, ARI not only maintains adipogenesis 
but also improves insulin sensitivity through adiponectin. However, ARI did not show 
any change in PPARγ expression when co-incubated with high doses of CLO; it did 
show a trend to increase adiponectin secretion but that effect was not significant. This 
might be because the concentration we used for ARI may not be sufficient to counter 
the effects of high CLO dose (20µM). The other proposed mechanism in reversing 
AAPs induced metabolic adverse effects by ARI could be by activation of P13K/Akt 
pathway. This pathway maintains cellular growth and metabolism, leading to an 
improvement in insulin sensitivity. Disturbance in this pathway leads to metabolic 
disorder related adverse effects. It was argued that this pathway augmented insulin 
through GLUT4 and AAPs targeted this P13K/Akt pathway, affecting GLUT 4 
activation. It was proposed that ARI activates this pathway through activation of the 
D2 receptor as the previous study showed that D2 receptor agonist drug bromocriptine 
regulates the P13K/Akt pathway (Deng et al., 2010). We have not investigated the 
effect of ARI on this pathway or its mediators; this could be an area for future research. 
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In our experiment, ROSI was used as positive control and it showed a trend to reverse 
CLO-mediated effect on adiponectin concentration in CLO-treated cells. It also 
showed a significant increase in PPARγ expression when co-incubated with both 
doses of CLO. Various in vitro preclinical and clinical studies have shown an increase 
in adiponectin secretion on administering ROSI alone, which proposed the idea that 
ROSI improved insulin sensitivity by increasing adiponectin secretion (Yamauchi et 
al., 2001, Maeda et al., 2002, Combs et al., 2002, Hirose et al., 2002, Leung et al., 
2016). It was also found that ROSI produced an insulin-sensitising effect through 
activation of PPARγ. It was then proposed that PPARγ might produce its effect 
through activation of adiponectin, increasing its levels leading to improvement in 
insulin sensitivity (Yu et al., 2002). PPARγ is mostly expressed in adipose tissue and 
insulin sensitivity improvement takes place mainly in skeletal muscle where PPARγ 
is less expressed. This postulated that ROSI modulates the signalling between 
adipocytes and muscle cells and may involve adiponectin to improve insulin 
sensitivity (Sharma et al., 2006). Various clinical trials of AAPs with ROSI showed 
increased weight gain but a decrease in HOMA-IR and small LDL particle number 
(Baptista et al., 2009, Mizuno et al., 2014). It was proposed that this small LDL particle 
number was an important risk factor in metabolic syndrome, leading to cardiovascular 
diseases (Friedlander et al., 2000, El Harchaoui et al., 2007), so lowering of this 
particle would decrease the risk factor in metabolic syndrome. However the weight 
gain caused by ROSI could be of concern when used concomitantly with AAPs. It 
should also be noted that due to cardiovascular complications caused, the clinical use 
of ROSI has been restricted in many countries.  
Our MET data showed a trend to increase in adiponectin secretion in CLO-treated 
cells, but the result was non-significant. This  coincided with the results from studies 
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which showed an increase in adiponectin secretion, both in vitro using primary human 
adipocytes and in vivo in  Zucker diabetic fatty rats (Schmid et al., 2013, Zulian et al., 
2011). This has been replicated in another preclinical study which also showed 
increased adiponectin secretion after using MET (Saad et al., 2015). Meta-analysis of 
MET along with AAPs showed reduction in weight, BMI, weight circumference, 
HOMA-IR, improvement in fasting glucose and triglycerides (Liu et al., 2015, Ehret 
et al., 2010, Rado and von Ammon Cavanaugh, 2016, Baptista et al., 2006, Wu et al., 
2008, Praharaj et al., 2011). Our data with MET also showed a trend to increase 
PPARγ expression in cells treated with 1µM CLO, suggesting that MET might activate 
PPARγ leading to activation of  adiponectin, in turn leading to increased insulin 
sensitivity. It was also proposed that MET may activate AMP-activated protein kinase, 
which ultimately improved insulin sensitivity (Pernicova and Korbonits, 2014). This 
suggests that MET may reverse metabolic toxic effects through multiple mechanisms. 
However, MET showed no change in PPARγ expression in adipocytes treated with 
high dose CLO (20uM). This could be related to the concentration as observed with 
ARI earlier.  
Our TEL data showed a trend to increase adiponectin secretion by both doses. PPARγ 
expression also showed a trend to increase by 5µM dose of TEL, suggesting 
interrelation between adiponectin and PPARγ. Nagel et al reported  interaction 
between adiponectin and PPARγ and proposed that TEL induces adiponectin through 
PPARγ activation (Nagel et al., 2006). A study by Benndorf and colleagues also 
reported improvement in insulin sensitivity through activation of PPARγ by TEL 
(Benndorf et al., 2006). Yamashita and colleagues studied the effect of concomitant 
use of TEL in OLA treated patients and it was proposed that TEL might improve 
insulin sensitivity by affecting adipokines levels, especially adiponectin (Yamashita et 
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al., 2008). It has been reported that ARB also acts as PPARγ agonist, which on 
activation increases the expression of PPARγ target genes which regulate lipid and 
carbohydrate metabolism (Iwai et al., 2007, Benson et al., 2004, Kurtz, 2006, Schupp 
et al., 2004). Our data showed that TEL improves insulin sensitivity through increase 
secretion of adiponectin suggesting its direct effect on adiponectin. However, TEL 
(10µM) but not 5µM TEL, showed decreased PPARγ expression in both doses of CLO 
treated cells, owing to TEL’s partial agonistic activity which showed that increase 
dose of TEL (10µM TEL) have more antagonistic effect instead of agonistic effect 
leading to decreased PPARγ expression. However, more research is required, 
especially on drug interaction between CLO and TEL to explore the exact mechanism.  
Our data on co-incubation of adjunctive drugs with AAPs suggest they might be able 
to reverse the metabolic adverse effects caused by AAPs through improvement in 
adiponectin secretion or activation of PPARγ or a combination of both. The role of 
adiponectin as insulin sensitising and anti-atherogenic protein has been well 
documented and it has been established that obese patients have lower adiponectin 
levels than non-obese (Yang et al., 2004). Maeda and colleagues showed the 
knockdown of adiponectin in mice resulted in hyperglycaemia and hyperinsulinemia. 
It has also been documented that the PPARγ agonist up-regulate serum adiponectin 
(Maeda et al., 2002). A study by Yang and colleagues on rats showed a positive 
correlation between PPARγ agonist and increased adiponectin levels, which resulted 
in improved insulin sensitivity and a lipid-lowering effect (Yang et al., 2004). Studies 
also proposed that PPARγ agonist may stimulate the production of adiponectin. This 
adiponectin then activates AMPK, which increases the fatty acid oxidation. This leads 
to the activation of cascade which ends with the uptake of glucose and lactose 
production by muscle cells. This results in reduced glucose levels and increased 
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sensitivity in liver and muscle (Guan et al., 2002, Combs et al., 2002, Gil-Campos et 
al., 2004). Apart from the activation of adiponectin by PPARγ, studies proposed that 
PPARγ also affects the insulin-signalling cascade and it does this by regulation of 
expression or phosphorylation of signalling molecules. Insulin, on binding to its 
tyrosine kinase receptors, starts a signalling cascade which leads to the activation of 
insulin receptor substrate and phosphatidylinositol-3-kinase (PI-3 kinase) and other 
downstream kinases which  regulate  processes like glucose uptake, lipid metabolism, 
differentiation and gene transcription regulation  (Jiang et al., 2004, Miyazaki et al., 
2003, Jiang et al., 2002). PPARγ also decreases FFA levels by inhibiting adipocyte 
lipolysis which modulates insulin sensitivity (Bays et al., 2004).  
In summary, adjunctive drugs (therapeutic concentration) effect on CLO-mediated 
adiponectin secretion and PPARγ expression in in vitro primary human adipocyte 
model have not previously been studied. All these 4 drugs have had an effect on 
adiponectin and PPARγ which may work together or independently to improve insulin 
sensitivity and can be a potential therapeutic target to reverse AAPs induced metabolic 
adverse effects. Our data demonstrated high inter-individual variability between the 3 
adipocyte donors which limits statistical significance of the results, and the 
conclusions that can be drawn. In future studies a large number of donors may decrease 
the variability. Figure 4.3 showed the proposed mechanisms of adjunctive drugs 
through adiponectin and PPARγ. 
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Lipidomics is defined as a global study of molecular lipids in a biological system 
which encompasses its analysis and characterisation along with interaction with other 
lipid classes and partners like proteins (Castro-Perez et al., 2010, Wenk, 2005). 
Lipidome encompasses  various lipid species present in a cell without which the cell 
cannot perform its physiological actions (Serhan et al., 2006). Lipidomics is 
considered to be a subgroup of metabolomics as shown in Figure 5.1. 
    
 Figure 5.1 Analysis of cells through global profiling (genomics, proteomics, and 




Lipidomics could be helpful in providing information on disease mechanisms. Lipids 
control many biological functions including regulatory, structural and bioenergetic 
functions. The key function of lipids includes energy storage, cell signalling, protein 
trafficking and membrane anchoring. Various studies have shown that disturbances in 
lipid metabolism can result in the onset and progression of many human diseases 
including obesity, cancer, Alzheimer’s disease and atherosclerosis (Cutler et al., 2004, 
Lusis, 2000, Menendez and Lupu, 2007, Shi and Burn, 2004). 
 
5.1.1 Classification of Lipids 
 
Lipids are hydrophobic substances which are soluble in organic solvents. Lipids are 
classified into 8 categories. These are further subclassified based on the attachment of 
hydrophilic and hydrophobic elements (Fahy et al., 2009). Table 5.1 shows the 














Table 5.1: Classification of lipids (LIPID MAPS Database) 
Category Abbreviation Subclasses 
Fatty acyls FA Fatty acids and conjugates, 
Eicosanoids  
Glycerolipids GL Diacylglycerol (DAG), 
Triacylglycerol (TAG) 
Glycerophospholipids GPLs Phosphatidylcholine (PC), 
Phosphatidylethanolamine 









Sterol lipids ST Cholesterol, cholesteryl 
ester 
Prenol lipids PL Isoprenoids 
Saccharolipids SP Acylaminosugars 





The cell membrane, which acts as a communication border between the interior and 
exterior of the cells, is composed of a phospholipid bilayer along with proteins and 
other lipids such as sterols and glycolipids. These membrane lipids play an important 
role in cell proliferation, signal transduction pathways, apoptosis and movement along 
the membrane. Glycerophospholipids (GPLs), sterol, and sphingolipids (SL) 
constitute the main bioactive lipids in a biological membrane of mammalian cells (Bou 
Khalil et al., 2010).This chapter will focus more on the SL subclass named ceramides 
(Cer). 
 
5.1.1.1 Sphingolipids (SL) 
 
SL are abundant in many living organisms including humans, plants, and yeast. SL, 
which contain a backbone of SL long-chain base (sphinganine and sphingosine), not 
only maintain the integrity of cell membranes but also regulate cell growth, 
differentiation, apoptosis, chemotaxis and signalling pathways (Haynes et al., 2009). 
The main classes of SL include Cer, dihydroceramides (DhCer), sphingomyelin, 
dihydrosphingomyelin, sphingosine, sphinganine, galactosyl ceramide and 
sphinganine-1-phosphate. Their structures are given in Figure 5.2. Sphingomyelin, 
which is comprised of Cer moiety, is linked to the phosphocholine group. 
Sphingomyelin’s function is the assembly of signalling molecules and regulation of 
trafficking of membrane proteins and various cellular processes (Lahiri and Futerman, 
2007). Cer, an important SL, acts as an apoptotic mediator while sphingosine-1-
phosphate regulates calcium homeostasis, cell growth, immune cells migration and 




Figure 5.2. Structure of Sphingolipid classes (adapted from Yang Yu, 2012) 
 
 
5.1.2 Analytical techniques used for lipidome profiling 
 
Lipidomic analysis has been a challenging task due to the high diversity of lipids. 
Initial studies have been focused on the analysis of individual lipid classes through 
thin layer chromatography (TLC). However, there was rapid progress in this field after 
the introduction of Mass Spectrometry (MS)-based techniques. Untargeted approaches 
for global analysis of lipids, and targeted analysis for specific lipid classes, have been 
applied to discover biomarkers for diseases, such as cardiovascular disease, cancer and 
metabolic diseases (Markgraf et al., 2016). Below, a brief description of various 




5.1.2.1 Chromatography  
 
Liquid chromatography (LC) techniques have successfully shown their usefulness in 
the analysis of complex lipids and their species. TLC, one of earlier developments of 
LC, also showed promising results in the separation and analysis of lipids. TLC is 
developed from paper chromatography and is composed of a thin layer of stationary 
phases such as silica or cellulose. Numerous combinations of aqueous stationary and 
organic mobile phases resulted in the separation of various classes of lipids; however, 
low resolution and the sensitivity of TLC mean that many important lipids remain 
undetected (Houjou et al., 2005, Hermansson et al., 2005). Another technology used 
was solid phase extraction (SPE). This technology is used to separate lipid complexes 
into its classes including fatty acids, cholesterol ester, acyl glycerol, and 
phospholipids. However, both techniques were replaced by high-performance liquid 
chromatography (HPLC) which gained attention due to its selective and efficient 
properties. In HPLC, the lipids are separated through normal-phase or reverse phase 
columns. In normal-phase, lipids are separated based on the polar head group while, 
in reverse-phase, separation is due to polarity, alkyl chain saturation, and chain length. 
Gas chromatography (GC) is another chromatographic technique widely used for the 
detection of fatty acids; however, this technology shows more efficient and selective 
results when combined with MS (Lesnefsky et al., 2000). 
 
5.1.2.2 Mass Spectrometry 
 
MS measures both the mass-to-charge ratio of molecules and its intensity, thus it acts 
as an important technique to separate and quantify various lipid species. However, the 
development of Electrospray Isonisation (ESI) and matrix-assisted laser 
desorption/ionisation (MALDI) has expanded the range of lipids analysed by MS in 
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the samples. Various lipidomic studies showed promising data after using these 
techniques (Pulfer and Murphy, 2003, Han and Gross, 2001, Griffiths, 2003). The ESI-
MS technology has been used for analysis of phospholipids, sphingolipids, and 
acylglycerol (Haynes et al., 2009, Brugger et al., 1997). Multidimensional MS-based 
shotgun lipidomics is another approach used for the identification of fatty acid isomers 
and various individual lipid species (Han, 2016). 
 
5.1.2.3 NMR Spectroscopy 
 
Nuclear Magnetic Resonance (NMR) is a powerful technology which provides 
information on the molecular structure of purified lipids (1H-NMR and 13C-NMR). It 
also provides information on the structure and dynamics of lipid membranes. 
However, the lipid restricted movement in bilayers or lipoproteins leads to poor 
resolution. Also, NMR techniques have moderate sensitivity compared to MS (Wenk, 




Table 5.2: Technologies for lipidomic research 
Technology Lipid class 
covered 
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ESI, electrospray ionization; MALDI, matrix-assisted laser 






5.1.3 Data Processing Software for Lipid Analysis 
 
Analytical instruments produce a huge amount of data to process. There are many 
types of data-processing software available for lipidomic analysis. The steps in the 
lipidomic analysis include peak detection, lipid identification, isotope correction, 
response correction, and quantification. However, the same software or data 
processing tools cannot be applied for different data formats as every vendor has 
different set ups for the detection of lipids. The examples include Lipid 
Qualitative/Quantitative Analysis (LipidQA) software which identifies and quantifies 
complex lipids from the data coming from the TSQ-7000 triple stage quadrupole mass 
spectrometer (Thermo-Finnigan) and the Q-TOF hybrid quadrupole time-of-flight 
(Waters-Micromass). The fatty acid analysis tool (FAAT) is specifically for data using 
mycobacteria species using Fourier transform mass spectrometry. The other types of 
software used are Lipid Profiler, LipidInspector and cognoscitive-contrast-angle 
algorithm and database (COCAD). MZmine software is open source software for 
LC/MS-based samples particularly focusing on lipidomics analysis from the 
UPLC/MS experimental setup (Ejsing et al., 2009, Leavell and Leary, 2006, 
Katajamaa et al., 2006). 
 
5.1.4 Lipid Databases  
 
Several databases exist which provide detailed information on lipids such as LIPID 
MAPS, Lipid Bank, Cyber lipids, and LIPIDAT. The most commonly used database 
is LIPID MAPS which represents the lipid compounds with a unique 12-digit 
identifier. The LIPID MAPS Proteome Database (LMPD) provides information on 
lipid-associated protein sequences and annotations while the LIPID MAPS Structure 
Database (LMSD) focuses on lipid structure as well as other related information with 
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respect to the classification scheme recommended by the LIPID MAPS consortium. 
LMSD is also a useful tool for mass spectrometry data. Providing information on 
classification, nomenclature and chemical representation, LIPID MAPS is considered 
a standard reference tool for the construction of lipid databases and management of 
lipidomics data. Lipid databases also provide information on lipid pathways. The 
Kyoto Encyclopedia of Genes and Genomes (KEGG) database provides information 
on metabolic pathways including lipid pathways. SphinGOMAP offers information 
about sphingolipids and glycosphingolipids lipid species. The LIPID MAPS 
biopathways workbench helps to display, edit and analyse lipids pathways (Yetukuri 
et al., 2007, Cotter et al., 2006, Fahy et al., 2009, Kanehisa et al., 2004). The summary 

















Table 5.3. Lipid databases and their characteristic features 
Lipid Database Description 
LIPID MAPS 
(www.lipidmaps.org) 
Provide information on lipid classification 
and structure, contain lipid-associated 




Provide collection of updated scientific 
knowledge on all aspects of lipids and 





Compilation of thermodynamic data and 
bibliographic information on lipids. It also 
includes the effect of pH, protein, drugs, 




Provide information on chemical structure, 
physical and chemical properties, 
biological activities and metabolism of 
lipids. Also, spectral information from 
instruments like ultraviolet, infrared 
spectrometry, nuclear magnetic resonance, 
mass spectrometry, thin layer 
chromatography and liquid 




Give information on lipid pathways and 
associated information such as name, 
structure, mass, formula, chemical 
reactions. Also, provide information on 
external links to other databases 
THE LIPID LIBRARY 
(http://www.lipidlibrary.co.uk/) 
Provide information on various classes of 
lipids  and their analysis both in mass 
spectrometry and chromatography 
sphinGOMAP 
(http://www.sphingomap.org/) 
Offers information on sphingo and 
glycosphingolipids 
 
5.1.5 Lipid Nomenclature 
 
Lipids are named in two different ways: 1) systematic name and, 2) common or trivial 
name. Common name includes abbreviations which show acyl or alkyl chain in 
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acylglycerols, sphingolipids and GPLs. The guidelines for lipid systematic names have 
been recommended by International Union of Pure and Applied Chemists and the 
International Union of Biochemistry and Molecular Biology (IUPAC-IUBMB) 
Commission on Biochemical Nomenclature (http://www.chem.qmul.ac.uk/iupac/). 
 
5.1.5.1 Sphingolipid nomenclature 
Sphingolipid structure have (i) amine-containing lipid backbones (sphingoid bases: 
sphingosine, sphinganine and phytosphingosine) with amide-linked fatty acids and a 
(ii) head group, which range from a simple hydroxyl in Cer to highly complex 
glycoconjugates. 
 
5.1.5.1.1 Sphingoid bases  
 The chemical name of sphingoid base (18-carbon), as shown in Figure 5.5 is 
(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol,which is referred as sphingosine, a major 
species found in  mammalian sphingolipids. It is now called as (E)-sphing-4-enine by 
the IUPAC nomenclature. Sphingoid base nomenclature provides the number of 
hydroxyl groups: d for the two (di-) hydroxyls of sphingosine and sphinganine, and t 
(tri-) for the additional hydroxyl in 4-hydroxysphinganine; followed by the chain 
length (typically 18 carbons); and the number of double bonds (0, 1 or  2); therefore, 
sphingosine is abbreviated d18:1 (Pruett et al., 2008).  
 
5.1.5.1.2 Nomenclature of ceramides 
 
 In ceramides, most of the sphingoid bases are N-acylated with long-chain fatty acids 
(Fig. 5.3). These fatty acids vary in chain length (14 to 36 carbon atoms), and by the 
presence or absence of a hydroxyl group on the carbon atom. The recent notation 
denotes “ceramide” for N-acylsphingosines; dihydroceramides for N-
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acylsphinganines; and, 4-hydroxyceramides and phytoceramides for N-acyl-4-
hydroxysphinganines. The fatty acyl chain length can also be shown as a prefix, such 
as C18-Cer for N-stearoylsphingosine. When the sphingoid base is abbreviated, the 
fatty acyl chain is presented after the sphingoid base; for example, N-
stearoylsphingosine or C18-Cer is abbreviated d18:1/18:0 (Zheng et al., 2006). 
 




Following table (Table 5.4) showed the systematic and common name of Cer18-Cer 
species which has been repeated throughout this chapter. 
 










































Other lipid nomenclature such as, GPL use a ‘’sn’’ notation which means 
stereospecific numbering. It means that the hydroxyl group of second carbon of 
glycerol (sn-2) is on the left side of a Fischer projection (a two-dimensional 
representation of an organic molecule by projection). The LIPID MAPS GPL 
abbreviations (PC, PE) are used to refer to species with one or two radyl side-chains 
where the structures of the side chains are indicated within parentheses in the 
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'Headgroup’ format for example PC (16:0/18:1(9Z)). The ‘O’-prefix is used to indicate 
the presence of an alkyl ether substituent such as PC (O-36:1). 
If the GPL  side chain regiochemistry and stereochemistry is not known but have 
information on total composition then abbreviation  such a PC (36:1) may be used to 
show total number of carbon and double bonds  for all chains (Fahy et al., 2009). 
 
5.1.6 Lipid Metabolic Pathways 
 
Four metabolic networks have been documented to play an important role in the 
pathogenesis of disease including SL, GPL, GL and non-esterified fatty acids 
(NEFA). This thesis focuses more on SL, especially Cer. 
 
5.1.6.1 Sphingolipid Metabolic Pathway 
 
Being one of the important components of a cell membrane, SL play an important role 
in many cellular functions such as proliferation, maturation, apoptosis and cellular 
stress response (Mao and Obeid, 2008). Among all SL, Cer is considered one of the 
most important SL which serves as a precursor for other SL like sphingosine and 
sphingosine-1-phosphate (S1P). Any change in this metabolic network disturbs the SL 
homeostasis which affects the cell membrane properties leading to failure of 
membrane protein functions (Paugh et al., 2008). At normal levels, Cer plays an 
important role in cell cycle arrest, cell growth, differentiation, necrosis, apoptosis, 
proliferation and stress response. Cer also regulates enzymes such as protein kinase C, 
raf-1, kinase suppressor of Ras and cellular protease cathepsin. SIP plays a role in 
proliferation, cell growth, cell migration, inflammation, angiogenesis and resistance 
to apoptotic cell death (Borodzicz et al., 2015, Markgraf et al., 2016). Cer can be 
induced by various stimuli like interleukins, interferons, TNF-α, oxidative stress, 
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ionising radiation and drugs (Borodzicz et al., 2015). Cer is produced by 3 pathway 
processes: 1) de novo synthesis from saturated fatty acids which takes place in 
endoplasmic reticulum; 2) by conversion of sphingomyelin into Cer by 
sphingomyelinase enzyme in the cell membrane (sphingomyelinase pathway); and, 3) 
salvage pathway in lysosomes, that break down complex SL into sphingosine which 
is reacylated back to Cer (Gulbins and Li, 2006). Of these, the most important pathway 
for synthesis of Cer is the de novo synthesis in which palmitate and serine combine to 
form 3-ketosphinganine catalysed by a rate-limiting enzyme, serine 
palmitoyltransferase (SPT). Sphinganine then forms DhCer by the action of the Cer 
synthase enzyme followed by Cer formation due to the action of the enzyme 
dihydroceramide desaturase. Cer can also be produced from degradation of 
sphingomyelins by the enzyme sphingomyelinase (SMase). Cer is degraded by the 
enzyme ceramidase (CDase) followed by formation of sphingosine which ultimately 
forms S1P. The sphingosine can be reacylated to form Cer, known as salvage pathway. 
Any change in the physiological function of enzymes leads to increased or decreased 
levels of Cer (Figure 5.4) (Blachnio-Zabielska et al., 2012b). SL is abundant in lipid 
rafts, which are basically subdomains of a plasma membrane containing a high 
concentration of cholesterol, so any changes in SL will produce changes in lipid raft 
composition and function altering cholesterol metabolism and trafficking. This also 
leads to an alteration in cell-cell communication and adhesion (Rog and Vattulainen, 
2014, Hakomori and Igarashi, 1995). It has also been documented that increased levels 
































Figure 5.4   Overview of Ceramide metabolism. SPT: serine 






















5.1.7 Role of Sphingolipids in CVD 
 
It has been proposed that factors like infection, inflammation, stress responses, UV 
light and some chemotherapeutics activate SMase which produces Cer. These factors 
cause translocation of SMase to an outer layer of the cell membrane which then leads 
to Cer formation making Cer-enriched membrane domains. These domains cluster 
receptors on the membrane to amplify signals, which are needed for the induction of 
apoptosis. The relation between SL, especially Cer, and apoptosis might be important 
in the pathogenesis of CVD (Schenck et al., 2007). It has been proposed that Cer may 
cause vasoconstriction and salt and water retention by activation of angiotensin II type 
2 receptors resulting in hypertension. An in vitro study on rat pheochromocytoma 
PC12W cells showed activation of angiotensin II type 2 receptors to be accompanied 
with an increase in Cer and S1P levels (Berry et al., 2001). Spijkers and colleagues’ 
study reported increased levels of Cer in patients with hypertension (Spijkers et al., 
2011). It has been suggested that Cer is involved in endothelial dysfunction leading to 
disturbance in blood flow regulation leading to hypertension (Kulkarni et al., 2017). 
Cer causes apoptosis of cardiomyocytes and this has been suggested to affect 
physiological functions of the heart (Borodzicz et al., 2015). Cer is associated with 
ischemic heart disease; an animal model of myocardial ischemia showed an increased 
level of Cer compared to the normal control (Zhang et al., 2001). Interestingly, plasma 
Cer levels and SMase activity are increased in patients with angina pectoris and acute 
myocardial infarction (Pan et al., 2014). SL roles have also been documented in 
patients with stroke. A study by Kubota and colleagues showed increased levels of 
Cer in patients with acute internal carotid artery occlusion (Kubota et al., 1989). It has 
been suggested that Cer has a tendency for self-aggregation due to its hydrophobicity 
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and hydrogen bonding capacity. This leads to aggregation of LDL resulting in the 
formation of atherosclerotic plaques. Cer, due to its proapoptotic mechanism, may lead 
to the rupture of atherosclerotic plaque causing development of thrombosis leading to 
ischemia, myocardial infarction, and stroke. Along with Cer, S1P causes thickening 
of the vascular wall through the proliferation of endothelial and smooth muscle cells 
which favour plaque stabilisation (Summers, 2006). 
 
 
5.1.7.1 Role of Sphingolipids in Metabolic Disease 
 
Among all the SL, Cer plays an important role in metabolic disease. Cer, formed from 
long chain fatty acyl coenzyme A, acts as a toxic lipid on its accumulation in tissues 
during obesity (Hage Hassan et al., 2014). Cer formation is regulated by Cer synthases 
(6 types) which, on activation, form a different acyl chain Cer (C14:0-C30:0). 
Research carried out in Cer synthase-deficient mice showed that altering Cer acyl-
chain lengths through deficiency of the specific Cer synthase enzyme may lead to 
tissue-specific effects (Turpin et al., 2014). In pancreatic beta cells, Cer 18, 22 and 24 
formed by Cer synthase type 4, cause apoptosis and blockade of this enzyme was 
found to halt the apoptotic process. In liver and adipose tissue, Cer 16 and 18 are 
suggested to be associated with insulin resistance (Turpin et al., 2014, Cinar et al., 
2014). In T2DM patients, the expression of Cer 16, 18 and 24 was found to be 
increased in muscle cells compared to lean individuals (Bajpeyi et al., 2014). Animal 
and in vitro studies have shown an inverse relationship between Cer levels and insulin 
sensitivity. Cer levels were found to be increased in insulin-resistant models of rodents 
and mice fed on a high-fat diet, and in intra-lipid infused mice (Samad et al., 2006, 
Schmitz-Peiffer et al., 1999). The inverse relationship between Cer and insulin 
sensitivity was also confirmed in vitro in cultured C2C12 and L6 myotubes and 3T3-
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L1 adipocytes (Hajduch et al., 2001, Schmitz-Peiffer et al., 1999, Summers, 2006). In 
humans, numerous studies also support the inverse relationship between insulin 
sensitivity and Cer contents. It has been shown that Cer content was increased and 
insulin sensitivity decreased in obese, T2DM and cardiovascular disease patients 
compared to lean individuals (Straczkowski et al., 2004, Amati et al., 2011, Coen et 
al., 2013, Straczkowski et al., 2007). It has been established that obesity is associated 
with low-grade inflammation. Cer acts as a link between inflammation and insulin 
resistance. Saturated fat activates toll-like receptors which increase the transcription 
of inflammatory cytokines like TNF-α and IL-6 which produce Cer (Hage Hassan et 
al., 2014). It has been proposed that impairment of mitochondrial function results in 
the development of toxic lipids like Cer which then lead to insulin resistance (Turpin 
et al., 2014). 
 
Numerous mechanisms by which Cer causes insulin resistance have been postulated 
which are discussed below (Fig 5.5). 
1) Various studies have shown that Cer decreases insulin-stimulated glucose 
transport and glycogen synthesis by blocking IRS-1 and PI3K in the insulin 
signalling pathway (Zundel and Giaccia, 1998, Kanety et al., 1996). However, 
other studies showed no effect of Cer on these molecules (Hajduch et al., 2001, 
Summers et al., 1998). Other groups, however, reported PKB/Akt as a target 
molecule of Cer in the insulin signalling pathway which led to decreased 
glucose transport. This has been observed in Cer-treated cell types including 
3T3-L1 adipocytes, L6 rat and C2C12 mouse skeletal muscle and MCF7 breast 




2) It has been documented that Cer inhibits PKB/Akt by blocking 2 pathways: 
protein phosphatase 2A (PP2A) and atypical PKC (aPKC). PP2A is a 
cytoplasmic serine/threonine phosphatase which regulates cellular processes, 
including metabolic enzymes, kinase cascades, hormone receptors and cell 
growth. It has been proposed that Cer activates PP2A which causes de-
phosphorylation of PKB/Akt, altering insulin signalling pathways (Janssens 
and Goris, 2001, Salinas et al., 2000). Another pathway by which Cer blocks 
PKB/Akt is by activation of PKC. PKC makes a complex with PKB/Akt and 
regulates its physiological action; increased Cer activates PKC which 
promotes the stabilisation of PKC/PKB/Akt complex and blocks the 
recruitment of PKB/Akt to the plasma membrane (Powell et al., 2003, Fox et 
al., 2007).  
3) Kinases such as c-Jun N-terminal Kinase (JNK) and I kappa kinase beta (IκKβ) 
have been reported to regulate insulin signalling. Cer activates JNK and IκKβ 
resulting in activation of transcription factors Jun and the nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB). These factors, in turn, may 
alter the expression of genes that inhibit proximal signalling events (Summers, 
2006, Summers et al., 1998). 
4) High Cer concentration increases reactive oxygen species (ROS) which causes 
mitochondrial dysfunction leading to apoptosis of cells. Mitochondrial 
dysfunction inhibits lipid oxidation leading to the formation of lipid 





Figure 5.5 Proposed mechanisms by which Cer cause insulin resistance (adapted from 
Summers SA, 2006). 
 
 
5.1.8 Lipidomic profiling of Adipocytes 
 
Adipocytes show versatile lipid metabolism machinery which comprises regulation 
between synthesis, modification, and breakdown. Lipid accumulation in adipocytes 
starts with fatty acid uptake or lipogenesis from glucose which leads to triglyceride 
storage in lipid droplets. Lipogenesis is regulated by various enzymes which include 
acetyl-CoA carboxylase, ATP-citrate lyase, and fatty acid synthase. Lipolysis, in 
which triglycerides break down to release fatty acids, is regulated by lipoprotein 
lipase, adipose-triglyceride lipase, and hormone-sensitive lipase. Fatty acids are 
precursors for all lipid types including PL, SL, sterols, and eicosanoids. Fatty acids 
are capable of regulating insulin sensitivity in adipocytes. Studies have shown that 
high levels of PUFA improve insulin sensitivity while high levels of saturated FA 
reduce insulin sensitivity (Lapid and Graff, 2017). Lipid profiles may change as an 
207 
 
adaptation to various factors like drugs, exercise, and diet or in a pathological 
condition like T2DM or hepatic steatosis. Therefore, lipids can act as a diagnostic 
biomarker and can be associated with various diseases like metabolic or 
cardiovascular disease (Han, 2016). Lipogenesis in adipocytes is regulated by 
transcriptional factors; most important are PPARγ, C/EBPα, and SREBP1. These 
factors increase the expression of enzymes that lead to fatty acid biosynthesis, 
transport and their conversion into TG. These transcriptional factors then activate 
other factors like fatty acid binding protein (FABP4), liver X receptor (LXR), delta 
kinase homolog 1 (DLK-1) and kruppel-like factor (KLF), leading to the formation of 
lipids including various species of FA, prostaglandins, steroid, Cer, and GPL. These 
transcriptional factors also induce expression of various genes involved in fatty acid 
and glucose uptake and lipogenesis thus maintaining the normal physiological 
function of adipocytes (Bergen and Burnett, 2013). Lipogenesis in adipocytes is also 
controlled by various hormones; insulin is considered one of the main hormones. In 
adipocytes, insulin promotes the uptake of glucose and its conversion into 
glycerophosphate which becomes esterified by 3 fatty acids to form triglycerides for 
storage. In times of caloric requirement, TG converts into FFA which is then 
transported to the liver and skeletal muscles where it is oxidised to use as an energy 
source (Hage Hassan et al., 2014) (Fig. 5.6)  
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Figure 5.6 Peripheral homeostasis of lipid oxidation for providing energy source 
(Adapted from Hassan et al.,2014). 
 
As adipocyte is a major organ for lipid metabolism, storage and release, any change 
in adipocyte lipidome may precede disease development and various lipid markers 
may be secreted into the blood. Various clinical studies of obesity and diabetes have 
shown increased levels of DAG, CE, TAG, and Cer in plasma of these patients 
compared to normal individuals (Tonks et al., 2016, Rauschert et al., 2016). Obesity 
is one of the main pathological features of metabolic syndrome and is characterised 
by increased body fat which is stored in adipose tissue. Pietilainen and colleagues 
proposed the hypothesis, adipose tissue expandability, according to which excess fat 
is stored in adipose tissue but once it reaches its limit, the excess fat is stored 
ectopically in peripheral tissues such as skeletal muscle, the liver and pancreas 
(Pietilainen et al., 2011). Lipidomic approaches can be used to characterise various 
lipid species present in adipose tissue and to understand how changes in these lead to 
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development of metabolic disease. Various researchers have conducted human studies 
and shown an association between varied lipid metabolites and obesity and insulin 
resistance. Pietilainen and colleagues’ using obese human adipose tissue, showed an 
increased association of TG, PC, PE, palmitic and arachidonic fatty acids with obesity. 
The precursor of arachidonic-derived lipid mediators, such as leukotriens and 
hydroxyeicosatetraenoic acid, which are important mediators of inflammation, make 
adipocytes more vulnerable to inflammation (Pietilainen et al., 2011). A study by Jove 
and colleagues on human subcutaneous adipose tissue showed an association of GPL 
and SL with obesity. Kolak and colleagues studied the human subcutaneous adipose 
tissue in obese individuals with a high liver fat content. Out of the 154 lipid species 
studied, the most prominent appeared to be increased concentration of TAG and Cer, 
specifically Cer 18, compared to obese individuals with normal liver fat (Kolak et al., 
2007). Research has provided information on the role of Cer in insulin resistance not 
only in skeletal muscle but also in adipocytes. It has been shown that intracellular 
levels of Cer increase in obese, insulin resistant rats (Turinsky et al., 1990) as well as 
obese, insulin-resistant humans (Adams et al., 2004). Shah and colleagues’ study on 
mice showed increased levels of Cer in plasma as well as adipose tissue, with an 
increase of more than 300% for Cer 18 (Shah et al., 2008b). Various studies have 
shown increased human adipose tissue Cer content in obese, T2DM individuals 
compared to normal individuals. Among various ceramides, Cer 14, 16, 18 and 24 
have been demonstrated to be increased in obese subcutaneous human adipose tissue 






5.1.9 Lipid species in Schizophrenia and antipsychotic therapy 
 
There is evidence of lipid abnormalities in many neurological disorders including 
schizophrenia and bipolar disorder. These abnormalities may cause an alteration in the 
neurotransmitter receptor function and brain glucose and lipid dysregulation which 
leads to schizophrenic symptoms. It has been demonstrated that schizophrenia is 
associated with increased concentration of PC, PE, and FA lipid classes (McEvoy et 
al., 2013). Schwarz et al have reported a significant increase in the levels of PC and 
FFA in gray and white matter and a significant increase in Cer in the white matter of 
schizophrenic patient samples. Interestingly, this study did not show any in FFA and 
Cer levels after antipsychotic treatment in the white and gray matter of samples 
compared to untreated schizophrenic controls. In contrast to this, Schwarz et al showed 
that antipsychotic treatment results in increased Cer concentrations in red blood cell 
(RBC) samples of schizophrenic patients (Schwarz et al., 2008). Limited research has 
been done so far to analyse the lipidomic changes in schizophrenic patients taking 
AAPs. Daouk and colleagues evaluated global plasma lipid changes in schizophrenic 
patients after 2-3 weeks of treatment with AAPs (OLA, RISP, and ARI). OLA and 
RISP showed increased concentrations of PC, PE, and TAG and their metabolites 
compared to ARI (Kaddurah-Daouk et al., 2007). A few studies have also reported the 
effect of AAPs on n3 and n6 PUFA within PC lipid class. Both n3 (eicosapentaenoic 
acid) and n6 (arachidonic acid) fatty acids are important for cell-signalling and enzyme 
regulation. The n6 fatty acids promote inflammatory conditions while n3 fatty acids 
tend to reduce it. So dysregulation of n3 and n6 fatty acids may divert the cells towards 
pathological conditions. AAPs, especially CLO and OLA, resulted in increased n6 
levels, suggesting inflammation as one of the causes of metabolic toxicity observed in 
AAP-treated schizophrenic patients (McEvoy et al., 2013, Glen et al., 1996). 
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5.1.10 Rationale  
 
An in-depth analysis of lipid molecules is crucial for the understanding of cellular 
physiology and pathology. Together, lipid profiling and computational methods have 
led to the recognition and involvement of specific lipids in metabolic and 
cardiovascular diseases (Oresic et al., 2008). Such work may then have the potential 
to identify lipid biomarkers of disease and /or identify therapeutic targets leading to 
the development of new drugs (Lapid and Graff, 2017). Adipocytes have been a central 
interest for the past few years due to their ability to store lipids and endocrine functions 
along with an established role in the pathogenesis of insulin resistance associated with 
metabolic diseases such as obesity and T2DM (Hage Hassan et al., 2014). Various 
studies have shown changes in lipid classes and their metabolites such as PE, PC, CE, 
TAG and Cer in obese diabetic patients compared to normal individuals (Blachnio-
Zabielska et al., 2012b, Kaddurah-Daouk et al., 2007). However, there are only a few 
studies which have investigated the role of adipocyte lipid species in metabolic 
toxicity arising as result of AAPs therapy (Kaddurah-Daouk et al., 2007, McEvoy et 
al., 2013). To our knowledge, there has been no information available on the global 
effect of AAPs on the lipidome of cultured human subcutaneous adipocytes. Our 
rationale was to characterise the lipid changes brought about by AAPs in primary 
human adipocytes and investigate what mechanistic role they play in AAP-induced 









This chapter tests the hypothesis that AAPs cause global changes in the adipocyte 
lipidome profile and this will contribute to the mechanistic role in AAP-induced 
metabolic toxicity. 
 
5.1.12 Aims and Objectives 
 
The aims and objectives are: 
1) To undertake LC-MS/MS based lipidomic profiling to assess the global changes in 
adipocyte lipid profile caused by AAPs. 
2) To validate selected lipid markers identified from the lipidomic profiling using 



















The materials were similar as described in section 3.2.1. 
 
5.2.2 Cell Culture 
 
Cell culture was performed as described in section 3.2.2.  
5.2.3 Collection of lipid pellets for lipidomic analysis 
 
On day 13, 48 hr after last drug addition, supernatants were aspirated carefully and 
2ml of PBS was added to each well twice, shaken briefly and aspirated.  600µl of 
trypsin was added in each well to detach the cells; this was followed by gentle pipetting 
to dislodge the cells and the lysate was collected in Eppendorf tubes. These tubes were 
centrifuged for 1 min at maximum speed to obtain a pellet at the bottom of the tube. 
The supernatant was discarded and 1ml of PBS was added to the pellet to wash it. The 
washing process was repeated one more time. After centrifugation for 30 sec, the 
supernatant was discarded leaving behind pellet only which was frozen at - 80°C for 
further analysis. 
 
5.2.4 Global lipidomic profiling of cultured primary human adipocytes  
 
Lipidomic profiling was performed at the Lipidomic Research facility, University of 
Highlands and Islands, Inverness, UK. The methodology used by Folch et al was 
applied for the extraction of adipocyte lipids (Folch et al., 1957). Briefly, a 50 µl 
aliquot of cell lysate was extracted with 950µl methanol and 2ml chloroform. 50µL 
methanol containing internal standards (PC 12:0/12:0, PE 14:0/14:0, Cer 17:0, DAG 
17:0/17:0, and TAG 17:0/17:0/17:0 ) was added and the mixture was then left to stand 
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at room temperature for 1 hr. 700 µl of 0.1 M KCl was added to partition the samples. 
The mixture was centrifuged at 2000 x g for 5 min to perform phase separation. The 
lower chloroform layer was evaporated to dryness under nitrogen gas and 
reconstituted in 200 µL methanol/chloroform (1/3, v/v) containing 5mM ammonium 
formate. 
 
5.2.4.1 Liquid chromatography/ Mass spectrometry (LC-MS) 
 
Extracted lipid samples were analysed by LC-MS. All analyses were performed using 
a Thermo Exactive Orbitrap mass spectrometer (Thermo Scientific, Hemel Hempsted, 
UK) equipped with a heated electrospray ionization probe and coupled to a Thermo 
Accela 1250 UHPLC system. Samples were injected on to a Thermo Hypersil Gold 
C18 column (2.1mm x 100 mm, 1.9μm). Mobile phase A consisted of water containing 
10 mM ammonium formate and 0.1% (v/v) formic acid. Mobile phase B consisted of 
90:10 isopropanol/acetonitrile containing 10 mM ammonium formate and 0.1% (v/v) 
formic acid. The flow rate was 400 µl/min. The samples were analysed in positive (2 
µL injection) and negative (5 µL injection) ion modes over the mass to charge ratio 
(m/z) range 250-2000 at a resolution of 100,000 and 1Hz scan speed. 
 
5.2.5 Data Processing and Multivariate data Analysis (MVDA) 
 
The raw LC-MS data were processed with Progenesis QI software (version 2.1, Non-
linear Dynamics, Newcastle, UK). Lipid identifications were made using LIPID 
MAPS (www.lipidmaps.org) and human metabolomics database (HMDB) 




In order to analyse systematically and extract important information, MVDA is 
conducted by which the association between lipid species and its effect on lipid 
metabolism can be studied. MVDA can be classified into;  
1) Unsupervised data analysis known as Principal component analysis (PCA) and,  
2) Supervised methods called as Partial least squares discriminant analysis (PLS-DA).  
 
In PCA, the data is projected to observe how the samples are clustering by themselves. 
Here, prior knowledge or classification of sample groups are not applicable and 
therefore is a unbiased analysis. PCA can also be used to decrease dimensionality of 
the data set and show outliers, sample grouping, trends of variation and systematic 
pattern.  
 
PLS-DA is a supervised method where the information about each sample group is 
supplied. PLS-DA was used to better discriminate control and treated cells. In other 
words it can be employed when sample group classification is already known. PLS-
DA can be used to find information on major trends, to find out lipid species 
responsible for the trends and variation among different sample group (Oresic, 2010). 
 
5.2.6 Gene expression 
 
Isolation of mRNA, reverse transcription and gene expression were measured by 
methodology as described in section 2.2.6.  
5.3 Statistical Analysis 
All statistical comparisons (5 donors) were made using t-test on StatsDirect software 
version 2.7.9. Differences were considered significant at p≤0.05. The result was shown 
as mean ± SD.  
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5.4 Results  
 
5.4.1 Global lipidomic analysis by MVDA 
  
5.4.1.1 Effect of CLO on global lipidomic analysis 
  
For CLO, both the PCA and the PLS-DA showed a clear separation between the three 
groups (Group 1- Vehicle; yellow; Group 2 – 1µM CLO, purple; Group 3 – 20µM 
CLO, brown) analysed (Fig 5.7 A-B). The separation of clusters were more evident in 
the samples which were analysed under negative ion mode (Fig 5.7 A-B). Even though 
there was some separation between the Vehicle and 1µM CLO clusters, these clusters 
were closely located suggesting the global differences in lipid profiles between vehicle 
(control) and those treated with therapeutic doses of CLO were not significant. 
However, samples treated with 20µM CLO cluster (Group 3, brown) showed a clear 
separation from both vehicle and 1µM CLO and were in a different quadrant. We also 
saw some degree of variability between the 5 donor adipocyte used depending on the 
ion modes used; whilst donors 0092, 511 and 101 displayed similar characteristics and 
clustered in the same quadrant, donors 400 and 395 were outliers (Fig 5.7 A on positive 
ion mode). Donor 101 was also repeated (shown as 101R in the Fig 5.7 A-B) and was 
used as a technical replicate. In the negative ion mode PCA, the samples showed lesser 
variability; this may suggest the variability was not only sample specific but also lipid 
related. PLS-DA analysis showed a better separation between groups analysed (Fig 


















 Positive Ion PCA-Clozapine Negative Ion PCA-Clozapine 
Figure 5.7: A) PCA analysis of cellular lipids in CLO treated samples of cultured primary human adipocytes in both positive and negative ion mode. PCA: Principal 




















Negative Ion PLSDA-Clozapine Positive Ion PLSDA-Clozapine 
Figure 5.7: B) PLS-DA  analysis of cellular lipids in CLO treated samples of cultured primary human adipocytes in both positive and negative ion mode. PLS-DA: 






5.4.1.2 Effect of OLA on global lipidomic analysis 
  
For OLA, both the PCA and the PLS-DA showed a clear separation between the three 
groups (Group 1- Vehicle; yellow; Group 2 – 0.2µM OLA, dark blue; Group 3 – 20µM 
OLA, light blue) analysed (Fig 5.8 A-B). The separation of clusters were more evident 
in the samples which were analysed under negative ion mode (Fig 5.8 A-B). Even 
though there was some separation between the Vehicle and 0.2µM OLA clusters, these 
clusters were closely located suggesting the global differences in lipid profiles 
between vehicle (control) and those treated with therapeutic doses of OLA were not 
significant. However, samples treated with 20µM OLA cluster (Group 3, light blue) 
showed a clear separation from both vehicle and 0.2µM OLA and were in a different 
quadrant. We also saw some degree of variability between the 5 donor adipocyte used 
depending on the ion modes used; whilst donors 0092, 395, 511 and 101 displayed 
similar characteristics and clustered in the same quadrant, donor 400 was outlier (Fig 
5.8 A on positive ion mode). Donor 101 was also repeated (shown as 101R in the Fig 
5.8 A-B) and was used as a technical replicate. In the negative ion mode PCA, the 
samples showed lesser variability; this may suggest the variability was not only sample 
specific but also lipid related. PLS-DA analysis showed a better separation between 





























Figure 5.8: A) PCA  analysis of cellular lipids in OLA treated samples of cultured primary human adipocytes in both positive and negative ion mode. PCA: 




Positive Ion PLSDA-Olanzapine 




Figure 5.8: B) PLS-DA  analysis of cellular lipids in OLA treated samples of cultured primary human adipocytes in both positive and negative ion mode. PLS-
DA: Partial least squares discriminant analysis, Pos: Positive ion mode, VEH/VD: Vehicle. Circles denoted as; Yellow: Vehicle, Dark blue: 0.2µM OLA, Light 




5.4.1.3 Effect of ARI on global lipidomic analysis 
  
For ARI, both the PCA and the PLS-DA showed lesser separation between the clusters 
of three groups (Group 1- Vehicle; yellow; Group 2 – 0.2µM ARI, green; Group 3 – 
10µM ARI, red) analysed (Fig 5.9 A-B). This was more evident in the samples which 
were analysed under negative ion mode (Fig 5.9 A-B). Even though there was some 
separation between the Vehicle, 0.2µM ARI and 10µM ARI clusters, these clusters 
were closely located suggesting the global differences in lipid profiles between vehicle 
(control) and those treated with therapeutic and the high dose of ARI were not 
significant. However there was clear difference between vehicle and high dose of ARI 
of donor 0092 and 511 showing global differences between them but should be viewed 
with caution as it was only seen with one sample (Fig 5.9A-B). We also saw some 
degree of variability between the 5 donor adipocyte used depending on the ion modes 
used; whilst donors 0092, 511, 101 and 400 displayed similar characteristics and 
clustered in the same quadrant, donors 395 was outlier (Fig 5.9 A on positive ion 
mode). Donor 101 was also repeated (shown as 101R in the Fig 5.9 A-B) and was used 
as a technical replicate. In the negative ion mode PCA, the samples showed lesser 
variability; this may suggest the variability was not only sample specific but also lipid 
























Positive Ion PCA-Aripiprazole Negative Ion PCA-Aripiprazole 
Figure 5.9: A) PCA  analysis of cellular lipids in ARI treated samples of cultured primary human adipocytes in both positive and negative ion mode. PCA: Principal 
component analysis, Pos: Positive ion mode, VEH/VD: Vehicle. Circles denoted as; Yellow: Vehicle, Green: 0.2µM ARI, Red: 10µM ARI. 
Vehicle 
0.2µM ARI 
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Vehicle 
0.2µM ARI 
10 µM ARI 
Figure 5.9: B) PLS-DA analysis of cellular lipids in ARI treated samples of cultured primary human adipocytes in both positive and negative ion mode. PLS-DA: 




Of the various lipid species detected, we focussed on the Cer class of species to 
investigate the effect of AAPs. 
 
5.4.2.1 Effect of CLO on Cer lipid species   
 
Our data showed that the therapeutic dose of CLO (1µM) induced a significant 
decrease in all of major Cer species except Cer 17:0 and Cer 19:0 in comparison with 
the vehicle. The higher dose of CLO (20µM) also resulted in significant decrease in 
various Cer species listed in brackets (16:1, 18:0, 20:0, 22:0, 22:1, 23:0, 24:0, 24;1, 
26:0 and 26:1). Cer 16:0 and 25:0 also showed decreased levels but the result was 
statistically non-significant. One of the Cer species (18:1) could not be detected in all 
the samples while 17:0 and 19:0 species showed no change after giving high dose of 
CLO (Fig 5.10A-D).  
 
Comparison between 1µM and 20µM CLO showed a trend to increase for various Cer 
species  (16:0, 17:0, 18:0, 20:0, 22:0, 23:0, 24:0, 25:0, 26:0 and 26:1); however, this 
was non-significant. Cer 16:1, 19:0, 22:1 and 24:1 did not show any change on 
comparison between therapeutic and high dose of CLO.  Cer 18:1 was not be detected 
in all of the donors following treatment with high dose of CLO (20µM) and was only 
detected in adipocytes treated with the therapeutic dose of CLO (1µM) (Fig 5.10 A-
D). 
 
5.4.2.2 Effect of OLA on Cer lipid species   
 
Both therapeutic and high dose of OLA showed significant decrease in all of the Cer 
species except 17:0 and 19:0 which showed no change compared to vehicle (Figure 




Comparison between 0.2µM and 20µM OLA showed a trend to increase for various 
Cer species (16:0, 18:0, 20:0, 22:0, 22:1, 23:0, 24:1, 25:0, 26:0 and 26:1) but the result 
was non-significant. However Cer 16:1, 17:0, 18:1, 19:0 and 24:0 did not show any 
change on comparison between therapeutic (0.2µM) and high dose (20µM) of OLA 
(Fig 5.10 A-D). 
 
5.4.2.3 Effect of ARI on Cer lipid species  
 
In contrast to the Cer results obtained with CLO and OLA, therapeutic dose of ARI 
(0.2µM) showed a trend to increase all of the Cer species levels; however, this was 
statistically non-significant. Higher dose of ARI (10µM) did not show any effect in 
any of the Cer species except Cer 18:1 and Cer 20:0; both these Cer showed a 
significant decrease in comparison to the vehicle. 
 
 Comparison between therapeutic and high dose of ARI showed a trend to decrease 
in all of the measured Cer species by high dose of ARI except Cer 17:0, there was no 














































































































Ceramide (d18:1/16:0)         Ceramide (d18:1/16:1)         
Ceramide (d18:1/17:0)         Ceramide (d18:1/18:0)         
Figure 5.10: A) Ceramide (d18) subspecies (16:0, 16:1, 17:0, 18:0) levels showing the effect of various concentrations of CLO, OLA and ARI on differentiated adipocytes. 




















































































































Ceramide (d18:1/18:1)         
Ceramide (d18:1/22:0)         Ceramide (d18:1/20:0)         
Ceramide (d18:1/19:0)         
Figure 5.10: B) Ceramide (d18) subspecies (18:1, 19:0, 20:0, 22:0) levels showing the effect of various concentrations of CLO, OLA and ARI on differentiated adipocytes. 
























































































































Ceramide (d18:1/22:1)         
Ceramide (d18:2/23:0)         
Ceramide (d18:1/23:0)         
Ceramide (d18:1/24:0)         
* 
Figure 5.10: C) Ceramide (d18) subspecies (22:1, 23:0, d18:2/23:0, 24:0) levels showing the effect of various concentrations of CLO, OLA and ARI on differentiated 























































































































Ceramide (d18:1/24:1)         Ceramide (d18:1/25:0)         
Ceramide (d18:1/26:0)         Ceramide (d18:1/26:1)         
* 
Figure 5.10: D) Ceramide (d18) subspecies (24:1, 25:0, 26:0, 26:1) levels showing the effect of various concentrations of CLO, OLA and ARI on differentiated adipocytes. 
All experiments were done in adipocytes cultured from 5 individual donors. Data was shown as mean ± SD; p ≤ 0.05. * VEH vs CLO, # VEH vs OLA.   
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5.4.3 Validation of Cer data  
 
To validate the Cer species data, we investigated the Cer biosynthesis pathway and 
selected 2 enzymes, Serine Palmitoyltransferase Long Chain Base Subunit 2 
(SPTLC2) and Dihydroceramide desaturase (DEGS1) as they both are involved in Cer 
synthesis. SPTLC2 is considered as a rate limiting enzyme which play role in de novo 
synthesis of Cer. We investigated the effect of AAPs on SPTLC2 and DEGS1 gene 
expression as an indirect method for validation of results obtained for Cer lipid 
species. 
 
5.4.3.1 Effect of AAPs on SPTLC2 and DEGS1 gene expression  
 
SPTLC2 and DEGS1 mRNA expression for each drug and dose is presented as a 
percentage of what was observed in comparison with the vehicle. The therapeutic dose 
of CLO (1µM) showed a trend to decrease SPTLC2 and DEGS1 expression although 
this was not statistically significant (Mean fold change±SD; SPTLC2:0.84±0.16; 
p=0.06, DEGS1:0.75±0.24; p=0.07). However, the higher dose of CLO (20µM) 
showed a significant decrease in the expression of both enzymes (SPTLC2: 0.60±0.13; 
p=0.003; DEGS1: 0.67±0.18; p=0.01). OLA on the other hand, showed significant 
decrease in expression of both enzymes by therapeutic as well as high dose (SPTLC2 
[0.2µM: 0.77±0.15; p=0.05, 20µM:0.62±0.16; p=0.007], DEGS1 [0.2µM:0.67±0.25; 
p=0.04, 20µM:0.83±0.11; p=0.02]). On the contrary, therapeutic dose of ARI(0.2µM) 
showed a trend to increase both SPTLC2 and DEGS1 expression although this was not 




However, high dose of ARI (10µM) showed an opposite effect to the therapeutic dose; 
it resulted in a significant decrease in DEGS1 expression (0.68±0.19; p=0.05) and 












































# # † 
Figure 5.11:  A) SPTLC2  and  B) DEGS1  gene expression showing the effect of various concentrations of CLO, OLA and ARI on differentiated adipocytes. All 
experiments were done in adipocytes cultured from 5 individual donors. Data was shown as mean ±SD; p≤0.05. * VEH vs CLO, # VEH vs OLA,  † VEH vs ARI. 
 
 
Fig. 5.11 A 




The study of lipids at the global level in adipocytes is a new but rapidly growing field 
which has the potential to uncover potential pathways and newer biomarkers which 
may be of use in clinical practice. The composition of lipids in adipocytes and their 
levels change with external perturbations may show of the various metabolic pathways 
which are of significance to normal glucose and lipid homeostasis as well as 
cardiometabolic disease pathogenesis. Understanding of global changes in lipids in 
complex diseases such as schizophrenia and the potential changes in their levels during 
treatment with AAPs could provide information about the mechanism of disease and 
response to drugs.  (Kaddurah-Daouk et al., 2007). SL, considered as one of the key 
classes of lipids, are active components of cell membranes. SL regulates cellular 
processes such as proliferation, maturation, and apoptosis. Among SL, Cer is 
considered as one of the most important lipid species which regulates cellular 
functions ranging from proliferation, differentiation, growth arrest and apoptosis 
(Hage Hassan et al., 2014). Various studies have shown an inverse association of Cer 
with insulin sensitivity in metabolic and cardiovascular diseases (Turpin et al., 2014, 
Blachnio-Zabielska et al., 2012b). AAPs have been documented to cause various 
metabolic adverse effects in schizophrenic patients. Among various mechanisms, 
insulin resistance is considered one of the main mechanisms by which AAPs cause 
metabolic adverse effects such as obesity, T2DM and CVD (Bartoli et al., 2015b, Liu 
et al., 2014). The data reported here represent the first attempt to map global lipid 
changes in in vitro primary human adipocytes following treatment with CLO, OLA, 
and ARI. Our multivariate data analysis showed that AAPs resulted in changes in lipid 
levels in cultured primary human adipocytes. We found the therapeutically relevant 




differentiating primary human adipocyte. However, the higher dose of CLO and OLA 
had a more profound effect on the lipidome of the adipocyte. On the other hand 
therapeutic dose of ARI did not show much a change in the global lipid profile. This 
suggests that CLO and OLA, which are notorious for causing metabolic adverse 
effects cause global changes in lipids when at higher concentrations particularly, and 
these may play a role in causing metabolic toxicity. This supports our hypothesis that 
some AAPs such as CLO and OLA when administered chronically could accumulate 
in the adipose tissue and cause deleterious effects which may explain the mechanisms 
behind AAP-induced cardiometabolic toxicity. This also coincided with Daouk et al’s 
study which showed that OLA brought about changes (increase) in lipids; Daouk’s 
study showed approximately 50 lipids were increased, while ARI showed fewer 
changes. Although Daouk et al investigated plasma samples obtained from 
schizophrenia patients whereas we interrogated in vitro samples, both studies suggest 
that AAPs associated with metabolic risk caused more disturbances in the lipid profile 
than those with reduced metabolic toxicity. 
 
We then further focussed on an individual lipid class, the ceramides.  Previous studies 
have shown changes in lipid classes and subclasses in metabolic deranged conditions 
like obesity and T2DM; however, it has been suggested that these patients showed 
more changes in GLP and SL levels compared to other lipids (Alshehry et al., 2016). 
Among SL, Cer showed an association with CVD (Stegemann et al., 2014, Spijkers et 
al., 2011). Cer are also documented as being associated with obesity and insulin 
resistance where its levels are increased (Nestel et al., 2014, Tonks et al., 2016). There 
is an inverse relationship between Cer and insulin sensitivity. This has been confirmed 
in various in vitro studies using 3T3-L1 adipocytes, L6 myotubes and C2C12 cultured 
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cells (Hajduch et al., 2001, Schmitz-Peiffer et al., 1999, Summers, 2006). A rodent 
model of insulin resistance (Samad et al., 2006) and clinical studies on insulin resistant 
obese and T2DM patients (Coen et al., 2010, Amati et al., 2011) have also shown 
increased levels of Cer compared to normal. This inclined us to look at the effect of 
AAPs on the Cer profile in our primary human adipocytes model. There are many Cer 
species; however, it has been suggested that Cer 16 and 18 are associated with insulin 
resistance (Turpin et al., 2014). Various preclinical (Shah et al., 2008b) and human 
obese and high fat studies (Kolak et al., 2007, Blachnio-Zabielska et al., 2012b) 
showed Cer 18 species to be increased in adipose tissue which inclined us to focus on 
this Cer species. Shah et al preclinical study in high fat diet mice showed a 300% 
increase in Cer 18 in adipose tissue which showed its association with metabolic 
disease (Shah et al., 2008a). Our data showed a decrease in Cer species (16:0, 18:0, 
18:1, 20:0, 22:0, 22:1, 24:0 ,24:1, 26:0, 26:1) on giving CLO and OLA while ARI 
showed no change compared to the control. 
 
Surprisingly, our data did not coincide with other studies which showed increased Cer 
levels in obese, T2DM patients. Tonks and colleagues’ study showed increased plasma 
and skeletal muscle Cer levels in obese insulin-resistant individuals. Although their 
study showed changes in all Cer 18 subclasses, the most prominent were related to 
18:0, 24:0 and 24:1 (Tonks et al., 2016). Tonks’ study was in line with other studies 
showing increased concentration of Cer 18:0 (Coen et al., 2010, Amati et al., 2011). 
Cer 18:0 was also found to be increased in insulin-resistant rodent models (Turner et 
al., 2013). Kolak et al study showed Cer 24:1, to be increased in high fat diet (Kolak 
et al., 2007). Since adipose tissue acts as the main fat storage hub, lipid metabolism, 
and release, changes in the adipocyte lipidome may be reflected in the blood (Lapid 
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and Graff, 2017). The reason for this contradiction could be model related. Our model 
used primary human adipocytes, and the models used preclinically and clinically were 
mice and human adipose tissue or plasma respectively. The differences in the models 
might be the cause of the contradictory results observed here. Also, clinical studies 
used a large number of patients while we were limited in the availability of the 
adipocytes from donors who came under the selection criteria. A large number of 
samples could provide us with a clear picture about Cer. There are also other 
significant changes between ours and others studies: for example, the patients in other 
studies had been diabetic or obese for a long period of time while our data was taken 
from adipocytes exposed to AAPs 13 days post differentiation. This suggests that 
changes in lipids take a long time to be observed or detected. Although our data 
showed some changes, a longer study duration might produce different results. 
Another reason could be a compensatory increase in Cer brought about by the 
adipocyte to counter the decrease induced by AAPs; we undertook lipid profiling at 
the end of 13 days of adipocyte differentiation and therefore we have not been able to 
investigate the changes in Cer (and other lipid species) in between this timeline.  
 
Interestingly, there are a few studies which indeed showed decreased levels of Cer. It 
has been proposed that Cer, along with other cellular functions, is also involved in 
adipocyte differentiation (Choi et al., 2011). Choi et al studied adipocyte 
differentiation in 3T3-L1 cells. Differentiation was induced by insulin and Cer 
analysis through HPLC was done after 6 days post differentiation. It was shown that 
Cer concentration in adipocytes decreased during adipogenesis compared to 
preadipocytes, while lipid droplets and TG content were increased, which is the 
characteristic feature of adipocytes (Choi et al., 2011). This data also coincided with 
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a study conducted on mice in which adipose tissue of ob/ob mice showed decreased 
levels of Cer compared to lean mice (Samad et al., 2006). TG synthesis in rat and 
human adipocytes require palmitic acid as a substrate. Palmitic acid is also required 
for SL biosynthesis so it was suggested that palmitic acid might be used for TG 
synthesis leading to a decrease in SL synthesis in adipocytes (Choi et al., 2011). 
Although our model was different from that of Choi et al, given AAPs accelerate 
adipogenesis as we have seen in our experiment (discussed in Chapter 3), increased 
diversion of palmitic acid to TG synthesis instead of SL during AAP-induced increase 
in adipogenesis could lead to decreased levels of Cer. This clearly shows the 
difficulties in dissecting insulin signalling pathways from adipogenesis in preclinical 
and clinical models and more research need to be done to explain the mechanisms 
involved. 
 
Our study coincided with Blachnio-Zabielska et al data in which they showed a 
decreased content of Cer in the subcutaneous adipose tissue of obese non-diabetic and 
diabetic subjects. However, their methodology was different as they used adipose 
tissue instead of cultured adipocytes and measured total Cer content instead of 
individual species (Blachnio-Zabielska et al., 2012b). They also proposed that disease 
itself (in this case insulin resistance in conditions like obesity and diabetes) increased 
the metabolism of Cer. It was further proposed that the disease might activate CDases 
enzyme which breaks down the Cer, decreasing its levels. They found increased 
expression of CDases in their study (Blachnio-Zabielska et al., 2012a). They also 
showed in their study that Cer18 was increased in obese males while Cer 24 was 
increased in obese females. This gender dimorphism might be a significant factor in 
assessing the data. All the primary adipocytes used in our study were derived from 
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female donors; hence, according to Blachnio-Zabielska et al study, there could be a 
possibility that Cer 24, instead of Cer 18, was more involved in causing insulin 
resistance. This suggests that AAPs might increase Cer 24, while decreasing Cer 18 
in female donors; this would however require more research to be undertaken in 
adipocytes established from both males and females. 
 
To validate Cer data, we investigated the Cer metabolism pathway by analysing the 
gene expression of two important enzymes involved in Cer synthesis. Cer is formed 
by the coupling of palmitoyl-CoA and serine which produce ketosphinganine by the 
rate limiting enzyme SPTLC. There are 3 isoforms of SPTLC enzymes, SPTLC 1, 2, 
and 3 with SPTLC2 being the most abundant in white subcutaneous adipose tissue. 
Ketosphinganine is converted into sphinganine followed by the formation of 
dihydroceramide (DhCer) and then Cer by the enzyme DhCer desaturase. DhCer 
desaturase has two isoforms; DEGS1 is found in most tissues; however, mostly it is 
expressed in the liver, muscle and adipose tissue while DEGS2 is seen in the intestines 
(Chaurasia et al., 2016). Our data showed decreased expression of SPTLC2 by CLO 
and OLA while ARI did not show any change. Blachnio-Zabielska and colleagues also 
studied Cer metabolising enzymes in subcutaneous adipose tissue in obese diabetic 
patients. Their study proposed that disease itself activates the CDases enzyme leading 
to a decrease in the content of Cer despite the increase in expression of SPTLC mRNA 
suggesting that there is more degradation of Cer than synthesis (Blachnio-Zabielska 
et al., 2012a). This has also been observed in a study conducted on ob/ob mice (Samad 
et al., 2006). However, our data showed a decrease in expression of SPTLC 2 which 
suggests that AAPs might block the SPTLC2 enzyme directly leading to a blockade 
of Cer synthesis or AAPs might activate CDases, although we did not measure the 
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effect of AAPs on CDases in our data, leading to decreased levels of Cer species. 
However, ARI showed no change in expression which suggests normal synthesis of 
Cer in the presence of ARI, showing ARI to have the least metabolic toxic effect 
compared to CLO and OLA.  
 
The final reaction involved in de novo Cer synthesis is mediated through enzyme 
DEGS1. It has been documented that the decreased expression or downregulation of 
DEGS1 increases the DhCer/Cer ratio in cellular models (Barbarroja et al., 2015). 
DhCer is also considered a modulator of cell cycle, apoptosis and autophagy. Genome-
wide association studies in mice identified DEGS1 as a candidate gene associated with 
lipid accumulation (Barbarroja et al., 2015). Understanding DEGS1 and its associated 
Cer metabolic pathway not only provides relevance but could also be considered as a 
potential therapeutic target for obesity-associated insulin resistance. Barbarroja et al 
showed that DEGS1 gene expression was found to be decreased in a high-fat diet 
mouse model and also in genetically induced obese mice (ob/ob). Our data coincided 
with this study in terms of the effect of CLO and OLA on DEGS1 mRNA expression. 
ARI however, showed an opposite effect with a trend to increase, but the result was 
statistically non-significant. Although our model was based on primary human 
adipocytes compared to Barbarroja’s model (mice adipocytes), it suggests that 
reduction in DEGS1 might be one of the potential mechanisms by which AAPs act 
and decrease Cer synthesis. Barbarooja et al also showed that this downregulation only 
happened in adipose tissue while liver and skeletal muscle did not show any change, 
demonstrating its specificity to adipose tissue (Barbarroja et al., 2015). 
Downregulation was also shown in visceral AT of obese patients showing an 
association of DEGS1 with metabolic diseases such as obesity or T2DM. As obesity 
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is characterised by low-grade inflammation, it has been documented that the 
modulators of obesity-associated inflammation cause down-regulation of DEGS1 
compared to normal individuals (Barbarroja et al., 2015). This suggests that AAP 
might cause inflammation resulting in decreased DEGS1 leading to decreased levels 
of Cer resulting in insulin resistance. 
 
Barbarroja and colleagues also studied the association between DEGS1 and 
adipogenic transcription markers. In an in vitro study on 3T3-L1 adipocytes, a direct 
correlation of pparγ2 and degs1 was shown. In vivo validation conducted on adipose 
tissue of PPARγ2KO (PPARγ2 knock-out mice) and POKO mice (a 
crossed ob/ob mice, having capability of storing large amounts of fat, with mice 
deficient  of PPARγ to generate ‘POKO mice’, having increased circulating levels of 
glucose and fat) showed decreased mRNA expression of DEGS1 in PPARγ2KO and 
POKO mice (Medina-Gomez et al., 2007). Decreased expression of PPARγ2 might 
lead to an alteration in adipocyte differentiation so DEGS1 indirectly affects adipocyte 
differentiation. However this contradict with our previous data where it showed 
increased PPARγ expression (chapter 3 & 4) while DEGS1 data showed decreased 
expression by AAPs (chapter 5). This contradiction might be due to (i) change in 
methodology as we performed our experiment on primary human adipocytes while 
Medina-Gomez study was done on mice (ii) Our data was performed on 3-5 donors 
which might not reflect the effect, more donors are required to see effect of AAPs on 
PPARγ and DEGS1 and their interaction. It has also been shown that downregulation 
of DEGS1 expression in DEGS1 knock down (KD) 3T3-L1 cells was associated with 
down-regulation of SPTLC and Cer synthase (Cer6) enzymes, suggestive of 
physiological readjustment of the biosynthetic pathway to compensate for the 
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dysregulation of DEGS1. It can be postulated that AAPs like CLO and OLA, but not 
ARI, decrease DEGS1 expression leading to alteration in the DhCer/Cer ratio resulting 
in an increased content of DhCer. This might suggest a potential role for DhCer in 
insulin resistance. There is a possibility that AAPs result in increase in DhCer levels 
when it results in a decrease in Cer as shown in our data (Mamtani et al., 2014, Weir 
et al., 2013).  
 
In conclusion, our lipidomic study suggests that metabotoxic AAPs, particularly at 
higher concentrations, might act directly on adipocytes and cause global changes in 
the adipocyte lipidome. AAPs such as CLO and OLA resulted in a reduction of several 
Cer species and this may be modulated by their interaction with various enzymes that 
mediate the Cer synthesis pathway. However, our data contradicted with some of the 
published data; this could be because of differences in methodology, duration of 
studies, gender dimorphism and individual lipid profiles investigated. It should be 
noted that there is also widespread contradiction between various studies on Cer in the 
existing literature. Detailed research with the use of modern technology is now 
required to find the mechanistic basis of various lipid species identified by our study 
to investigate their role in AAP-induced metabolic toxicity; this will be important not 
only for mechanism elucidation but also for the development of biomarkers and 





























6.1 Overview of the thesis 
 
Schizophrenia is a chronic psychiatric disorder affecting 0.5-1% of the world’s 
population. It is characterised by positive symptoms such as hallucinations and 
delusions; negative symptoms such as lack of motivation, social withdrawal, 
disorganised speech and behaviour; and, cognitive symptoms. These symptoms 
typically appear in adolescence and early adulthood. It has been estimated that people 
suffering from schizophrenia have a 20% shorter life expectancy than the general 
population, with cardiovascular disease being the leading cause of death (Heald et al., 
2017). Disturbance in connections and changes in neurotransmitters such as dopamine, 
glutamate, serotonin and acetylcholine in various brain regions including the midbrain, 
nucleus accumbens, thalamus and prefrontal cortices have been proposed as being 
involved in the pathophysiology of schizophrenia (Lewis and Lieberman, 2000). 
AAPs are considered as the primary drugs to treat schizophrenia because of their better 
tolerability, improvement in schizophrenic symptoms and better adverse effect profile 
as compared to typical antipsychotics which cause extrapyramidal adverse effects. 
However, long term use of AAPs is associated with metabolic syndrome which consist 
of obesity, glucose intolerance, insulin resistance, T2DM, dyslipidemia and 
hypertension, all leading to cardiovascular disease thereby contributing to overall 
mortality and morbidity in schizophrenia (Sapra et al., 2018). The prevalence of 
metabolic syndrome is considered to be 23-50% in AAP-treated schizophrenic patients 
(Gautam and Meena, 2011, Bai et al., 2011). Among AAPs, CLO and OLA are 
considered to be associated with greater risk; QTP, RISP, ILP and PLP intermediate 
risk; while ARI, AMI and ZIP are associated with smaller risk of adverse metabolic 
effects (Bak et al., 2014). It is of utmost importance to find the mechanisms by which 
AAPs cause metabolic adverse effects so that the benefit-risk profile of these drugs 
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can be improved. Various mechanisms have been proposed which include lipid 
accumulation, dyslipidemia, inflammation, insulin resistance and mitochondrial 
dysfunction; however, no absolute mechanism has emerged (Coccurello and Moles, 
2010, Masaki et al., 2004). White adipose tissue has been a subject of interest for 
several years in metabolic disease research and is now considered a ‘hot spot’ in 
biomedical research (Trayhurn and Wood, 2005). Metabolic syndrome is associated 
with dysregulated adipose function and metabolism affecting not only its fat storage 
activity but also its endocrine functions. The understanding of adipose tissue biology 
and the deleterious changes associated with obesity could potentially throw light on 
the mechanisms involved in metabolic toxicity caused by AAPs (Gustafson et al., 
2007). Adipose tissue secretes various products such as adiponectin, leptin, resistin, 
TNF-α, MCP-1, retinol binding protein 4, and adipocyte-type fatty acid binding 
protein, some of which elicit their effects on peripheral tissues and thereby play a role 
in glucose and lipid homeostasis. Transcription factors especially PPARγ, CEBPα and 
SREBP1 also play a role in maintenance and maturation of adipocytes. Disturbance in 
homeostasis of these transcription factors by AAPs might also lead to metabolic 
toxicity (Oda, 2008). 
 
The main aim of this PhD project was to characterise the effect of AAPs on adipocyte 
function and metabolism in order to improve our understanding of the molecular 
mechanisms that are involved in AAP-induced metabolic toxicity. For this we used 
two different in vitro models: a murine adipocyte cell line, 3T3-F442A, and primary 
human subcutaneous adipocytes. We preferred the 3T3-F442A preadipocyte model as 
it showed more advanced commitment for differentiation compared to the 3T3-L1 or 
OP9 model (Ruiz-Ojeda et al., 2016). Chapter 2 focused on the effects of CLO and 
246 
 
OLA as exemplar AAPs with high metabolic toxic profile, and ARI as a drug with 
very low metabolic liability. We characterised the effect of the above AAPs on 
adipocyte lipid accumulation, adipokine secretion and the expression of various 
adipogenic transcription factors using a chronic drug toxicity model. AAPs were used 
in two different concentrations: a therapeutically relevant concentration, and a higher 
concentration which reflect potential accumulation of these drugs in the adipose tissue. 
This would therefore resemble a clinical scenario where patients have been exposed 
to AAPs for a long period of time. Our lipid accumulation data coincided with other 
in vitro (Hu et al., 2010, Tsubai et al., 2017) as well as clinical studies (Francesco and 
Cervone, 2014) which suggested that CLO and OLA but not ARI increased 
adipogenesis by acting directly on adipocytes leading to lipid accumulation. However 
this also contradicted with some other studies which showed no effect of AAPs on fat 
cell formation (Hauner et al., 2003). The contradiction may have arised due to a 
difference in methodology; or models used; or drug treatment duration. Our data also 
suggested the interaction between AAPs and adipogenic transcription factors as an 
underlying mechanism for AAP-induced metabolic toxicity. PPARγ, considered as a 
master regulator of adipogenesis, without which adipocytes cannot mature and 
perform physiological action was one of them. PPARγ is considered to be involved in 
glucose and lipid homeostasis thus improving insulin resistance (Liu et al., 2014). Our 
data coincided with other studies, showing increased PPARγ expression following 
incubation of adipocytes with CLO while OLA and ARI did not show any change 
(Sarvari et al., 2014, Sertie et al., 2011). This suggests that AAPs, especially CLO, 
might activate PPARγ thereby resulting in increased adipogenesis, leading to 
increased lipid accumulation and weight gain. Lipin 1, another transcription factor on 
which the effect of AAPs was reported for the first time, was considered to act as a 
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key factor for the maintenance and maturation of adipocytes. Our data showed 
increased lipin 1 expression with CLO but not OLA or ARI. PPARγ and lipin1 are 
also interrelated as lipin1 co-activates PPARγ2 and then regulates the network 
between PPARγ2 and C/EBPα. This suggests that AAPs might activate PPARγ 
indirectly through lipin1 which leads to increased adipogenesis and lipid 
accumulation; however, more research is required to see the effect of AAPs on lipin1 
(Koh et al., 2008).  
 
Insulin has an inhibitory effect on FFA release but, due to insulin resistance, this is 
inhibited and more FFA will be released, either stored in adipose tissue or peripherally 
leading to tissue steatosis. FFA also causes glucose intolerance by decreasing glucose 
intake in muscles leading to diabetes (Adiels et al., 2005). Our data coincided with 
previous studies which showed increased FFA with CLO and OLA except ARI, which 
did not show any change (Kaddurah-Daouk et al., 2007, Canfran-Duque et al., 2013, 
Jassim et al., 2012). This suggests that increased FFA levels might be one of the 
mechanisms by which AAPs cause metabolic adverse effects leading to insulin 
resistance. Our study on 3T3-F442A also investigated the effect of AAPs on 
adipokines. Adiponectin is considered as an insulin sensitiser and anti-inflammatory 
factor released from adipocytes and activates AMPK which increased the fatty acid 
oxidation. This step kick-start a series of reactions leading to increased uptake of 
glucose in muscle cells where it is converted into lactate. This diversion of glucose to 
muscle resulted in a reduction in liver gluconeogenesis triggering more uptake of 
glucose from plasma. Increased fatty acid oxidation, decreased gluconeogenesis in the 
liver and decreased glucose levels in plasma ultimately improves peripheral insulin 
sensitivity. However, decreased adiponectin levels lead to insulin resistance and 
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diabetes (Gil-Campos et al., 2004). It has been shown by various clinical studies 
(Bartoli et al., 2015b, Shah et al., 2008a) and an in vitro study on 3T3-L1 (Tsubai et 
al., 2017) that AAPs reduce adiponectin secretion. However, we observed 
contradictory data in our experiment with CLO where it showed an increased 
adiponectin secretion when treated with CLO while OLA and ARI showed decreased 
secretion. We also observed a discrepancy in the level of proinflammatory markers 
such as IL-6 and TNF-α secreted by the drug-treated adipocyte. Inflammation is 
considered one of the mechanisms by which AAPs cause metabolic toxicity. It has 
been postulated that pro-inflammatory markers like IL-6 and TNF-α act on insulin 
receptor and block its phosphorylation which leads to insulin resistance (Makki et al., 
2013). Various clinical studies (Pollmacher et al., 2000, Makki et al., 2013) showed 
increase in IL-6 and TNF-α levels after giving AAPs while our IL-6 data showed no 
change with all the drugs while TNF-α was only increased with CLO (Makki et al., 
2013). We can argue here that our data spanned only 10 days with only 4 drug 
additions while, clinically, patients take AAPs for long period of time which could be 
the cause of the contradictory data. 
 
We then used a primary human subcutaneous model to validate the murine adipocyte 
results and also to explain some of the discrepant data we obtained in the murine 
model.   
 
Preadipocytes (Chapter 3) obtained from healthy female abdominal subcutaneous 
adipose tissues were subjected to the same chronic AAPs treatment as preformed with 
the murine adipocytes. Interestingly, the human adiponectin data coincided with what 
was observed clinically; we observed a clear decrease in adiponectin secretion with 
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higher doses CLO and OLA which was not observed with ARI. Importantly, the 
reduction on adiponectin with therapeutic concentrations of CLO and OLA were 
minimal. The CLO accumulation assay which was performed in both primary human 
adipocytes and murine adipocytes showed that primary human adipocytes 
accumulated 20 times more CLO than murine adipocytes. This may suggest that the 
uptake of CLO into murine adipocytes was very less. This could be the reason for the 
contradictory result we observed in our murine model. This may also suggests that the 
uptake of AAPs in murine cells is operated through a different mechanism compared 
to primary human adipocytes. We have used the primary human adipocytes as our 
preferred model in subsequent experiments.  
Our data showed that CLO and, to some extent, OLA cause increased lipid 
accumulation in primary human adipocytes whereas ARI showed no change. This 
coincided with other studies performed on isolated subcutaneous adipose tissue 
(Hemmrich et al., 2006, Himmerich et al., 2011, Pavan et al., 2010). This suggests that 
AAPs directly affect the adipocytes and increase lipid accumulation leading to obesity 
and weight gain. Our PPARγ mRNA data did not show any change after using AAPs 
which coincided with other studies performed on primary human adipocytes (Nimura 
et al., 2015, Sarvari et al., 2014, Sertie et al., 2011). Our PPARγ protein data did show 
a trend to increase with CLO and OLA but not ARI; however, we also observed a high 
degree of variability in response between our biological replicates (adipocyte donors) 
and, therefore, these results were statistically non-significant. Due to limitations in the 
availability of adipocytes from donors plus the difficulty of performing a chronic 
toxicity experiment in a large number of replicates, we were restricted to only 3 
biological replicates. Increased sample size could reduce this variability. However, 
when these samples were analysed individually, the trend of expression was consistent 
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between all 3 biological replicates. Lipin1 was investigated for the first time; however, 
the result varied between biological replicates for the individual doses of AAPs and it 
was difficult to conclude how lipin1 was affected by AAPs. As mentioned earlier, lipin 
1 is important for the maturation and maintenance of adipocytes, therefore future 
studies with an increased sample size are required to study its role in metabolic 
toxicity. Decreased levels of adiponectin have been observed in insulin resistant 
patients and in conditions such as obesity and diabetes mellitus (Jin et al., 2008). Our 
data coincided with clinical studies where CLO and OLA but not ARI showed 
decreased adiponectin secretion (Klemettila et al., 2014, Pollmacher et al., 2000) 
which suggests that AAPs act directly on adipocytes and decrease adiponectin 
secretion which may lead to insulin resistance. Another important adipokine is leptin, 
the role of which is to suppress food intake and cause weight loss; our data showed an 
increase in leptin levels with CLO but not OLA while ARI showed a decrease in leptin 
levels which coincided with previous studies (Potvin et al., 2015, Paredes et al., 2014, 
Jin et al., 2008, Ak et al., 2013, Tanaka et al., 2008). Increased leptin levels without 
weight loss in obese patients have been observed previously which suggests the 
development of leptin resistance in these patients (Potvin et al., 2015). This suggests 
that AAPs could cause leptin resistance leading to increase in leptin levels. 
Inflammation is also considered one of the important mechanisms by which AAPs 
cause metabolic toxicity. The pro-inflammatory markers act on insulin signalling 
mediators such as IRS1 and block its phosphorylation leading to insulin resistance 
(Makki et al., 2013). Our IL-6 data coincided with previous studies where CLO and 
OLA but not ARI showed increased IL-6 levels. This suggests IL-6 as one of the main 
inflammatory markers which plays a role in metabolic toxicity by potential blockade 




Minimising weight gain and metabolic adverse effects caused by AAPs in 
schizophrenic patients is of clinical and societal importance (Sugawara et al., 2017). 
Chapter 4 focused on adjunctive therapeutic strategies to investigate whether they can 
reverse or arrest the deleterious effects of AAPs on adipocytes. Previous studies have 
shown co-administration of various drugs such as TOPI, sibutramine, MET, 
nizatidine, amantadine, ARI, and, modafinil with AAPs to improve the metabolic 
toxicity profile. Various RCTs showed improvement in metabolic adverse effects after 
concomitant use of MET, ARI and TOPI (Zimbron et al., 2016). However, previous 
studies could not recommend any specific drug for broad clinical usage due to 
limitations in clinical studies; moreover, none of these studies have investigated the 
mechanisms behind therapeutic reversal of AAP-induced metabolic toxicity (Maayan 
et al., 2010). We used MET, ARI, TEL as potential therapeutic options and 
coincubated with CLO in the primary human adipocyte model. We selected CLO as it 
showed prominent changes in adiponectin secretion and PPARγ expression compared 
to OLA, as described in Chapter 3.  MET, drug of choice in T2DM, was reported to 
cause weight loss and improved glucose levels and insulin sensitivity in diabetic 
subjects (Baptista et al., 2008, Baptista et al., 2007). TEL is an angiotensin II receptor 
blocker and mainly used as a antihypertensive. It was reported that TEL showed 
improvement in insulin resistance in metabolic syndrome patients (Derosa et al., 
2007). Preclinical and in vitro studies have also proposed the role of TEL in improving 
insulin resistance through PPARγ activation (Benndorf et al., 2006, Souza-Mello et 
al., 2010, Foryst-Ludwig et al., 2010, Pushpakom et al., 2017). Makita’s study showed 
improved adiponectin levels in glucose intolerant patients showing the efficacy of 
TEL in insulin resistant patients (Makita et al., 2008). ROSI, used as a positive control, 
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which has PPARγ agonistic activity, also showed improvement in insulin sensitivity; 
however, it was withdrawn clinically due to cardiovascular complications (Singh et 
al., 2007). Our data showed that all adjunctive drugs cause a trend to reverse the CLO-
mediated reduction in adiponectin secretion although the result was statistically non-
significant due to the high inter-individual variability observed. Our studies coincided 
with other studies showing improvement in adiponectin secretion on giving these 
adjunctive drugs alone to metabolically deranged patients with conditions like obesity, 
diabetes mellitus or insulin resistant (Wang et al., 2013, Zulian et al., 2011, Makita et 
al., 2008). This suggests that adjunctive drugs may act directly on adipocytes and 
maintain adiponectin levels leading to improved insulin sensitivity.  Our PPARγ data 
showed that all adjunctive drugs except 10µM Tel reversed PPARγ expression when 
given along with a therapeutic dose of CLO. This suggests that adiponectin and 
PPARγ are interrelated and adjunctive drugs might activate PPARγ which then 
activates adiponectin leading to an improvement in insulin resistance. This further 
suggests that adjunctive drugs not only maintain adipogenesis, as PPARγ is a master 
regulator of adipogenesis, but also improve insulin resistance through adiponectin. 
Data of adjunctive drugs with high dose CLO showed no change in expression by ARI, 
MET and TEL5µM. This suggests that the concentration we used for adjunctive drugs 
may not be sufficient to counter the effects of high dose of CLO (20µM). However, 
10µM TEL showed decreased PPARγ expression when given both with therapeutic 
and high dose of CLO despite increased adiponectin secretion. This might be due to 
TEL’s partial agonistic activity which showed that increase dose of TEL (10µM TEL) 
have more antagonistic effect instead of agonistic effect leading to decreased PPARγ 
expression. Our adjunctive drugs data with CLO suggest that these drugs can reverse 
the AAP-induced metabolic adverse effects through adiponectin or PPARγ or 
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combination of both. Various studies also suggested a positive correlation between 
PPARγ with adiponectin and reported that PPARγ agonist stimulates serum 
adiponectin secretion which was confirmed from our data (Guan et al., 2002, Combs 
et al., 2002, Yang et al., 2004).  
 
Chapter 5 focused on how AAPs may affect the adipocyte lipidome on a global using 
cultured primary human adipocytes. Lipidomics profiling of adipocytes is a new field; 
it has the potential to uncover novel mechanisms of pathogenesis and identify new 
biomarkers of toxicity. Lipogenesis in adipocytes involves numerous complex 
pathways, regulated by various transcriptional factors especially PPARγ, CEBPα and 
SREBP1.These transcriptional factors induce various other genes which are involved 
in fatty acid and glucose uptake. Various enzymes and hormones, the most important 
of which is insulin, also regulate these pathways. Numerous studies have reported 
increased levels of DAG, CE, TAG and Cer in the plasma of obese and diabetic 
patients as compared to normal subjects (Tonks et al., 2016, Rauschert et al., 2016). 
Our PCA and PLS-DA data showed that higher dose of CLO and OLA but not 
therapeutic concentrations cause profound change in global lipid profile while ARI 
did not show much change in the adipocyte lipidome. This change in global lipid 
profile by CLO and OLA clearly suggest that these AAPs when used chronically could 
accumulate in adipose tissue leading to deleterious effects on the adipocyte lipid 
content and contribute to AAP-induced cardiometabolic toxicity. Our results 
coincided with Daouk et al’s study which also showed global changes in lipids after 
giving OLA but not ARI in schizophrenic patients suggesting a role of adipocyte lipids 
in causing metabolic toxicity. Previous studies on obese and diabetic patients have 
shown remarkable changes in GLP and SL compared to other lipids (Alshehry et al., 
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2016). Among SL, Cer showed an association with CVD (Spijkers et al., 2011). Cer 
is synthesised de novo by a combination of serine and palmitoyle CoA regulated by 
enzymes SPT. Cer regulate cellular function including proliferation, differentiation, 
growth arrest and apoptosis. On accumulation in tissues during obesity, it acts as a 
toxic lipid leading to dysregulation of cellular functions resulting in insulin resistance 
(Hage Hassan et al., 2014). It has been proposed that Cer blocks the IRS-1 and PI3K 
insulin signalling pathway thus blocking insulin stimulated glucose transport and 
glycogen synthesis leading to insulin resistance (Summers et al., 1998, Schmitz-
Peiffer et al., 1999). High levels of Cer also lead to increased ROS which causes 
mitochondrial dysfunction leading to apoptosis of cells. This will form lipid 
metabolites that block the insulin signalling pathway (Hage Hassan et al., 2014). 
Preclinical (Samad et al., 2006) as well as clinical studies on insulin resistant patients 
(Amati et al., 2011, Gertow et al., 2014) showed increased levels of Cer suggesting its 
association with metabolic deranged conditions like obesity and T2DM. Cer could be 
a potential lipid biomarker by which AAPs act on and produce metabolic toxicity. We 
measured Cer 18 species levels as it has been suggested that it is associated with 
insulin resistance and its levels have been found to be increased in adipose tissue in 
obese patients (Kolak et al., 2007, Turpin et al., 2014). Contrary to the published data 
in obese patients (Tonks et al., 2016, Coen et al., 2010) and an insulin resistant rodent 
model (Turner et al., 2013) where increased Cer 18 levels were shown, our data with 
CLO and OLA but not ARI showed decreased Cer 18 species levels (16:0, 18:0, 18:1, 
20:0, 22:0, 22:1, 24:0 ,24:1, 26:0, 26:1). The reason for this contradiction could be (i) 
the difference in the model as previous studies were on mice or human adipose tissue 
or plasma compared to ours which used cultured human adipocytes; (ii) the difference 
in the number of samples as we used only five donors due to a limitation in the 
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availability of donors compared to the large number of patients in previous studies (a 
large number of samples could lead to different data); (iii) the duration of the study as 
obese or diabetic patients were in this condition for a long period of time while our 
study span was about 13 days. Long study duration with more drug additions might 
produce the same results as mentioned for previous studies. However, there are a few 
studies which showed decreased levels of Cer in subcutaneous adipose tissue of obese 
and diabetic subjects arguing that the disease (insulin resistance in obesity and 
diabetes) itself increased the metabolism of Cer (Blachnio-Zabielska et al., 2012b, 
Blachnio-Zabielska et al., 2012a). Blachnio-Zabielska and colleagues’ study reported 
that obese males showed an increased content of Cer 18 while obese females showed 
Cer 24 respectively. This may suggest the possibility that Cer 24 instead of Cer 18 was 
more involved in causing insulin resistance. As we used primary human adipocytes 
from female donors in our study there could be possibility that AAPs might increase 
Cer 24 while decreasing Cer 18 however more research is required involving both 
male and females donors to find the changes in Cer levels. Although we did not 
measure Cer 24 in our study, a decrease in Cer 18 might be reflected in our data 
because of this gender difference. Another study by Choi and colleagues on 3T3-L1 
showed decreased Cer content in adipocytes compared to preadipocytes as 
adipogenesis progressed. They proposed that TG synthesis requires palmitic acid, 
which is also required for synthesis of Cer, so in a condition of increased lipid droplet 
formation, palmitic acid may be used for synthesis of TG instead of Cer leading to 
decreased Cer content (Choi et al., 2011). As our AAP data showed more lipid 
accumulation, as discussed in Chapter 3, there is a possibility that palmitic acid was 
used for synthesis of TG which resulted in decreased levels of Cer. However, more 
detailed research is required to explore this. We then validated our Cer data by 
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investigating the Cer synthesis pathway through quantitative gene expression analysis 
of important Cer synthesis enzymes, SPTLC2 and DEGS1. Cer is formed by coupling 
palmitoyle CoA and serine by rate limiting enzyme SPTLC2 while DEGS1 convert 
DhCer to Cer. Our data showed decreased mRNA expression of SPTLC2 and DEGS1 
with CLO and OLA but not ARI. This suggests that CLO and OLA might block these 
enzymes leading to decreased Cer content. Our DEGS1 data also coincided with 
Barbarroja’s study in which decreased DEGS1 mRNA expression was shown in 
isolated adipocytes from a high fat diet mouse and genetically induced mice (ob/ob) 
(Barbarroja et al., 2015) leading to an increased DhCer/Cer ratio, increased DhCer 
levels and decreased Cer levels. This downregulation of DEGS1 was also observed in 
the visceral AT of obese patients suggesting an association between DEGS1 and 
DhCer levels with metabolic disease (Barbarroja et al., 2015). DhCer could have a 
potential role in causing insulin resistance in metabolic deranged patients. Although 
we did not measure DhCer levels in our experiment, there is a possibility that AAPs 
block DEGS1 enzymes leading to increased DhCer levels, while decreasing Cer 
levels. This increase in DhCer levels might cause insulin resistance leading to 
cardiovascular complications. More research is required to explore DhCer as recent 
reports have shown a positive correlation between DhCer and insulin resistance in 
obese subjects rather than Cer (Weir et al., 2013, Mamtani et al., 2014).  
6.2 Conclusion 
 
In conclusion, novel data has been presented in this thesis that could add to the 
evidence base on the pathogenesis of metabolic toxicity caused by AAPs. These data 
relate to increased adipogenesis, the role of transcription factors, inflammation, 
changes in adipokines and lipids levels. However, the results clearly showed that the 
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effect of metabotoxic AAPs (CLO and OLA) on adipocytes (lipid accumulation, 
adipokine release, adipogenic transcription factor expression and lipid content) 
significantly varies from that of a metabolically friendly AAP (ARI). This thesis also 
highlights the importance of (i) adipocyte lipidomics and its role in insulin resistance 
and, (ii) the potential of adjunctive therapeutic strategies in reversing AAP-induced 
metabolic adverse effects. This will help to develop new potential targets, biomarkers 
or drugs to treat AAP-induced metabolic toxicity. For this purpose, a greater 
understanding of the mutual interaction between drugs and peripheral tissues such as 
liver, skeletal muscle and adipose tissue that mediate insulin resistance is required. 
6.3 Future work 
 
Various studies have postulated different mechanisms for AAP-induced metabolic 
toxicity but the absolute mechanisms are unclear. There is still a lot of work which 
needs to be done in this area which is discussed below: 
1-Various animal studies have been conducted to find the underlying mechanism of 
AAP-induced metabolic toxicity but still no absolute model has been presented which 
mimics schizophrenic-like conditions. Studies on animal models also showed a lot of 
variation in data among species. An animal model with knock out models of 
adipogenic genes such as PPARγ and lipin1 may be helpful to understand the 
mechanism involved in AAP-induced metabolic toxicity. 
 
2- Our 3T3-F442A preadipocyte cell line model showed a decreased accumulation of 
CLO in the cells. It is necessary to perform detailed studies on adipocyte transporters 
to find the uptake of various drugs into the adipose tissue. 
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3- There is very little information about the effect of AAPs on the lipid profiles of 
mature adipocytes and this need to be investigated using advanced technologies such 
as UPLC/MS. This would provide a large set of data to help find more comprehensive 
conclusions in terms of finding potential biomarkers, drug targets and better treatment 
options. 
4- A large cohort (donors) of cultured primary human adipocytes is required to study 
the effect of AAPs on metabolic parameters. Factors such as age, sex, drug dosage, 
drug pharmacokinetics and methodology should be carefully selected which might 
represent the data in a different way.  
5- A few studies have been performed on adjunctive therapy given concomitantly with 
AAPs; however, these small studies showed promising result in reversing metabolic 
toxic effects. A detailed study is required to explore the effect of various adjunctive 
strategies to identify the best candidate drugs that can be taken forward into in vivo 
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